image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
c45888e7b2590dba0193e2b2619af4ad56822631065d7cf56417e68002069a9f.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">RFS</td><td colspan="2">OS</td></tr><tr><td>HR (95%CI)</td><td><i>P</i> value</td><td>HR (95%CI)</td><td><i>P</i> value</td></tr><tr><td>Univariate analysis</td><td></td><td></td><td></td><td></td></tr><tr><td>Age, yrs (<50 vs. ≥50)</td><td>0.994 (0.973-1.015)</td><td>0.553</td><td>0.659 (0.315-1.534)</td><td>0.368</td></tr><tr><td>Gender (male vs. female)</td><td>1.160 (0.046-2.910)</td><td>0.753</td><td>1.037 (0.307-3.507)</td><td>0.953</td></tr><tr><td>HBsAg (negative vs. positive)</td><td>1.996 (0.622-6.400)</td><td>0.245</td><td>1.627 (0.383-6.913)</td><td>0.509</td></tr><tr><td>HBeAg (negative vs. positive)</td><td>0.929 (0.420-2.054)</td><td>0.856</td><td>2.457 (0.831-7.262)</td><td>0.104</td></tr><tr><td>AFP,ng/ml (≤400 vs. >400)</td><td>1.847 (1.081-3.156)</td><td>0.025</td><td>3.016 (1.326-6.859)</td><td>0.008</td></tr><tr><td>Liver cirrhosis (absent vs. present)</td><td>0.886 (0.493-1.594)</td><td>0.686</td><td>0.792 (0.341-1.838)</td><td>0.587</td></tr><tr><td>Vascular invasion (absent vs. resent)</td><td>2.183 (1.167-4.084)</td><td>0.015</td><td>4.228 (1.798-9.942)</td><td>0.001</td></tr><tr><td>Intrahepatic metastasis (absent vs. present)</td><td>3.674 (2.056-6.566)</td><td>0.000</td><td>3.079 (1.270-7.764)</td><td>0.013</td></tr><tr><td>Tumor size, cm (≤5 vs. >5)</td><td>2.884 (1.358-6.125)</td><td>0.006</td><td>1.720 (0.644-4.589)</td><td>0.279</td></tr><tr><td>Tumor number (single vs. multiple)</td><td>3.464 (1.932-6.211)</td><td>0.000</td><td>2.622 (1.038-6.622)</td><td>0.041</td></tr><tr><td>Differentiation (poor/moderate vs. well)</td><td>1.986 (1.084-3.641)</td><td>0.026</td><td>3.729 (1.391-10.000)</td><td>0.009</td></tr><tr><td>AJCC stage(I-II vs. III-IV)</td><td>3.131 (1.805-5.430)</td><td>0.000</td><td>5.081 (2.273-11.360)</td><td>0.000</td></tr><tr><td>PBLD (low vs. high)</td><td>0.447 (0.260-0.769)</td><td>0.004</td><td>0.384 (0.165-0.894)</td><td>0.027</td></tr><tr><td>Multivariate analysis</td><td></td><td></td><td></td><td></td></tr><tr><td>Tumor size, cm (≤5 vs. >5)</td><td>2.839 (1.270-6.345)</td><td>0.011</td><td></td><td></td></tr><tr><td>AJCC stage (I-II vs. III-IV)</td><td>2.400 (1.137-5.066)</td><td>0.022</td><td>9.349 (1.754-49.842)</td><td>0.009</td></tr><tr><td>PBLD (low vs. high)</td><td>0.502 (0.282-0.891)</td><td>0.019</td><td>0.364 (0.138-0.957)</td><td>0.040</td></tr></table> |
4106c5e87e5fdfe1850917365168cdd6aff6fb9489db2705658c1760551caee1.png | simple | <table><tr><td>Language</td><td>Number of Manual signs</td><td>Number of mouth gestures</td><td>% of signs accompanied by mouth gestures</td><td>Number of mouthings</td><td>% of signs accompanied by mouthings</td></tr><tr><td>British Sign Language</td><td>1552</td><td>539</td><td>35</td><td>560</td><td>36</td></tr><tr><td>Sign Language of the Netherlands</td><td>1162</td><td>458</td><td>39</td><td>299</td><td>26</td></tr><tr><td>Swedish Sign Language</td><td>1619</td><td>624</td><td>39</td><td>831</td><td>51</td></tr></table> |
f65229e20db59ceedbcdd050cc592e665cfc4d92cb5139005ebe075827329402.png | simple | <table><tr><td></td><td>RA control</td><td>MTX group</td><td>TAC group</td><td>TAC + MTX group</td></tr><tr><td></td><td><i>n</i> = 35</td><td><i>n</i> = 55</td><td><i>n</i> = 29</td><td><i>n</i> = 14</td></tr><tr><td>Male/female</td><td>12/23</td><td>11/44</td><td>9/20</td><td>1/13</td></tr><tr><td>Age in years, mean ± SD</td><td>70.54 ± 10.84</td><td>63.80 ± 11.50</td><td>69.28 ± 9.87</td><td>61.00 ± 11.68</td></tr><tr><td>Weight in kg, mean ± SD</td><td>53.32 ± 9.54</td><td>52.87 ± 11.83</td><td>52.22 ± 12.24</td><td>50.84 ± 9.42</td></tr><tr><td>BMI, mean ± SD</td><td>21.79 ± 3.47</td><td>21.69 ± 3.69</td><td>21.84 ± 4.43</td><td>21.51 ± 3.23</td></tr><tr><td>RA duration in years, mean ± SD</td><td>11.66 ± 12.52</td><td>14.11 ± 10.90</td><td>10.52 ± 9.74</td><td>12.14 ± 7.07</td></tr><tr><td>MTX dose in mg/week, mean ± SD</td><td>-</td><td>7.80 ± 2.37</td><td>-</td><td>8.29 ± 3.22</td></tr><tr><td>TAC dose in mg/day, mean ± SD</td><td>-</td><td>-</td><td>2.05 ± 0.74</td><td>1.64 ± 0.57</td></tr><tr><td>Use of prednisolone, number (%) of patients</td><td>21 (60.0)</td><td>30 (54.5)</td><td>21 (72.4)</td><td>6 (42.9)</td></tr><tr><td>Prednisolone dose in mg/day, mean ± SD</td><td>6.06 ± 4.23</td><td>4.98 ± 2.97</td><td>3.89 ± 1.99</td><td>3.00 ± 1.26</td></tr><tr><td>DAS28 (CRP), mean ± SD</td><td>2.79 ± 1.17</td><td>2.61 ± 0.98</td><td>2.79 ± 1.23</td><td>2.10 ± 0.71</td></tr><tr><td>HAQ-DI, mean ± SD</td><td>0.85 ± 0.84</td><td>0.62 ± 0.76</td><td>0.76 ± 0.88</td><td>0.53 ± 0.41</td></tr><tr><td>SDAI, mean ± SD</td><td>9.03 ± 6.32</td><td>8.15 ± 7.33</td><td>10.36 ± 10.63</td><td>4.60 ± 4.06</td></tr><tr><td>CDAI, mean ± SD</td><td>7.83 ± 5.40</td><td>7.45 ± 6.73</td><td>9.68 ± 10.51</td><td>3.95 ± 3.84</td></tr><tr><td>IP (%)</td><td>6 (17.1)</td><td>7 (12.7)</td><td>13 (44.8)</td><td>0</td></tr><tr><td>COPD (%)</td><td>3 (8.6)</td><td>1 (1.8)</td><td>2 (6.9)</td><td>0</td></tr><tr><td>Smoking history (%)</td><td>3 (8.6)</td><td>5 (9.1)</td><td>3 (10.3)</td><td>1 (7.1)</td></tr></table> |
354f0e0bb29a7a0047b5e7c4052300af514f7c17584816d1dbe6a12ac48f3145.png | complex | <table><tr><td></td><td colspan="3">Associative memory training group</td><td colspan="3">Active control group</td></tr><tr><td></td><td>Pre training <i>M</i> (<i>SD</i>)</td><td>Post training <i>M</i> (<i>SD</i>)</td><td>Effect size</td><td>Pre training <i>M</i> (<i>SD</i>)</td><td>Post training <i>M</i> (<i>SD</i>)</td><td>Effect size</td></tr><tr><td>Item memory</td><td>−0.19 (0.85)</td><td>0.29 (0.79)</td><td>0.58</td><td>−0.08 (0.70)</td><td>−0.04 (0.62)</td><td>0.06</td></tr><tr><td>Associative memory</td><td>−0.04 (0.70)</td><td>0.13 (0.59)</td><td>0.13</td><td>−0.13 (0.55)</td><td>−0.03 (0.81)</td><td>0.15</td></tr><tr><td>Spatial memory</td><td>−0.23 (0.68)</td><td>0.18 (0.55)</td><td>0.67</td><td>−0.07 (0.65)</td><td>−0.12 (0.76)</td><td>0.28</td></tr><tr><td>Reasoning</td><td>−0.03 (0.73)</td><td>0.19 (0.87)</td><td>0.28</td><td>−0.20 (0.66)</td><td>−0.05 (0.64)</td><td>0.38</td></tr></table> |
d1eac19ff895bd714b687f1c9f6f944ec76c3153b4d7c7de599a3765c2c1612f.png | complex | <table><tr><td> </td><td colspan="3">IC<sub>50</sub> (μM)<sup>a</sup></td></tr><tr><td>Compound</td><td>HCT-116</td><td>HepG-2</td><td>MCF-7</td></tr><tr><td>6a</td><td>>100</td><td>>100</td><td>>100</td></tr><tr><td>6b</td><td>>100</td><td>94.62 ± 6.93</td><td>>100</td></tr><tr><td>6c</td><td>>100</td><td>58.34 ± 2.38</td><td>>100</td></tr><tr><td>6d</td><td>95.46 ± 4.08</td><td>52.95 ± 1.87</td><td>>100</td></tr><tr><td>6e</td><td>37.46 ± 1.24</td><td>24.55 ± 0.47</td><td>55.34 ± 2.72</td></tr><tr><td>6f</td><td>>100</td><td>>100</td><td>>100</td></tr><tr><td>6g</td><td>>100</td><td>>100</td><td>>100</td></tr><tr><td>6h</td><td>>100</td><td>>100</td><td>>100</td></tr><tr><td>6i</td><td>3.67 ± 1.79</td><td>13.00 ± 0.67</td><td>3.58 ± 0.28</td></tr><tr><td>6j</td><td>14.00 ± 1.02</td><td>18.41 ± 1.03</td><td>25.87 ± 1.88</td></tr><tr><td>6k</td><td>25.42 ± 1.22</td><td>12.74 ± 0.83</td><td>14.38 ± 0.98</td></tr><tr><td>6l</td><td>99.14 ± 4.52</td><td>83.78 ± 3.41</td><td>>100</td></tr><tr><td>6m</td><td>95.59 ± 5.88</td><td>83.74 ± 2.29</td><td>>100</td></tr><tr><td>6n</td><td>8.57 ± 0.52</td><td>3.97 ± 0.19</td><td>1.04 ± 0.08</td></tr><tr><td>6o</td><td>80.50 ± 2.48</td><td>57.00 ± 1.44</td><td>94.00 ± 1.44</td></tr><tr><td>6p</td><td>27.80 ± 0.96</td><td>60.60 ± 2.92</td><td>27.20 ± 1.58</td></tr><tr><td>6q</td><td>5.99 ± 0.42</td><td>3.81 ± 0.13</td><td>7.67 ± 0.62</td></tr><tr><td>6r</td><td>>100</td><td>>100</td><td>>100</td></tr><tr><td>9a</td><td>>100</td><td>>100</td><td>>100</td></tr><tr><td>9b</td><td>>100</td><td>>100</td><td>>100</td></tr><tr><td>9c</td><td>>100</td><td>>100</td><td>>100</td></tr><tr><td>9d</td><td>55.30 ± 1.78</td><td>27.70 ± 1.04</td><td>98.40 ± 5.74</td></tr><tr><td>9e</td><td>>100</td><td>91.60 ± 5.44</td><td>>100</td></tr><tr><td>9f</td><td>98.20 ± 4.44</td><td>>100</td><td>>100</td></tr><tr><td>11a</td><td>70.13 ± 3.20</td><td>55.25 ± 3.18</td><td>39.42 ± 1.06</td></tr><tr><td>11b</td><td>>100</td><td>>100</td><td>>100</td></tr><tr><td>11c</td><td>>100</td><td>>100</td><td>>100</td></tr><tr><td>Dox.</td><td>3.70 ± 0.26</td><td>3.56 ± 0.17</td><td>2.57 ± 0.18</td></tr></table> |
8b4c8800a092ef1e608d875754cdafc8888ceac7861b38129888df563c445bc2.png | simple | <table><tr><td>GO term ID</td><td>Functional area (GO term of category biological process)</td><td>No. of genes</td></tr><tr><td>GO:0033555</td><td>Multicellular organismal response to stress</td><td>2</td></tr><tr><td>GO:0070997</td><td>Neuron death</td><td>3</td></tr><tr><td>GO:0050877</td><td>Neurological system process</td><td>5</td></tr><tr><td>GO:0009991</td><td>Response to extracellular stimulus</td><td>5</td></tr><tr><td>GO:0007399</td><td>Nervous system development</td><td>6</td></tr><tr><td>GO:0071704</td><td>Organic substance metabolic process</td><td>11</td></tr><tr><td>GO:0016043</td><td>Cellular component organization</td><td>13</td></tr><tr><td>GO:0065007</td><td>Biological regulation</td><td>17</td></tr></table> |
b2e2493aea1f7e0a4189517143349a599225dd09722cc86298b6be38ecac6c2a.png | simple | <table><tr><td>Temperature (°C)</td><td>Activity (U/mL)±SD</td></tr><tr><td>30</td><td>0.073148±0.000327</td></tr><tr><td>35</td><td>0.154167±0.000655</td></tr><tr><td>40</td><td>0.078241±0.000982</td></tr><tr><td>45</td><td>0.037963±0.000327</td></tr></table> |
946dcfe7c14157228f75cd96ee858d62574e43490bf44d1f178530a9fdde5fb8.png | complex | <table><tr><td>Outcome over the last three months</td><td>ControlN=301</td><td>Brief adviceN=291</td><td>Coefficient/OR*95% CI</td></tr><tr><td colspan="4">Weekly alcohol consumption (units)</td></tr><tr><td> Mean (SD)</td><td>20.3 (16.6)</td><td>18.1 (15.6)</td><td>−2.33</td></tr><tr><td> Median (IQR)</td><td>15.7 (8.3–29.9)</td><td>14.1 (6.5–25.1)</td><td>−4.69 to 0.03</td></tr><tr><td colspan="4">Had unprotected sex (%)</td></tr><tr><td> No</td><td>123 (40.9)</td><td>137 (47.1)</td><td>0.89</td></tr><tr><td> Yes</td><td>178 (59.1)</td><td>154 (52.9)</td><td>0.63 to 1.25</td></tr><tr><td colspan="4">Average units on drinking days</td></tr><tr><td> Mean (SD)</td><td>10.4 (5.8)</td><td>9.3 (5.3)</td><td>−1.13</td></tr><tr><td> Median (IQR)</td><td>9.4 (6.5–13.4)</td><td>8.6 (5.6–11.4)</td><td>−1.96 to −0.29</td></tr><tr><td colspan="4">Proportion of days abstinent</td></tr><tr><td> Mean, (SD)</td><td>70.7 (22.6)</td><td>70.9 (22.1)</td><td>0.20</td></tr><tr><td> Median (IQR)</td><td>75.6 (62.2–87.8)</td><td>75.6 (58.9–87.8)</td><td>−3.03 to 3.44</td></tr><tr><td colspan="4">Drinking excessively (M-SASQ) (%)</td></tr><tr><td> No</td><td>55 (18.3)</td><td>70 (24.1)</td><td>0.70</td></tr><tr><td> Yes</td><td>246 (81.7)</td><td>221 (75.9)</td><td>0.46 to 1.05</td></tr><tr><td colspan="4">Number of sexual partners</td></tr><tr><td> Mean (SD)</td><td>1.9 (2.9)</td><td>1.6 (2.2)</td><td>−0.13</td></tr><tr><td> Median (IQR)</td><td>1 (1–2)</td><td>1 (1–2)</td><td>−0.29 to 0.02</td></tr><tr><td colspan="4">Number of unprotected partners</td></tr><tr><td> Mean (SD)</td><td>0.8 (1.1)</td><td>0.6 (0.8)</td><td>−0.11</td></tr><tr><td> Median (IQR)</td><td>1 (0–1)</td><td>1 (0–1)</td><td>−0.31 to 0.08</td></tr><tr><td colspan="4">Occurrence of regretted sex (%)</td></tr><tr><td> No</td><td>273 (90.7)</td><td>263 (90.4)</td><td>1.05</td></tr><tr><td> Yes</td><td>28 (9.3)</td><td>28 (9.6)</td><td>0.60 to 1.84</td></tr><tr><td colspan="4">Unprotected sex after drinking (%)</td></tr><tr><td>No</td><td>165 (54.8)</td><td>183 (62.9)</td><td>0.79</td></tr><tr><td>Yes</td><td>136 (45.2)</td><td>108 (37.1)</td><td>0.56 to 1.11</td></tr><tr><td colspan="4">Unprotected sex after feeling drunk (%)</td></tr><tr><td> No</td><td>245 (81.4)</td><td>234 (80.4)</td><td>1.15</td></tr><tr><td> Yes</td><td>56 (18.6)</td><td>57 (19.6)</td><td>0.76 to 1.75</td></tr><tr><td colspan="4">Unplanned pregnancy (n=316)</td></tr><tr><td> No</td><td>160 (98.8)</td><td>152 (98.7)</td><td>1.05</td></tr><tr><td> Yes</td><td>2 (1.2)</td><td>2 (1.3)</td><td>0.16 to 6.79</td></tr><tr><td colspan="4">New diagnosis of sexually transmitted infection</td></tr><tr><td> No</td><td>287 (95.3)</td><td>283 (97.3)</td><td>0.58</td></tr><tr><td> Yes</td><td>14 (4.7)</td><td>8 (2.7)</td><td>0.25 to 1.384</td></tr><tr><td>Health related quality of life (SD)</td><td>0.922 (0.144)</td><td>0.910 (0.150)</td><td>−0.013−0.037 to 0.109</td></tr></table> |
0a6aa60a1ed6e75a990690dd4830d2c7e684906fb212873798e3f04c185514c3.png | complex | <table><tr><td>Conditions</td><td>Reactor 1</td><td>Reactor 2</td></tr><tr><td>Carrier</td><td>Corncob</td><td>Concrete block</td></tr><tr><td rowspan="3">External carbon</td><td rowspan="3">No</td><td>Phase 1: no </td></tr><tr><td>Phase 2: yes (C/N = 2.5)</td></tr><tr><td>Phase 3: yes (C/N = 3.5)</td></tr><tr><td rowspan="3">Microbial test</td><td>Unused corncob</td><td>Unused concrete</td></tr><tr><td>Used corncob (surface)</td><td>Used concrete (surface)</td></tr><tr><td>Used corncob (core)</td><td>Used concrete (core)</td></tr></table> |
45da4bbf618cbaa2f3edbc1ffd1589fa178d4bef783302c0476a7af53dd29041.png | simple | <table><tr><td>Parameters</td><td>Chronic HBV patients</td><td>Health volunteers</td></tr><tr><td>No.</td><td>22</td><td> 20</td></tr><tr><td>Age (years)</td><td></td><td></td></tr><tr><td> Mean ± SD</td><td>45.9 ± 8.1</td><td>38.5 ± 11.8*</td></tr><tr><td> Median</td><td>46</td><td>36.5</td></tr><tr><td> Range</td><td>30–61</td><td>25–58</td></tr><tr><td>Sex N(%)</td><td></td><td></td></tr><tr><td> Male</td><td>17 (77.3)</td><td>14 (70)</td></tr><tr><td> Female</td><td>05 (22.7)</td><td>6 (30)</td></tr><tr><td>Years from HBV diagnosis</td><td></td><td></td></tr><tr><td> Mean ± SD</td><td>10.3 ± 1.6</td><td>NA</td></tr><tr><td>HBV DNA (log10 copies/ml)</td><td></td><td></td></tr><tr><td> Mean</td><td>5.8</td><td>NA</td></tr><tr><td> SD</td><td>0.2</td><td></td></tr><tr><td>ALT (U/L)</td><td></td><td></td></tr><tr><td> Median</td><td>27.6</td><td>15.4*</td></tr><tr><td> Range</td><td>10.1–445.6</td><td>5.6–37.5</td></tr><tr><td>AST (U/L)</td><td></td><td></td></tr><tr><td> Median</td><td>26.8</td><td>11.3*</td></tr><tr><td> Range</td><td>7.1–312.4</td><td>2.5–25.4</td></tr><tr><td>HbsAg (log <sub>10</sub> IU/ml)</td><td></td><td></td></tr><tr><td> Median</td><td>1082.5</td><td>NA</td></tr><tr><td> Range</td><td>90.0–12795.0</td><td></td></tr></table> |
6bc124ac6bf304374a6d8901d06b6da18679e7a58430c16f5013155ea54a08cd.png | complex | <table><tr><td>Program</td><td colspan="2">Nucleotide</td><td colspan="2">Exon</td><td colspan="2">Gene</td></tr><tr><td></td><td>Sensitivity</td><td>Specificity</td><td>Sensitivity</td><td>Sensitivity</td><td>Specificity</td><td>Sensitivity</td></tr><tr><td>Pair-wise GeneMapper</td><td>99.95</td><td>99.93</td><td>91.3</td><td>95.1</td><td>52.2</td><td>52.2</td></tr><tr><td>Multiple species GeneMapper</td><td>99.95</td><td>99.93</td><td>91.5</td><td>95.2</td><td>52.6</td><td>52.6</td></tr></table> |
5239fd4eaea963b7209f19ce1aeed98c5cba004accc82ba8ba3a7686654c7aff.png | simple | <table><tr><td>Methods</td><td>TP</td><td>FP</td><td>FN</td></tr><tr><td>[24, 25]</td><td>93.4%</td><td>0.18%</td><td>6.6%</td></tr><tr><td>Proposed</td><td>96.8%</td><td>0.12%</td><td>3.2%</td></tr></table> |
d05cd1d6c320a5ef91ca5c1a34c8a48a6242de4027b63787d00e2c72ec696cb2.png | simple | <table><tr><td>Subject </td><td> 1 </td><td> 2 </td><td> 3 </td><td> 4 </td><td> 5 </td><td> 6 </td><td> 7 </td><td> 8 </td><td> 9 </td><td> 10 </td></tr><tr><td>Accuracy</td><td> 88.23%</td><td> 92.10%</td><td> 78.57%</td><td> 86.53%</td><td> 77.77%</td><td> 67.39%</td><td> 68.18%</td><td> 80.35%</td><td> 69.04%</td><td> 69.56%</td></tr></table> |
575463b48874c8a11d172fd2df4957dd962356e55e1ba6c06bf2086d43b7f315.png | simple | <table><tr><td>Variables </td><td>IS (<i>n</i> = 198)</td><td>Controls (<i>n</i> = 236)</td><td><i>P</i> value</td></tr><tr><td>Age (years, mean ± SD)</td><td>57.2 ± 11.8 </td><td>55.4 ± 11.7</td><td>0.12</td></tr><tr><td>Gender (%)</td><td> </td><td> </td><td> </td></tr><tr><td>Male </td><td>122 (61.6)</td><td>155 (65.7)</td><td>0.38</td></tr><tr><td>Female</td><td>76 (38.4)</td><td>81 (34.3)</td><td> </td></tr><tr><td>Hypertension (%)</td><td>119 (60.1)</td><td>22 (9.3)</td><td><0.001</td></tr><tr><td>Diabetes mellitus (%)</td><td>40 (20.2)</td><td>8 (3.4)</td><td><0.001</td></tr><tr><td>Hypercholesterolemia (%)</td><td>27 (13.6)</td><td>26 (11.0)</td><td>0.41</td></tr><tr><td>Hypertriglyceridemia (%)</td><td>56 (28.3)</td><td>61 (25.8)</td><td>0.57</td></tr></table> |
16f2d81a69930da3b889f46fe17cadd80110245ef23f62abecc802a6048ee334.png | complex | <table><tr><td rowspan="3"></td><td colspan="4">Mbeya</td><td colspan="4">Mtwara</td><td colspan="4">Mwanza</td></tr><tr><td colspan="2">Health facilities (N = 18)</td><td colspan="2">Non-HF AM providers (N = 38)<sup>a</sup></td><td colspan="2">Health facilities (N = 16)</td><td colspan="2">Non-HF AM providers (N = 21)</td><td colspan="2">Health facilities (N = 26)</td><td colspan="2">Non-HF AM providers (N = 89)</td></tr><tr><td>N</td><td>% (95% CI)</td><td>N</td><td>% (95% CI)</td><td>N</td><td>% (95% CI)</td><td>N</td><td>% (95% CI)</td><td>N</td><td>% (95% CI)</td><td>N</td><td>% (95% CI)</td></tr><tr><td>% of outlets with anti-malarials in stock</td><td>18</td><td>100.0</td><td>38</td><td>100.0</td><td>16</td><td>100.0</td><td>20</td><td>95.2 (87.6–102.9)</td><td>26</td><td>100.0</td><td>81</td><td>91.0 (86.0–96.0)</td></tr><tr><td>% of outlets with RDTs in stock or microscopy</td><td>16</td><td>88.9 (76.7–101.1)</td><td>3</td><td>7.9 (0.7–15.1)</td><td>11</td><td>68.8 (49.7–87.8)</td><td>0</td><td>0.0</td><td>21</td><td>80.8 (68.1–935.)</td><td>1</td><td>1.2 (− 0.71–2.96)</td></tr></table> |
ee046305565df75238f91b7ae6eb15575cbe2a23d8f663d1108e31c9b98d0b40.png | simple | <table><tr><td>Benign prostatic hyperplasia patients</td><td><i>n</i> = 49</td></tr><tr><td>IPSS Score (Barry et al., 1992)</td><td></td></tr><tr><td>0–7</td><td>0</td></tr><tr><td>8–19</td><td>24</td></tr><tr><td>20–35</td><td>17</td></tr><tr><td>Unknown</td><td>8</td></tr><tr><td>Prostate cancer patients</td><td><i>n</i> = 30</td></tr><tr><td>Gleason score (Epstein, 2010)</td><td></td></tr><tr><td>6 (3+3)</td><td>19</td></tr><tr><td>7 (3+4)</td><td>3</td></tr><tr><td>7 (4+3)</td><td>4</td></tr><tr><td>Unknown</td><td>4</td></tr></table> |
bb2edc7b7c8f49ea276dce674bf2ceacd054c2efb65287ccff61a7f5d1bae080.png | complex | <table><tr><td>Antibiotic<sup>a</sup></td><td colspan="8">Minimal inhibitory concentration (μg/ml)<sup>b</sup></td></tr><tr><td></td><td colspan="2">NVT2001S</td><td colspan="2">Δ<i>ompK35</i></td><td colspan="2">Δ<i>ompK36</i></td><td colspan="2">Δ<i>ompK35/36</i></td></tr><tr><td></td><td>NO<sup>c</sup></td><td>LCP</td><td>NO</td><td>LCP</td><td>NO</td><td>LCP</td><td>NO</td><td>LCP</td></tr><tr><td>Aztreonam</td><td>≤1</td><td>≤1</td><td>≤1</td><td>≤1</td><td>≤1</td><td>≤1</td><td>≤1</td><td>≤1</td></tr><tr><td>Ampicillin</td><td>≥<underline>32</underline></td><td>≥<underline>32</underline></td><td>≥<underline>32</underline></td><td>≥<underline>32</underline></td><td>≥<underline>32</underline></td><td>≥<underline>32</underline></td><td>≥<underline>32</underline></td><td>≥<underline>32</underline></td></tr><tr><td>Piperacillin/TZB</td><td>≤4</td><td>≤4</td><td>≤4</td><td>≤4</td><td>≤4</td><td>≤4</td><td>≤4</td><td>≤4</td></tr><tr><td>Cefazolin </td><td>≤8</td><td>≤8</td><td>≤8</td><td>≤8</td><td><underline>16</underline></td><td><underline>16</underline></td><td>≥<underline>32</underline></td><td>≥<underline>32</underline></td></tr><tr><td>Cephalothin</td><td>≤8</td><td>≤8</td><td>≤8</td><td>≤8</td><td><underline>16</underline></td><td><underline>16</underline></td><td>≥<underline>32</underline></td><td>≥<underline>32</underline></td></tr><tr><td>Cefoxitin </td><td>≤4</td><td>≤4</td><td>≤4</td><td>≤4</td><td><underline>16</underline></td><td><underline>16</underline></td><td><underline>32</underline></td><td><underline>32</underline></td></tr><tr><td>Ceftriaxone</td><td>≤1</td><td>≤1</td><td>≤1</td><td>≤1</td><td>≤1</td><td>≤1</td><td>≤1</td><td>≤1</td></tr><tr><td>Cefpodoxime</td><td>≤0.25</td><td>≤0.25</td><td>≤0.25</td><td>≤0.25</td><td>≤0.25</td><td>≤0.25</td><td>0.5</td><td>0.5</td></tr><tr><td>Cefotaxime </td><td>≤0.25</td><td>≤0.25</td><td>≤0.25</td><td>≤0.25</td><td>≤0.25</td><td>≤0.25</td><td>≤0.25</td><td>≤0.25</td></tr><tr><td>Cefotaxime/CLA</td><td>≤0.12</td><td>≤0.12</td><td>≤0.12</td><td>≤0.12</td><td>≤0.12</td><td>≤0.12</td><td>0.25</td><td>0.25</td></tr><tr><td>Ceftazidime </td><td>≤0.25</td><td>≤0.25</td><td>≤0.25</td><td>≤0.25</td><td>≤0.25</td><td>≤0.25</td><td>0.5</td><td>0.5</td></tr><tr><td>Ceftazidime/CLA</td><td>≤0.12</td><td>≤0.12</td><td>0.25</td><td>0.25</td><td>≤0.12</td><td>≤0.12</td><td>0.5</td><td>0.5</td></tr><tr><td>Cefepime</td><td>≤1</td><td>≤1</td><td>≤1</td><td>≤1</td><td>≤1</td><td>≤1</td><td>≤1</td><td>≤1</td></tr><tr><td>Ciprofloxacin</td><td>≤1</td><td>≤1</td><td>≤1</td><td>≤1</td><td>≤1</td><td>≤1</td><td>≤1</td><td>≤1</td></tr><tr><td>Gentamicin</td><td>≤4</td><td>≤4</td><td>≤4</td><td>≤4</td><td>≤4</td><td>≤4</td><td>≤4</td><td>≤4</td></tr></table> |
3a756bdd634c56a82f51ab460ce9441fba3fbf441349ea844a4c6c5f435c54c5.png | complex | <table><tr><td></td><td>Radiographic OA</td><td>Pain</td><td>Mean</td><td>SE</td><td colspan="2">95% CI of the mean</td><td><i>P-</i>value</td><td>95% CI for difference</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>Lower</td><td>Upper</td><td></td><td></td></tr><tr><td>sC2C</td><td>K/L 1</td><td>-</td><td>5.49</td><td>0.04</td><td>5.40</td><td>5.57</td><td>0.02*</td><td>-0.19 to -0.04</td></tr><tr><td>Ln (pmol/ml)</td><td></td><td>+</td><td>5.75</td><td>0.07</td><td>5.61</td><td>5.91</td><td></td><td></td></tr><tr><td></td><td>K/L 2</td><td>-</td><td>5.43</td><td>0.07</td><td>5.29</td><td>5.57</td><td>1.00</td><td>-0.36 to 0.35</td></tr><tr><td></td><td></td><td>+</td><td>5.44</td><td>0.11</td><td>5.21</td><td>5.66</td><td></td><td></td></tr><tr><td>sCPII</td><td>K/L 1</td><td>-</td><td>7.38</td><td>0.07</td><td>7.24</td><td>7.52</td><td>0.01*</td><td>-0.83 to -0.10</td></tr><tr><td>Ln (ng/ml)</td><td></td><td>+</td><td>7.84</td><td>0.11</td><td>7.62</td><td>8.07</td><td></td><td></td></tr><tr><td></td><td>K/L 2</td><td>-</td><td>7.05</td><td>0.11</td><td>6.83</td><td>7.28</td><td>1.00</td><td>-0.44 to 0.71</td></tr><tr><td></td><td></td><td>+</td><td>6.92</td><td>0.18</td><td>6.56</td><td>7.28</td><td></td><td></td></tr><tr><td>uCTX-II/Cr</td><td>K/L 1</td><td>-</td><td>5.04</td><td>0.14</td><td>4.76</td><td>5.32</td><td>0.07</td><td>-1.48 to 0.03</td></tr><tr><td>Ln (ng/μmol creatinine)</td><td></td><td>+</td><td>5.77</td><td>0.22</td><td>5.32</td><td>6.22</td><td></td><td></td></tr><tr><td></td><td>K/L 2</td><td>-</td><td>5.38</td><td>0.23</td><td>4.92</td><td>5.83</td><td><0.05*</td><td>-2.36 to -0.05</td></tr><tr><td></td><td></td><td>+</td><td>6.56</td><td>0.36</td><td>5.82</td><td>7.29</td><td></td><td></td></tr><tr><td>sC2C</td><td>K/L 1</td><td>-</td><td>0.15</td><td>0.03</td><td>0.10</td><td>0.20</td><td>1.00</td><td>-1.12 to 0.17</td></tr><tr><td>/sCPII</td><td></td><td>+</td><td>0.12</td><td>0.04</td><td>0.04</td><td>0.21</td><td></td><td></td></tr><tr><td></td><td>K/L 2</td><td>-</td><td>0.27</td><td>0.04</td><td>0.19</td><td>0.36</td><td>1.00</td><td>-0.17 to 0.26</td></tr><tr><td></td><td></td><td>+</td><td>0.23</td><td>0.07</td><td>0.09</td><td>0.37</td><td></td><td></td></tr><tr><td>uCTX-II/sCPII</td><td>K/L 1</td><td>-</td><td>0.09</td><td>0.06</td><td>-0.03</td><td>0.22</td><td>1.00</td><td>-0.39 to 0.29</td></tr><tr><td></td><td></td><td>+</td><td>0.14</td><td>0.10</td><td>-0.06</td><td>0.35</td><td></td><td></td></tr><tr><td></td><td>K/L 2</td><td>-</td><td>0.42</td><td>0.10</td><td>0.21</td><td>0.63</td><td><0.05*</td><td>-1.07 to 0</td></tr><tr><td></td><td></td><td>+</td><td>0.95</td><td>0.17</td><td>0.62</td><td>1.29</td><td></td><td></td></tr><tr><td>uNTX/Cr</td><td>K/L 1</td><td>-</td><td>3.71</td><td>0.11</td><td>3.48</td><td>3.93</td><td>1.00</td><td>-0.89 to 0.33</td></tr><tr><td>Ln (ng/ml creatinine)</td><td></td><td>+</td><td>3.99</td><td>0.18</td><td>3.62</td><td>4.35</td><td></td><td></td></tr><tr><td></td><td>K/L 2</td><td>-</td><td>3.33</td><td>0.18</td><td>2.96</td><td>3.70</td><td>0.73</td><td>-1.49 to 0.41</td></tr><tr><td></td><td></td><td>+</td><td>3.87</td><td>0.29</td><td>3.27</td><td>4.47</td><td></td><td></td></tr><tr><td>sHA</td><td>K/L 1</td><td>-</td><td>2.77</td><td>0.13</td><td>2.51</td><td>3.03</td><td>0.06</td><td>-1.40 to 0.01</td></tr><tr><td>Ln (pmol/ml)</td><td></td><td>+</td><td>3.46</td><td>0.21</td><td>3.04</td><td>3.89</td><td></td><td></td></tr><tr><td></td><td>K/L 2</td><td>-</td><td>3.66</td><td>0.21</td><td>3.24</td><td>4.09</td><td>1.00</td><td>-1.42 to 0.78</td></tr><tr><td></td><td></td><td>+</td><td>3.98</td><td>0.34</td><td>3.29</td><td>4.67</td><td></td><td></td></tr></table> |
f030540814dbaabd6df8934fc3b0f5af231fa6c7af8f862ba8d7dceab62952c4.png | complex | <table><tr><td></td><td colspan="2">Swab</td><td>N</td></tr><tr><td>Score Card</td><td>Bacterial</td><td>Viral</td><td></td></tr><tr><td>Positive</td><td>21</td><td>19</td><td>40</td></tr><tr><td></td><td>(True Positive)</td><td>(False Positive)</td><td></td></tr><tr><td>Negative</td><td>2</td><td>40</td><td>42</td></tr><tr><td></td><td>(False Negative)</td><td>(True Negative)</td><td></td></tr><tr><td>N</td><td>23</td><td>59</td><td>82</td></tr></table> |
c6b192c7d0befdbab33337a73ed65a0af775d3200fc6ae42528d2671222bed41.png | complex | <table><tr><td colspan="2">Microbiology of prosthetic infection (1 day- > 1 year) after haernia or ventral mesh repair</td></tr><tr><td><i>Staphylococcus aureus</i></td><td>50–60 %</td></tr><tr><td><i>Staphylococcus spp</i></td><td>10–20 %</td></tr><tr><td><i>Enterococcus spp</i></td><td>10–20 %</td></tr><tr><td>Gram-neg</td><td>5–10 %</td></tr><tr><td>Pseudomonas, <i>Streptococcus spp</i>, <i>Mycobacteria spp</i>, mixed flora</td><td>rare</td></tr></table> |
2b9df26811d7889793c474048241c13f9b5b6df5d1c14e2a8da292e30816b713.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">Richest Quintile</td><td colspan="2">Poorest Quintile</td><td colspan="3">Difference</td><td colspan="3">Ratio</td></tr><tr><td>Earliest Survey</td><td>Latest Survey</td><td>Earliest Survey</td><td>Latest Survey</td><td>Earliest Survey</td><td>Latest Survey</td><td><i>p</i>-val</td><td>Earliest Survey</td><td>Latest Survey</td><td><i>p</i>-val</td></tr><tr><td>Stunting</td><td>47.7</td><td>27.4</td><td>59.3</td><td>47.1</td><td>−11.6</td><td>−19.7</td><td>0.057</td><td>0.8</td><td>0.6</td><td>0.002</td></tr><tr><td>Wasting</td><td>8.9</td><td>7.4</td><td>12.1</td><td>11.7</td><td>−3.2</td><td>−4.3</td><td>0.656</td><td>0.7</td><td>0.6</td><td>0.559</td></tr><tr><td>Underweight</td><td>31.0</td><td>16.6</td><td>43.8</td><td>33.4</td><td>−12.8</td><td>−16.8</td><td>0.237</td><td>0.7</td><td>0.5</td><td>0.003</td></tr><tr><td>NNMR</td><td>42.3</td><td>45.3</td><td>33.7</td><td>36.8</td><td>8.6</td><td>8.4</td><td>0.991</td><td>1.3</td><td>1.2</td><td>NA</td></tr><tr><td>IMR</td><td>88.2</td><td>67.7</td><td>77.9</td><td>67.0</td><td>10.3</td><td>0.7</td><td>0.669</td><td>1.1</td><td>1.0</td><td>NA</td></tr><tr><td>U5MR</td><td>137.6</td><td>78.4</td><td>136.1</td><td>89.7</td><td>1.5</td><td>−11.3</td><td>0.603</td><td>1.0</td><td>0.9</td><td>NA</td></tr><tr><td>Measles vaccination</td><td>53.1</td><td>79.9</td><td>18.7</td><td>47.1</td><td>34.3</td><td>32.8</td><td>0.825</td><td>2.8</td><td>1.7</td><td>0.023</td></tr><tr><td>Full immunization</td><td>34.8</td><td>50.9</td><td>7.2</td><td>17.5</td><td>27.6</td><td>33.4</td><td>0.419</td><td>4.8</td><td>2.9</td><td>0.153</td></tr><tr><td>Contraceptive</td><td>26.1</td><td>57.2</td><td>3.2</td><td>30.9</td><td>23.0</td><td>26.2</td><td>0.538</td><td>8.3</td><td>1.8</td><td>0.000</td></tr><tr><td>ANC4+</td><td>34.8</td><td>60.2</td><td>4.1</td><td>8.6</td><td>30.7</td><td>51.7</td><td>0.000</td><td>8.6</td><td>7.0</td><td>0.481</td></tr><tr><td>SBA</td><td>25.4</td><td>55.6</td><td>0.9</td><td>4.5</td><td>24.5</td><td>51.0</td><td>0.000</td><td>29.6</td><td>12.3</td><td>0.060</td></tr></table> |
cd7e1a4f11c12bb4dadddbff46bd0309363e0b914d6676bbaecfeaa3b89ec3a5.png | complex | <table><tr><td>Item #</td><td>VII. Monitoring, Evaluation, and Information Systems</td><td colspan="2">Burkina Faso</td><td colspan="2">Dominican Republic—national</td><td colspan="2">Dominican Republic—subnational</td><td colspan="2">Ghana</td><td colspan="2">Mali</td><td colspan="2">Total</td></tr><tr><td></td><td></td><td><i>N</i></td><td>Score</td><td><i>N</i></td><td>Score</td><td><i>N</i></td><td>Score</td><td><i>N</i></td><td>Score</td><td><i>N</i></td><td>Score</td><td><i>N</i></td><td>Score</td></tr><tr><td>1.</td><td>Monitoring and evaluation of national HRH plan</td><td>16</td><td>5.1</td><td>22</td><td>4.5</td><td>14</td><td>5.4</td><td>16</td><td>4.8</td><td>22</td><td>5.1</td><td>90</td><td>5.0</td></tr><tr><td>2.</td><td>Monitoring and evaluation implementation capacity</td><td>16</td><td>4.7</td><td>23</td><td>4.8</td><td>15</td><td>5.6</td><td>16</td><td>4.6</td><td>24</td><td>4.4</td><td>94</td><td>4.8</td></tr><tr><td>3.</td><td>Use of data in HRH planning</td><td>18</td><td>5.2</td><td>22</td><td>4.4</td><td>15</td><td>4.6</td><td>16</td><td>4.9</td><td>24</td><td>5.3</td><td>95</td><td>4.9</td></tr><tr><td>4.</td><td>Staffing and employment information system</td><td>19</td><td>4.1</td><td>21</td><td>3.9</td><td>14</td><td>4.2</td><td>16</td><td>5.5</td><td>24</td><td>4.8</td><td>94</td><td>4.5</td></tr><tr><td>5.</td><td>Interoperability</td><td>16</td><td>4.1</td><td>22</td><td>4.4</td><td>12</td><td>4.7</td><td>15</td><td>3.9</td><td>19</td><td>5.1</td><td>84</td><td>4.4</td></tr><tr><td>6.</td><td>National health workforce registry</td><td>15</td><td>4.8</td><td>21</td><td>4.6</td><td>14</td><td>5.4</td><td>15</td><td>5.1</td><td>21</td><td>5.8</td><td>86</td><td>5.1</td></tr><tr><td>7.</td><td>Health worker licensure and registration system</td><td>16</td><td>5.3</td><td>22</td><td>5.0</td><td>15</td><td>6.4</td><td>17</td><td>7.6</td><td>20</td><td>4.6</td><td>90</td><td>5.8</td></tr><tr><td>8.</td><td>Information and communications technology infrastructure and capacity</td><td>18</td><td>3.8</td><td>23</td><td>4.9</td><td>16</td><td>5.8</td><td>18</td><td>4.4</td><td>25</td><td>5.0</td><td>100</td><td>4.8</td></tr><tr><td colspan="2">Average respondents and scores</td><td>17</td><td>4.6</td><td>22</td><td>4.6</td><td>14</td><td>5.3</td><td>16</td><td>5.1</td><td>22</td><td>5.0</td><td>92</td><td>4.9</td></tr></table> |
baf2727aea2f429bb787f7fd8f04fdf62ac0624af6e6bb8fa7789fe6e10f2c83.png | complex | <table><tr><td>Variables</td><td>Results</td></tr><tr><td>Male, n (%)</td><td>20 (48.8)</td></tr><tr><td>Age, years</td><td>49.39 ± 0.82</td></tr><tr><td colspan="2">Position, n (%)</td></tr><tr><td> President of hospital</td><td>1 (2.4)</td></tr><tr><td> Vice president of hospital</td><td>2 (4.9)</td></tr><tr><td> Director of department</td><td>30 (73.2)</td></tr><tr><td> Vice director of department</td><td>7 (17.1)</td></tr><tr><td> No position</td><td>1 (2.4)</td></tr><tr><td colspan="2">Title, n (%)</td></tr><tr><td> Chief physician</td><td>35 (85.4)</td></tr><tr><td> Vice-chief physician</td><td>6 (14.6)</td></tr><tr><td colspan="2">Experience in the clinical work of digestive diseases, n (%)</td></tr><tr><td> >20 years</td><td>33 (80.5)</td></tr><tr><td> 10–20 years</td><td>8 (19.5)</td></tr><tr><td colspan="2">Grade of hospital, n (%)</td></tr><tr><td> Tertiary, class A</td><td>35 (85.4)</td></tr><tr><td> Tertiary, class B</td><td>5 (12.2)</td></tr><tr><td> Second level, class A</td><td>1 (2.4)</td></tr><tr><td colspan="2">Number of beds in the hospital, n (%)</td></tr><tr><td> >1000</td><td>34 (82.9)</td></tr><tr><td> 800–1000</td><td>3 (7.3)</td></tr><tr><td> 500–800</td><td>3 (7.3)</td></tr><tr><td> Others</td><td>1 (2.4)</td></tr><tr><td colspan="2">Number of beds in the Department of Gastroenterology, n (%)</td></tr><tr><td> >120</td><td>8 (19.5)</td></tr><tr><td> 80–120</td><td>10 (24.4)</td></tr><tr><td> 40–80</td><td>15 (36.6)</td></tr><tr><td> Others</td><td>8 (19.5)</td></tr><tr><td colspan="2">Number of patients with liver cirrhosis admitted to the Department of Gastroenterology every year, n (%)</td></tr><tr><td> >200</td><td>19 (46.3)</td></tr><tr><td> 100–200</td><td>9 (22.0)</td></tr><tr><td> 50–100</td><td>13 (31.7)</td></tr><tr><td colspan="2">Number of patients with liver cirrhosis and gastroesophageal varices admitted to the Department of Gastroenterology every year, n (%)</td></tr><tr><td> >200</td><td>15 (36.6)</td></tr><tr><td> 100–200</td><td>7 (17.1)</td></tr><tr><td> 50–100</td><td>16 (39.0)</td></tr><tr><td> Others</td><td>3 (7.3)</td></tr></table> |
172b4243176396b7dc7f2495c767b163b0563512daaff65c85b79f8899b2e62e.png | simple | <table><tr><td>Measure</td><td>Content validity </td><td>Construct validity</td><td>Internal consistency</td><td>Interrater agreement </td><td>Reliability </td><td>Responsiveness</td></tr><tr><td>Cosmesis visual analog scale (VAS)</td><td>?</td><td>?</td><td>?</td><td>?</td><td>?</td><td>?</td></tr><tr><td>Disabilities of the arm, shoulder, and hand questionnaire (DASH)</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Hand function visual analog scale (VAS)</td><td>?</td><td>?</td><td>?</td><td>?</td><td>?</td><td>?</td></tr><tr><td>Hand-specific ADL questionnaire</td><td>?</td><td>0</td><td>0</td><td>?</td><td>?</td><td>?</td></tr><tr><td>Michigan Hand Outcomes Questionnaire (MHQ)</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td></tr><tr><td>Patient Evaluation Measure (PEM)</td><td>0</td><td>+</td><td>+</td><td>0</td><td>+</td><td>+</td></tr><tr><td>Patient-Rated Wrist Evaluation</td><td>+</td><td>+</td><td>+</td><td>0</td><td>+</td><td>+</td></tr><tr><td>Perceived grip strength scale</td><td>?</td><td>?</td><td>?</td><td>?</td><td>?</td><td>?</td></tr><tr><td>Scale of hand-specific activity performance</td><td>?</td><td>?</td><td>?</td><td>?</td><td>?</td><td>?</td></tr></table> |
b667e5c999bbba741432a022d3c6f22a2dd4756fc695d026e783dd0e9eaf3640.png | simple | <table><tr><td>Variable</td><td>Patients (n)</td><td>Number of patients (IMP-Expression) (%)</td><td></td><td></td><td></td><td>p-Value (linear by linear)</td></tr><tr><td></td><td></td><td>0</td><td>1</td><td>2</td><td>3</td><td></td></tr><tr><td>pT-status</td><td></td><td></td><td></td><td></td><td></td><td>0.5</td></tr><tr><td>pT2</td><td>213</td><td>46 (21.6%)</td><td>131 (61.5%)</td><td>34 (16%)</td><td>2 (0.9%)</td><td></td></tr><tr><td>pT3&4</td><td>212</td><td>25 (11.8%)</td><td>163 (76.9%)</td><td>23 (10.8%)</td><td>1 (0.5%)</td><td></td></tr><tr><td>Gleason score</td><td></td><td></td><td></td><td></td><td></td><td>0.048</td></tr><tr><td>5-6</td><td>129</td><td>29 (22.5%)</td><td>85 (65.9%)</td><td>14 (10.9%)</td><td>1 (0.8%)</td><td></td></tr><tr><td>7</td><td>182</td><td>28 (15.4%)</td><td>127 (69.8%)</td><td>26 (14.3%)</td><td>1 (0.5%)</td><td></td></tr><tr><td>8-9</td><td>114</td><td>14 (12.3%)</td><td>82 (71.9%)</td><td>17 (14.9%)</td><td>1 (0.9%)</td><td></td></tr><tr><td>Margin status</td><td></td><td></td><td></td><td></td><td></td><td>0.115</td></tr><tr><td>R0</td><td>262</td><td>54 (20.6%)</td><td>171 (65.3%)</td><td>34 (13%)</td><td>3 (1.1%)</td><td></td></tr><tr><td>R1</td><td>163</td><td>17 (10.4%)</td><td>123 (75.5%)</td><td>23 (14.1%)</td><td>0 (0%)</td><td></td></tr><tr><td>PSA (pre-OP)</td><td></td><td></td><td></td><td></td><td></td><td>0.21</td></tr><tr><td>< 10 ng/ml</td><td>192</td><td>37 (19.3%)</td><td>130 (67.7%)</td><td>24 (12.5%)</td><td>1 (0.5%)</td><td></td></tr><tr><td>≥10 ng/ml</td><td>233</td><td>34 (14.6%)</td><td>164 (70.4%)</td><td>33 (14.2%)</td><td>2 (0.9%)</td><td></td></tr><tr><td>Age</td><td></td><td></td><td></td><td></td><td></td><td>0.693</td></tr><tr><td>≤64 y</td><td>230</td><td>33 (14.3%)</td><td>168 (73%)</td><td>27 (11.7%)</td><td>2 (0.9%)</td><td></td></tr><tr><td>> 64 y</td><td>195</td><td>38 (19.5%)</td><td>126 (64.6%)</td><td>30 (15.4%)</td><td>1 (0.5%)</td><td></td></tr></table> |
ecb9ba1fcab5cb1a9549b26786c0c119d81a4a5e738f8a1014e19ac04ea49603.png | simple | <table><tr><td>NAbs</td><td>OSEs</td><td>Properties/Functions</td></tr><tr><td>T15/E06</td><td>PC head-group of oxidized phosphatidylcholine</td><td>Blockage of OxLDL uptake by macrophages (Horkko et al., 1999; Binder et al., 2003)Binding to OxLDL and apoptotic cells and atherosclerotic lesions (Palinski et al., 1996; Chang et al., 1999, 2004)Inhibition of apoptotic cell/blebs mediated endothelial cell activation resulting in decreased monocyte adhesion (Huber et al., 2002; Chang et al., 2004)Inhibition OxPAPC-induced IL-6 secretion by lung tissue macrophage (Imai et al., 2008)Enhancement of <i>in vivo</i> apoptotic cell clearance in B cell-deficient (μMT) and sIgM<sup>-/-</sup> mice (Ogden et al., 2005; Chen et al., 2009a)Protection from atherosclerosis (Binder et al., 2003; Faria-Neto et al., 2006)Clinical score reduction in collagen induced arthritis (Chen et al., 2009a)</td></tr><tr><td>E014</td><td>Malondialdehyde</td><td>Binding to OxLDL, apoptotic cells, and atherosclerotic lesions (Palinski et al., 1996)Binding to apoptotic and cholesterol induced microvesicles (Huber et al., 2002; Liu et al., 2012)</td></tr><tr><td>NA-17</td><td>Malondialdehyde</td><td>Binding to OxLDL and apoptotic cells (Chou et al., 2009)Enhancement of clearance of apoptotic cells by macrophages in Rag1<sup>-/-</sup> mice <i>in vivo</i> (Chou et al., 2009)</td></tr><tr><td>LR01</td><td>Oxidized cardiolipin</td><td>Binding to OxLDL, apoptotic cells, and atherosclerotic lesions (Tuominen et al., 2006)</td></tr></table> |
c338cbe3b4e8bc3d74875cbfc6f31af3760637ad75cd99e5ebab0134845fbd62.png | simple | <table><tr><td>Prevalence (%) in Control arm</td><td>Reduction in Prevalence due to each intervention (ECF or HH) individually</td><td>Prevalence (%) in ECF or HH arm</td><td>Overall number of communities needed (equally split into 4 arms)</td></tr><tr><td>k = 0.15</td><td></td><td></td><td></td></tr><tr><td>0.6</td><td>30%</td><td>0.42</td><td>24</td></tr><tr><td>0.8</td><td>30%</td><td>0.56</td><td>20</td></tr><tr><td>1.0</td><td>30%</td><td>0.7</td><td>18</td></tr><tr><td>1.0</td><td>20%</td><td>0.8</td><td>41</td></tr><tr><td>1.0</td><td>10%</td><td>0.9</td><td>168</td></tr><tr><td>k = 0.2</td><td></td><td></td><td></td></tr><tr><td>0.6</td><td>30%</td><td>0.42</td><td>30</td></tr><tr><td>0.8</td><td>30%</td><td>0.56</td><td>26</td></tr><tr><td>1.0</td><td>30%</td><td>0.7</td><td>24</td></tr><tr><td>1.0</td><td>20%</td><td>0.8</td><td>54</td></tr><tr><td>1.0</td><td>10%</td><td>0.9</td><td>227</td></tr><tr><td>k = 0.25</td><td></td><td></td><td></td></tr><tr><td>0.6</td><td>30%</td><td>0.42</td><td>45</td></tr><tr><td>0.8</td><td>30%</td><td>0.56</td><td>42</td></tr><tr><td>1.0</td><td>30%</td><td>0.7</td><td>39</td></tr><tr><td>1.0</td><td>20%</td><td>0.8</td><td>93</td></tr><tr><td>1.0</td><td>10%</td><td>0.9</td><td>398</td></tr></table> |
b773b969a6ef9d6daa14bcce250110dd2f0cd7e82d4f5a9e6f0630223e1ca489.png | simple | <table><tr><td>Independent Variables **</td><td>Intercept</td><td>US-Born</td><td>SE</td><td><i>p</i> value</td></tr><tr><td>α-Carotene </td><td>4.59</td><td>−1.03</td><td>0.21</td><td><0.0001</td></tr><tr><td>β-Carotene </td><td>18.13</td><td>−3.27</td><td>0.84</td><td>0.0001</td></tr><tr><td>β-Cryptoxanthin </td><td>17.2</td><td>−3.79</td><td>0.75</td><td><0.0001</td></tr><tr><td>Lutein/zeaxanthin </td><td>21.76</td><td>−3.754</td><td>0.75</td><td><0.0001</td></tr><tr><td>Lycopene</td><td>19.99</td><td>1.15</td><td>0.84</td><td>0.1713</td></tr><tr><td>Vitamin A </td><td>38.66</td><td>−1.59</td><td>0.72</td><td>0.0263</td></tr><tr><td>Vitamin E </td><td>782.36</td><td>−43.15</td><td>12.81</td><td>0.0008</td></tr></table> |
5a9cc02acb964011664f085cdf00dcd083600e612a8401ed371d9f651e3e7408.png | complex | <table><tr><td rowspan="2">Adverse events</td><td colspan="2">All treated patients (<i>n</i> = 42)</td></tr><tr><td>Any grade</td><td>Grade 3–5<sup>a</sup></td></tr><tr><td colspan="3">Skin and subcutaneous tissue disorders</td></tr><tr><td> Pruritus</td><td>6 (14.3)</td><td>0</td></tr><tr><td> Maculopapular rash</td><td>6 (14.3)</td><td>0</td></tr><tr><td> Vitiligo</td><td>3 (7.1)</td><td>0</td></tr><tr><td> Skin hypopigmentation</td><td>2 (4.8)</td><td>0</td></tr><tr><td> Dry skin</td><td>2 (4.8)</td><td>0</td></tr><tr><td colspan="3">General disorders and administration site conditions</td></tr><tr><td> Malaise</td><td>5 (11.9)</td><td>0</td></tr><tr><td colspan="3">Endocrine disorders</td></tr><tr><td> Hypothyroidism</td><td>4 (9.5)</td><td>0</td></tr><tr><td> Hyperthyroidism</td><td>2 (4.8)</td><td>0</td></tr><tr><td> Hypophysitis</td><td>2 (4.8)</td><td>1 (2.4)</td></tr><tr><td colspan="3">Gastrointestinal disorders</td></tr><tr><td> Diarrhea</td><td>3 (7.1)</td><td>0</td></tr><tr><td> Nausea</td><td>2 (4.8)</td><td>0</td></tr><tr><td> Abdominal pain</td><td>2 (4.8)</td><td>0</td></tr><tr><td> Upper abdominal pain</td><td>2 (4.8)</td><td>0</td></tr><tr><td> Colitis</td><td>2 (4.8)</td><td>1 (2.4)</td></tr><tr><td colspan="3">Laboratory results</td></tr><tr><td> Elevated AST</td><td>3 (7.1)</td><td>0</td></tr><tr><td> Elevated eosinophil count</td><td>3 (7.1)</td><td>0</td></tr><tr><td> Elevated ALT</td><td>2 (4.8)</td><td>0</td></tr><tr><td colspan="3">Blood and lymphatic system disorders</td></tr><tr><td> Anemia</td><td>2 (4.8)</td><td>2 (4.8)</td></tr></table> |
164c4dafdf8b26b5c512816bdf3870495e45c5b0b7355d719fde1e35dd705a08.png | simple | <table><tr><td>Probe/Chromosome</td><td><i>S.ita-</i>Y1(c)</td><td>Qing 9(c)</td><td><i>S.adh-</i>W94(c)</td><td><i>S.lac-</i>W74(c)</td><td><i>S.par-</i>W79(c)</td><td><i>S.pal-</i>N193(c)</td><td><i>S.gla-</i>W12(c)</td><td><i>S. are-</i>N196(c)</td><td><i>S. pli-</i>N195(c)</td></tr><tr><td>S. vir-Q24(p)</td><td><i>√</i></td><td><i>×</i></td><td><i>×</i><sup><i>*</i></sup></td><td><i>×</i></td><td><i>×</i></td><td><i>×</i></td><td><i>×</i><sup><i>*</i></sup></td><td><i>×</i></td><td><i>×</i></td></tr><tr><td>S. adh-W94(p)</td><td><i>×</i><sup><i>*</i></sup></td><td><i>√</i></td><td> </td><td><i>×</i></td><td><i>×</i></td><td><i>×</i></td><td><i>×</i><sup><i>*</i></sup></td><td><i>×</i></td><td><i>×</i></td></tr><tr><td>S. gri-W8(p)</td><td><i>×</i><sup><i>*</i></sup></td><td> </td><td><i>×</i><sup><i>*</i></sup></td><td><i>√</i></td><td><i>×</i></td><td><i>×</i></td><td><i>×</i></td><td><i>×</i></td><td><i>×</i></td></tr><tr><td>Qing 9(p)</td><td> </td><td> </td><td><i>√</i></td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>S. gla-W12(p)</td><td> </td><td> </td><td> </td><td> </td><td><i>√</i></td><td><i>×</i></td><td> </td><td><i>×</i></td><td><i>×</i></td></tr><tr><td>S. pli-N195(p)</td><td> </td><td> </td><td> </td><td> </td><td> </td><td><i>√</i></td><td> </td><td><i>×</i></td><td> </td></tr></table> |
e7037d4a0505ba914e98780f820f9dfdfdd01c66de60ee530ae4b8138520b073.png | simple | <table><tr><td>Variables</td><td>No. of patients (<i>n</i> = 74)</td><td>Percentage (%)</td></tr><tr><td>Gender</td><td></td><td></td></tr><tr><td>Male</td><td>32</td><td>43.24</td></tr><tr><td>Female</td><td>42</td><td>56.76</td></tr><tr><td>Age (years)</td><td>54.36 ± 13.13</td><td>-</td></tr><tr><td>Hospital stay (days)</td><td>19.47 ± 10.19</td><td>-</td></tr><tr><td>Clinical presentation</td><td></td><td></td></tr><tr><td>Gastrointestinal hemorrhage</td><td>37</td><td>50.00</td></tr><tr><td>Abdominal pain</td><td>25</td><td>33.78</td></tr><tr><td>Palpable mass</td><td>5</td><td>6.76</td></tr><tr><td>others<sup>a</sup></td><td>7</td><td>9.46</td></tr><tr><td>Tumor location (portion)</td><td></td><td></td></tr><tr><td>First</td><td>17</td><td>22.97</td></tr><tr><td>Second</td><td>35</td><td>47.30</td></tr><tr><td>Third</td><td>12</td><td>16.22</td></tr><tr><td>Forth</td><td>10</td><td>13.51</td></tr><tr><td>Tumor size (cm)</td><td>5.08 ± 2.90</td><td>-</td></tr><tr><td>No. of mitosis</td><td></td><td></td></tr><tr><td>≤5/50 HPF</td><td>41</td><td>55.41</td></tr><tr><td>6–10/50 HPF</td><td>27</td><td>36.49</td></tr><tr><td>>10/50 HPF</td><td>6</td><td>8.10</td></tr><tr><td>Modified NIH risk classification</td><td></td><td></td></tr><tr><td>Low</td><td>32</td><td>43.24</td></tr><tr><td>Intermediate</td><td>8</td><td>10.81</td></tr><tr><td>High</td><td>34</td><td>45.96</td></tr><tr><td>Mutational analysis</td><td></td><td></td></tr><tr><td><i>KIT</i> exon 11</td><td>9</td><td>12.16</td></tr><tr><td><i>KIT</i> exon 9</td><td>3</td><td>4.05</td></tr><tr><td>NA</td><td>62</td><td>83.78</td></tr><tr><td>Preoperative imatinib therapy</td><td>1</td><td>1.35</td></tr><tr><td>Postoperative adjuvant therapy</td><td>16</td><td>21.62</td></tr><tr><td>Patients with emergency visit</td><td>5</td><td>6.76</td></tr><tr><td>Patients with metastases at diagnosis</td><td>2</td><td>2.70</td></tr><tr><td>Tumor recurrence or metastasis</td><td>19</td><td>25.68</td></tr><tr><td>Death case</td><td>14</td><td>18.92</td></tr></table> |
44321f3c4174eff0a7e91b4f305e33fd52ac8c479540304dbcd6101960a40a4d.png | complex | <table><tr><td></td><td>Placebo</td><td>1-day</td><td>3-day</td><td>7-day</td></tr><tr><td>Number of subjects</td><td>26</td><td>26</td><td>27</td><td>27</td></tr><tr><td>Age (years)*</td><td>41.0 ± 2.2</td><td>41.9 ± 2.2</td><td>38.5 ± 1.7</td><td>36.5 ± 1.4</td></tr><tr><td colspan="5">Gender</td></tr><tr><td> Male</td><td>9</td><td>6</td><td>14</td><td>16</td></tr><tr><td> Female</td><td>17</td><td>20</td><td>13</td><td>11</td></tr><tr><td>Duration of SAR (years)*</td><td>13.4 ± 1.3</td><td>19.3 ± 1.8</td><td>16.8 ± 1.7</td><td>17.5 ± 1.6</td></tr><tr><td>Specific IgE titer*</td><td>3.77 ± 0.19</td><td>3.88 ± 0.19</td><td>3.70 ± 0.12</td><td>3.56 ± 0.18</td></tr><tr><td>TNSS in screening*</td><td>0.05 ± 0.03</td><td>0.10 ± 0.04</td><td>0.11 ± 0.05</td><td>0.14 ± 0.04</td></tr></table> |
818769e98e97e199ab44182f89a4ade6cc9587df0ed36297988c6ab6c85a54ed.png | complex | <table><tr><td colspan="2"></td><td>YoudenCut-off</td><td>Sensitivity (%)</td><td>Specificity (%)</td><td>AUC</td><td>95% CI</td><td><i>P</i>-value</td></tr><tr><td rowspan="4"><i>Rest</i></td><td>GLS (%)</td><td>>−18.55</td><td> 77.27</td><td>68.18</td><td>0.72</td><td>0.56–0.87</td><td> 0.006</td></tr><tr><td>GLSR (s<sup>−1</sup>)</td><td>>−91.09</td><td> 68.18</td><td>72.73</td><td>0.75</td><td>0.60–0.89</td><td> 0.0008</td></tr><tr><td>E’ (s<sup>−1</sup>)</td><td>≤84.53</td><td> 86.36</td><td>54.55</td><td>0.70</td><td>0.54–0.86</td><td> 0.01</td></tr><tr><td>A’ (s<sup>−1</sup>)</td><td>≤108.86</td><td>100</td><td>32</td><td>0.59</td><td>0.42–0.77</td><td> 0.28</td></tr><tr><td rowspan="4"><i>Stress</i></td><td>GLS (%)</td><td>>−19.80</td><td> 77.3</td><td>72.7</td><td>0.82</td><td>0.70–0.94</td><td><0.001</td></tr><tr><td>GLSR (s<sup>−1</sup>)</td><td>>−99.7</td><td> 63.6</td><td>86.4</td><td>0.74</td><td>0.58–0.89</td><td> 0.003</td></tr><tr><td>E’ (s<sup>−1</sup>)</td><td>≤81.65</td><td> 50</td><td>82</td><td>0.67</td><td>0.50–0.83</td><td> 0.04</td></tr><tr><td>A’ (s<sup>−1</sup>)</td><td>≤58.65</td><td> 36.36</td><td>86.36</td><td>0.58</td><td>0.41–0.76</td><td> 0.34</td></tr><tr><td colspan="2"><i>Strain model</i><sup>a</sup></td><td>28%</td><td> 96</td><td>68</td><td>0.87</td><td>0.76–0.97</td><td><0.0001</td></tr></table> |
4efc6635768fa1a0e25674ceb66a8b3584515dde1d494ec230c279c0fb09841b.png | simple | <table><tr><td>Morbidity</td><td>Measuring instrument</td><td>Data source</td></tr><tr><td>Diagnoses</td><td>ICD-10 codes</td><td>chart review</td></tr><tr><td>Diseases</td><td>self-developed questionnaire</td><td>GP interview</td></tr><tr><td></td><td>self-developed questionnaire</td><td>patient interview</td></tr><tr><td></td><td>Four-Dimensional Symptom Questionnaire (4DSQ) [11]</td><td>patient interview</td></tr><tr><td></td><td>Geriatric Depression Scale (GDS) [12]</td><td>patient interview</td></tr><tr><td></td><td>Clinical Dementia Rating (CDR) [13]</td><td>rated by interviewer</td></tr><tr><td>Functional Status</td><td></td><td></td></tr><tr><td>Activities of daily living</td><td>Barthel Index [22]</td><td>patient interview</td></tr><tr><td></td><td>Instrumental Activities of Daily Living (IADL) Scale [23]</td><td>patient interview</td></tr><tr><td>Motor skills</td><td>FFB-Mot [24]</td><td>patient interview</td></tr><tr><td>Vision and hearing</td><td>2 items rated on a 4 point scale</td><td>patient interview</td></tr><tr><td>Cognitive impairment</td><td>CERAD [25] subtests word list and animal naming</td><td>cognitive tests by interviewer</td></tr><tr><td></td><td>Letter Digit Substitution Test (LDST) [26]</td><td>cognitive tests by interviewer</td></tr><tr><td>Pain</td><td>Graded Chronic Pain Scale (GCPS) [27]</td><td>patient interview</td></tr><tr><td>Health-related quality of life</td><td>EuroQoL (EQ-5D) Scale [28]</td><td>patient interview</td></tr><tr><td>Resources/Risk Factors</td><td></td><td></td></tr><tr><td>Physical risk factors</td><td>Body-Mass-Index and Waist-to-Hip-Ratio</td><td>physical checkup by GP</td></tr><tr><td>Physical activity</td><td>International Physical Activities Questionnaire (IPAQ) [29]</td><td>patient interview</td></tr><tr><td>Nutrition</td><td>12 items for frequency and portion size of nutriments</td><td>patient interview</td></tr><tr><td>Alcohol use</td><td>AUDIT-C [30]</td><td>patient interview</td></tr><tr><td></td><td>total amount of alcohol consumption per week</td><td>patient interview</td></tr><tr><td>Smoking behavior</td><td>9 items indicating current smoking status and pack years</td><td>patient interview</td></tr><tr><td>General self-efficacy</td><td>General Self-efficacy Scale [31]</td><td>patient interview</td></tr><tr><td>Social support</td><td>F-SOZU K14 [32]</td><td>patient interview</td></tr><tr><td>Medical care</td><td>Patient Assessment of Chronic Illness Care (PACIC) [33]</td><td>patient interview at baseline</td></tr><tr><td></td><td>age and gender of GP/size and location of surgery</td><td>GP interview</td></tr><tr><td>Utilization of medical services (incl. medication)</td><td>15 items (short form), respectively 91 items (long form)</td><td>patient interview</td></tr><tr><td>Sociodemographic Data</td><td></td><td></td></tr><tr><td>Age and gender</td><td>age and gender</td><td>chart review</td></tr><tr><td>Migrant status</td><td>standardised indicators for mapping migrant status [34]</td><td>patient interview at baseline</td></tr><tr><td>Marital status</td><td>marital status</td><td>patient interview</td></tr><tr><td>Living conditions</td><td>independent or assisted living</td><td>patient interview</td></tr><tr><td>Household size</td><td>household size/household members under 15 years</td><td>patient interview</td></tr><tr><td>Education</td><td>CASMIN classification [35]</td><td>patient interview at baseline</td></tr><tr><td>Former occupation</td><td>German epidemiological standard questionnaire [36]</td><td>patient interview at baseline</td></tr><tr><td>Income</td><td>household size adjusted net income</td><td>patient interview</td></tr><tr><td>Wealth</td><td>home ownership</td><td>patient interview</td></tr></table> |
5de66913410bae57fe4f63c9d0bf1109faf8b37e3dab60672bc3ccf5a270789e.png | complex | <table><tr><td> </td><td><i>ß</i></td><td>SE (<i>ß</i>)</td><td>Stand. <i>ß</i></td><td>T</td><td><i>p</i></td></tr><tr><td colspan="6">Annual fastest men</td></tr><tr><td>6 hrs</td><td>0.015</td><td>0.130</td><td>0.023</td><td>0.114</td><td>0.910</td></tr><tr><td>12 hrs</td><td>-0.023</td><td>0.155</td><td>-0.029</td><td>-0.151</td><td>0.881</td></tr><tr><td>24 hrs</td><td>0.193</td><td>0.118</td><td>0.275</td><td>1.642</td><td>0.110</td></tr><tr><td>48 hrs</td><td>0.184</td><td>0.147</td><td>0.229</td><td>1.248</td><td>0.223</td></tr><tr><td>72 hrs</td><td>0.084</td><td>0.222</td><td>0.084</td><td>0.377</td><td>0.710</td></tr><tr><td>6 d</td><td>0.039</td><td>0.154</td><td>0.047</td><td>0.252</td><td>0.803</td></tr><tr><td>10 d</td><td>0.296</td><td>0.432</td><td>0.194</td><td>0.686</td><td>0.506</td></tr><tr><td colspan="6">Annual fastest women</td></tr><tr><td>6 hrs</td><td>0.033</td><td>0.182</td><td>0.041</td><td>0.183</td><td>0.856</td></tr><tr><td>12 hrs</td><td>0.330</td><td>0.126</td><td>0.450</td><td>2.617</td><td>0.014*</td></tr><tr><td>24 hrs</td><td>-0.058</td><td>0.124</td><td>-0.086</td><td>-0.465</td><td>0.645</td></tr><tr><td>48 hrs</td><td>0.249</td><td>0.140</td><td>0.318</td><td>1.775</td><td>0.087</td></tr><tr><td>72 hrs</td><td>0.136</td><td>0.316</td><td>0.107</td><td>0.430</td><td>0.673</td></tr><tr><td>6 d</td><td>0.385</td><td>0.083</td><td>0.666</td><td>4.640</td><td><0.0001*</td></tr><tr><td>10 d</td><td>-0.067</td><td>0.401</td><td>-0.048</td><td>-0.166</td><td>0.871</td></tr></table> |
b0dfc63442099e9d3b64b45d64e75ac7fea4d2b5b98009c960dceb4404268ddd.png | complex | <table><tr><td></td><td>Male</td><td>Female</td><td>Age < 55 years</td><td>Age ≥ 55 years</td><td>OA</td><td>RA</td><td>THR</td><td>TKR</td></tr><tr><td colspan="9">Core domains</td></tr><tr><td rowspan="2"> Joint pain</td><td>8 (7–9)</td><td>9 (8–9)</td><td>9 (7–9)</td><td>9 (8–9)</td><td>9 (8–9)</td><td>9 (7–9)</td><td>9 (8–9)</td><td>9 (7–9)</td></tr><tr><td colspan="2">***</td><td colspan="2"></td><td colspan="2"></td><td colspan="2">**</td></tr><tr><td rowspan="2"> Function</td><td>9 (8–9)</td><td>9 (8–9)</td><td>9 (8–9)</td><td>9 (8–9)</td><td>9 (8–9)</td><td>9 (8–9)</td><td>9 (8–9)</td><td>9 (8–9)</td></tr><tr><td colspan="2">***</td><td colspan="2">*</td><td colspan="2">*</td><td colspan="2"></td></tr><tr><td rowspan="2"> Patient satisfaction</td><td>8 (8–9)</td><td>9 (8–9)</td><td>9 (8–9)</td><td>9 (8–9)</td><td>9 (8–9)</td><td>8 (8–9)</td><td>9 (8–9)</td><td>8 (8–9)</td></tr><tr><td colspan="2">***</td><td colspan="2"></td><td colspan="2"></td><td colspan="2">***</td></tr><tr><td rowspan="2"> Revision surgery</td><td>7 (4–9)</td><td>8 (5–9)</td><td>7 (5–9)</td><td>8 (5–9)</td><td>8 (5–9)</td><td>7 (5–9)</td><td>8 (5–9)</td><td>7 (5–9)</td></tr><tr><td colspan="2">***</td><td colspan="2"></td><td colspan="2"></td><td colspan="2"></td></tr><tr><td rowspan="2"> Adverse events</td><td>8 (6–9)</td><td>9 (7–9)</td><td>8 (7–9)</td><td>8 (7–9)</td><td>8 (7–9)</td><td>8 (5–9)</td><td>8 (7–9)</td><td>8 (6–9)</td></tr><tr><td colspan="2">***</td><td colspan="2"></td><td colspan="2"></td><td colspan="2"></td></tr><tr><td rowspan="2"> Death</td><td>9 (5–9)</td><td>9 (6–9)</td><td>9 (6–9)</td><td>9 (6–9)</td><td>9 (6–9)</td><td>8 (6–9)</td><td>9 (7–9)</td><td>9 (5–9)</td></tr><tr><td colspan="2">***</td><td colspan="2"></td><td colspan="2"></td><td colspan="2">*</td></tr><tr><td>Additional domains</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td rowspan="2"> Cost</td><td>7 (5–8)</td><td>7 (5–9)</td><td>7 (5–8)</td><td>7 (5–8)</td><td>7 (5–8)</td><td>7 (5–9)</td><td>7 (5–8)</td><td>7 (5–8)</td></tr><tr><td colspan="2">***</td><td colspan="2">*</td><td colspan="2"></td><td colspan="2"></td></tr><tr><td rowspan="2"> Patient participation</td><td>7 (6–9)</td><td>8 (7–9)</td><td>8 (6–9)</td><td>8 (6–9)</td><td>8 (6–9)</td><td>8 (7–9)</td><td>8 (6–9)</td><td>8 (6–9)</td></tr><tr><td colspan="2">***</td><td colspan="2"></td><td colspan="2"></td><td colspan="2"></td></tr></table> |
bdf887bfe36d2c5bc4b14afe78250c315964cf0f80af4ba3879cfc3a35c925b2.png | complex | <table><tr><td></td><td>No. households without bed nets (%, 95 % CI)</td><td>No. households with untreated bed nets (%, 95 % CI)</td><td>No. households with expired ITNs/LLINs (%, 95 % CI)</td><td>No. households with ITNs/LLINs (%, 95 % CI)</td></tr><tr><td colspan="5">Sex of household head</td></tr><tr><td>Male (<i>n</i> = 144)</td><td>1 (0.7, 0–3.8)</td><td>59 (41, 32.9–49.5)</td><td>36 (25, 18.2-32.9)</td><td>126 (87.5, 81–92.4)</td></tr><tr><td>Female (<i>n</i> = 524)</td><td>1 (0.2, 0–1.1)</td><td>185 (35.3, 31.2–39.6)</td><td>20 (3.8, 2.3–5.8)</td><td>477 (91, 88.3–93.3)</td></tr><tr><td><i>x</i><sup>2</sup> value</td><td>-</td><td>1.56</td><td>66.0</td><td>1.60</td></tr><tr><td>P-value</td><td>-</td><td>0.2110</td><td><0.0001</td><td>0.2054</td></tr><tr><td colspan="5">Age of household head (years)</td></tr><tr><td><35 (<i>n</i> = 233)</td><td>0 (0, 0–1.6)</td><td>89 (38.2, 31.9–44.8)</td><td>34 (14.6, 10.3–19.8)</td><td>208 (89.3, 84.6–92.9)</td></tr><tr><td>≥35 (<i>n</i> = 435)</td><td>2 (0.5, 0.06–1.7)</td><td>155 (35.6, 31.1–40.3)</td><td>22 (5.1, 3.2–7.6)</td><td>395 (90.8, 87.7–93.3)</td></tr><tr><td><i>x</i><sup>2</sup> value</td><td>-</td><td>0.43</td><td>17.96</td><td>0.41</td></tr><tr><td>P-value</td><td>-</td><td>0.5117</td><td>0.00002</td><td>0.5237</td></tr><tr><td colspan="5">Ethnics</td></tr><tr><td>Kachin (<i>n</i> = 610)</td><td>2 (0.3, 0.04–1.2)</td><td>303 (49.7, 45.6–53.7)</td><td>54 (8.9, 6.7–11.4)</td><td>556 (91.1, 88.6–93.3)</td></tr><tr><td>Others<sup>a</sup> (<i>n</i> = 58)</td><td>0 (0, 0–6.1)</td><td>24 (41.4, 28.6–55.1)</td><td>2 (3.4, 0.4–11.9)</td><td>47 (81.0, 68.6–90.1)</td></tr><tr><td><i>x</i><sup>2</sup> value</td><td>-</td><td>1.46</td><td>1.37</td><td>6.17</td></tr><tr><td>P-value</td><td>-</td><td>0.2273</td><td>0.2415</td><td>0.0130</td></tr><tr><td colspan="5">School education years</td></tr><tr><td>Illiterate (<i>n</i> = 144)</td><td>0 (0, 0–2.5)</td><td>52 (36.1, 28.3–44.5)</td><td>1 (0.7, 0–3.8)</td><td>126 (87.5, 81–92.4)</td></tr><tr><td>1–3y (<i>n</i> = 129)</td><td>1 (0.8, 0.02–4.2)</td><td>49 (38, 29.6–46.9)</td><td>2 (1.6, 0.2–5.5)</td><td>120 (93, 87.2–96.8)</td></tr><tr><td>4–6y (<i>n</i> = 225)</td><td>0 (0, 0–1.6)</td><td>75 (33.3, 27.2–39.9)</td><td>40 (17.8, 13–23.4)</td><td>216 (96, 92.5–98.2)</td></tr><tr><td>7–9y (<i>n</i> = 117)</td><td>1 (0.9, 0.02–4.7)</td><td>42 (35.9, 27.2–45.3)</td><td>13 (11.1, 16.1–18.3)</td><td>106 (90.6, 83.8–95.2)</td></tr><tr><td>≥10y (<i>n</i> = 53)</td><td>0 (0, 0–6.7)</td><td>26 (49.1, 35.1-63.2)</td><td>0 (0, 0–6.7)</td><td>35 (66, 51.7–78.5)</td></tr><tr><td><i>x</i><sup>2</sup> value</td><td>3.45</td><td>4.73</td><td>50.76</td><td>46.23</td></tr><tr><td><i>P</i>-value</td><td>0.4849</td><td>0.3164</td><td><0.0001</td><td><0.0001</td></tr><tr><td colspan="5">Family wealth index</td></tr><tr><td>1 Most poor (<i>n</i> = 498)</td><td>1 (0.2, 0–1.1)</td><td>175 (35.1, 30.9–39.5)</td><td>28 (5.6, 3.8–8)</td><td>467 (93.8, 91.3–95.7)</td></tr><tr><td>2 (<i>n</i> = 116)</td><td>0 (0, 0–3.1)</td><td>51 (44, 34.8–53.5)</td><td>27 (23.3, 15.9–32)</td><td>113 (97.4, 92.6–99.5)</td></tr><tr><td>3 (<i>n</i> = 24)</td><td>1 (4.2, 0.1–21.1)</td><td>10 (41.7, 22.1–64.4)</td><td>1 (4.2, 0.1–21.1)</td><td>17 (70.8, 48.9–87.4)</td></tr><tr><td>4 (<i>n</i> = 10)</td><td>0 (0, 0–60.2)</td><td>8 (80, 44.4–97.4)</td><td>0 (0, 0–60.2)</td><td>6 (60, 26.2–87.8)</td></tr><tr><td>5 Least poor (<i>n</i> = 0)</td><td>0</td><td>0</td><td>0</td><td>0</td></tr><tr><td><i>x</i><sup>2</sup> value</td><td>12.19</td><td>11.11</td><td>38.77</td><td>39.06</td></tr><tr><td><i>P</i>-value</td><td>0.0068</td><td>0.0111</td><td><0.0001</td><td><0.0001</td></tr><tr><td colspan="5">Geographical zone</td></tr><tr><td>Lowland (<i>n</i> = 226)</td><td>0 (0, 0–1.6)</td><td>102 (45.1, 38.5–51.9)</td><td>6 (2.7, 1.0–5.7)</td><td>202 (89.4, 84.6–93.1)</td></tr><tr><td>Foothill (<i>n</i> = 299)</td><td>0 (0, 0–1.2)</td><td>94 (31.4, 26.2–37.0)</td><td>11 (3.7, 1.9–6.5)</td><td>262 (87.6, 83.3–91.1)</td></tr><tr><td>Mid hill (<i>n</i> = 18)</td><td>1 (5.6, 0.1–27.3)</td><td>6 (33.3, 13.3–59.0)</td><td>8 (44.4, 21.5–69.2)</td><td>18 (100.0, 81.5–100.0)</td></tr><tr><td>Upper hill (<i>n</i> = 125)</td><td>1 (0.8, 0.02–4.4)</td><td>42 (33.6, 25.4–42.6)</td><td>31 (24.8, 17.5–33.3)</td><td>121 (96.8, 92.1–99.2)</td></tr><tr><td><i>x</i><sup>2</sup> value</td><td>19.29</td><td>11.10</td><td>92.01</td><td>10.59</td></tr><tr><td><i>P</i>-value</td><td>0.0002</td><td>0.0112</td><td><0.0001</td><td>0.0141</td></tr><tr><td>Total (<i>n</i> = 668)</td><td>2 (0.3, 0.04–1.1)</td><td>244 (36.5, 32.9–40.3)</td><td>56 (8.4, 6.4–10.7)</td><td>603 (90.2, 87.8–92.4)</td></tr></table> |
f3f517c724cdececaae0503ca060fb92607a558206a57b263bf5b2622c78487c.png | complex | <table><tr><td rowspan="2">Noise receiving point</td><td colspan="4">Noise at boundary of substation</td></tr><tr><td>Plan A</td><td>Plan B</td><td>Plan C</td><td>Plan D</td></tr><tr><td>Point 1</td><td>62.1</td><td>62</td><td>48.5</td><td>47</td></tr><tr><td>Point 2</td><td>57.5</td><td>53.5</td><td>55.5</td><td>41.9</td></tr><tr><td>Point 3</td><td>54.1</td><td>52.7</td><td>49</td><td>38.8</td></tr><tr><td>Point 4</td><td>56.1</td><td>55.9</td><td>45.1</td><td>41.1</td></tr><tr><td>Point 5</td><td>52.2</td><td>51.9</td><td>41.5</td><td>37.2</td></tr><tr><td>Point 6</td><td>51.7</td><td>51.5</td><td>40.3</td><td>36.7</td></tr><tr><td>Point 7</td><td>55.3</td><td>55.3</td><td>41</td><td>40.3</td></tr><tr><td>Point 8</td><td>55.7</td><td>55.5</td><td>45.3</td><td>40.7</td></tr><tr><td>Point 9</td><td>54</td><td>53.1</td><td>47.4</td><td>38.8</td></tr><tr><td>Point 10</td><td>53.8</td><td>48.9</td><td>52.4</td><td>38.2</td></tr><tr><td>Point 11</td><td>53.8</td><td>48.8</td><td>52.3</td><td>38.1</td></tr><tr><td>Point 12</td><td>52.3</td><td>52.1</td><td>40.4</td><td>37.2</td></tr><tr><td>Point 13</td><td>53.6</td><td>53.4</td><td>43.2</td><td>38.6</td></tr><tr><td>Point 14</td><td>51.3</td><td>51</td><td>40.2</td><td>36.2</td></tr><tr><td>Point 15</td><td>50.9</td><td>50.8</td><td>38.7</td><td>35.9</td></tr><tr><td>Point 16</td><td>52.4</td><td>52.4</td><td>38.6</td><td>37.4</td></tr></table> |
a402f2e4d94ac6cedf0c439d357655ff2294c80b1defa7687d717592816c0e28.png | complex | <table><tr><td>Characteristics</td><td>Awareness (n)</td><td><i>x</i><sup>2</sup></td><td><i>P</i> – value</td><td>Percentage %</td></tr><tr><td colspan="5">Sex</td></tr><tr><td>Male</td><td>51</td><td>1.03</td><td>0.31</td><td>43.2</td></tr><tr><td>Female</td><td>67</td><td></td><td></td><td>56.8</td></tr><tr><td colspan="5">Age</td></tr><tr><td>18–29</td><td>8</td><td></td><td></td><td>6.8</td></tr><tr><td>30–39</td><td>22</td><td></td><td></td><td>18.6</td></tr><tr><td>40–49</td><td>42</td><td>31.58</td><td><i>p</i> < 0.0001</td><td>35.6</td></tr><tr><td>50–59</td><td>20</td><td></td><td></td><td>16.9</td></tr><tr><td>60–69</td><td>10</td><td></td><td></td><td>22.0</td></tr><tr><td>Total</td><td>118</td><td></td><td></td><td>100</td></tr><tr><td colspan="5"> Religious affiliation</td></tr><tr><td>Christian</td><td>109</td><td></td><td></td><td>92.4</td></tr><tr><td>Muslim</td><td>9</td><td>0.12</td><td>0.73</td><td>7.6</td></tr><tr><td>Total</td><td>118</td><td></td><td></td><td>100</td></tr><tr><td colspan="5"> Educational status</td></tr><tr><td>None</td><td>21</td><td></td><td></td><td>17.8</td></tr><tr><td>Primary</td><td>35</td><td></td><td></td><td>29.7</td></tr><tr><td>Junior High School</td><td>50</td><td>20.37</td><td><i>p</i> < 0.0001</td><td>42.4</td></tr><tr><td>Senior High School</td><td>10</td><td></td><td></td><td>8.5</td></tr><tr><td>Tertiary level</td><td>2</td><td></td><td></td><td>1.7</td></tr><tr><td>Total</td><td>118</td><td></td><td></td><td>100</td></tr></table> |
ee310a1e0eaf6bbd1cd24a6b01fcd94b345e1f955ad9ead7775b3acf4b6e56de.png | simple | <table><tr><td>Causes of death<sup>a</sup></td><td>All patients (<i>n</i> = 345)</td><td>Patients with primary GF (<i>n</i> = 22)</td><td>Patients without primary GF (<i>n</i> = 323)</td></tr><tr><td>Relapse</td><td>18 (5.2 %)</td><td>1 (4.5 %)</td><td>17 (5.3 %)</td></tr><tr><td>Infections</td><td>27 (7.8 %)</td><td>8 (36.4 %)</td><td>19 (5.9 %)</td></tr><tr><td>Hemorrhage</td><td>7 (2.0 %)</td><td>3 (13.6 %)</td><td>4 (1.2 %)</td></tr><tr><td>GVHD</td><td>3 (0.9 %)</td><td>0 (0 %)</td><td>3 (0.9 %)</td></tr><tr><td>Others</td><td>8 (2.4 %)</td><td>1 (4.5 %)</td><td>7 (2.1 %)</td></tr></table> |
3efc27033fd45c7a61cd6bc1dd4d5dc0f556f95547d510ca6de0bb2300120557.png | simple | <table><tr><td>Primer (F: forward, R: reverse)</td><td>Sequence (5′–3′)</td><td>Product size (base pairs)</td><td>Description</td></tr><tr><td><i>fimA</i>-F</td><td>CTAAATCCGCCGATCAAA</td><td>193</td><td>Type-1 fimbrial gene</td></tr><tr><td><i>fimA</i>-R</td><td>GAGGAGACAGCCAGCAAA</td><td>193</td><td>Type-1 fimbrial gene</td></tr><tr><td><i>fimZ</i>-F</td><td>GACGAACACCCTATTGTAAGA</td><td>202</td><td>Type-1 fimbrial gene</td></tr><tr><td><i>fimZ</i>-R</td><td>GTTCCTGGATAGATTTGATTC</td><td>202</td><td>Type-1 fimbrial gene</td></tr><tr><td><i>flhD</i>-F</td><td>GCATACATCCGAGTTGCTAA</td><td>237</td><td>Flagellar gene</td></tr><tr><td><i>flhD</i>-R</td><td>TGAGTCAAACGGGTGATC</td><td>237</td><td>Flagellar gene</td></tr><tr><td><i>fliZ</i>-F</td><td>GGAATATGTCGTGCGTTTA</td><td>221</td><td>Flagellar gene</td></tr><tr><td><i>fliZ</i>-R</td><td>TATCAGAACTGGCGGTAAA</td><td>221</td><td>Flagellar gene</td></tr><tr><td><i>invF</i>-F</td><td>TGAGAATGCTGGGAGAAGAC</td><td>194</td><td>SPI-1 gene</td></tr><tr><td><i>invF</i>-R</td><td>AAAATGTGAAGGCGATGAGT</td><td>194</td><td>SPI-1 gene</td></tr><tr><td><i>sseB</i>-F</td><td>AACGTGCCAGAAATACCCAG</td><td>199</td><td>SPI-2 gene</td></tr><tr><td><i>sseB</i>-R</td><td>CCTTTATCCAGCTTCCCATG</td><td>199</td><td>SPI-2 gene</td></tr><tr><td>16S-F</td><td>TTCCTCCAGATCTCTACGCA</td><td>552</td><td>Housekeeping gene 16S</td></tr><tr><td>16S-R</td><td>GTGGCTAATACCGCATAACG</td><td>552</td><td>Housekeeping gene 16S</td></tr></table> |
438d14b914035d9483b8e35a0508a7ccd54a73c41ca158cb5b449acd4ee52e0a.png | simple | <table><tr><td>Stages</td><td>R1</td><td>R2</td><td>R3</td><td>R4</td><td>R5</td><td>R6</td><td>R7</td></tr><tr><td>Pre-processing of each view (normal calculation, format conversion, <i>etc.</i>)</td><td>5 m</td><td>4m30s</td><td>4m</td><td>3m30s</td><td>3m</td><td>2m30s</td><td>2m</td></tr><tr><td>Definition of the ortho-image from the 3D model</td><td>2m</td><td>1m47s</td><td>1m35s</td><td>1m23s</td><td>1m13s</td><td>1m2s</td><td>45s</td></tr><tr><td>Definition of corresponding pairs between the model and the external image</td><td>3m</td><td>3m10s</td><td>3m20s</td><td>3m30s</td><td>3m45s</td><td>4m5s</td><td>5m</td></tr><tr><td>New colour modification/assignation</td><td>1m</td><td>56s</td><td>50s</td><td>43s</td><td>35s</td><td>31s</td><td>23s</td></tr><tr><td>Filling of colour-holes</td><td>10m</td><td>9m6s</td><td>8m10s</td><td>7m15s</td><td>6m25s</td><td>5m30s</td><td>4m</td></tr><tr><td>Merging of colour with the whole coloured model</td><td>3m</td><td>2m40s</td><td>2m20s</td><td>2m</td><td>1m49s</td><td>1m36s</td><td>1m10s</td></tr></table> |
498d670cac0fbbf83572f683577407b28f1b148118ec835224e83f8b4c415b46.png | complex | <table><tr><td colspan="3">Virus</td><td colspan="4">EV71</td><td colspan="4">CV-A16</td><td colspan="4">CV-A6</td><td colspan="4">EV71and CV-A16 co-infection</td><td colspan="4">Untyped EV</td></tr><tr><td colspan="2"></td><td>V-P</td><td>P</td><td>Cons ratio (%)</td><td>M</td><td>F</td><td>P</td><td>Cons ratio (%)</td><td>M</td><td>F</td><td>P</td><td>Cons ratio (%)</td><td>M</td><td>F</td><td>P</td><td>Cons ratio (%)</td><td>M</td><td>F</td><td>P</td><td>Cons ratio (%)</td><td>M</td><td>F</td></tr><tr><td rowspan="7">Age year</td><td>0-</td><td>219</td><td>69</td><td>5.39</td><td>43</td><td>26</td><td>46</td><td>4.24</td><td>33</td><td>13</td><td>39</td><td>7.47</td><td>28</td><td>11</td><td>7</td><td>8.54</td><td>5</td><td>2</td><td>58</td><td>10.07</td><td>34</td><td>24</td></tr><tr><td>1-</td><td>718</td><td>264</td><td>20.61</td><td>176</td><td>88</td><td>150</td><td>13.81</td><td>95</td><td>55</td><td>173</td><td>33.14</td><td>103</td><td>70</td><td>17</td><td>20.73</td><td>9</td><td>8</td><td>114</td><td>19.79</td><td>75</td><td>39</td></tr><tr><td>2-</td><td>714</td><td>270</td><td>21.08</td><td>173</td><td>97</td><td>208</td><td>19.15</td><td>123</td><td>85</td><td>115</td><td>22.03</td><td>70</td><td>45</td><td>19</td><td>23.17</td><td>13</td><td>6</td><td>102</td><td>17.71</td><td>59</td><td>43</td></tr><tr><td>3-</td><td>1063</td><td>376</td><td>29.35</td><td>245</td><td>131</td><td>376</td><td>34.62</td><td>229</td><td>147</td><td>117</td><td>22.41</td><td>74</td><td>43</td><td>27</td><td>32.93</td><td>15</td><td>12</td><td>167</td><td>28.99</td><td>101</td><td>66</td></tr><tr><td>4-</td><td>504</td><td>177</td><td>13.82</td><td>113</td><td>64</td><td>192</td><td>17.68</td><td>127</td><td>65</td><td>48</td><td>9.20</td><td>33</td><td>15</td><td>9</td><td>10.98</td><td>7</td><td>2</td><td>78</td><td>13.54</td><td>41</td><td>37</td></tr><tr><td>5-</td><td>163</td><td>64</td><td>5.00</td><td>37</td><td>27</td><td>61</td><td>5.62</td><td>40</td><td>21</td><td>13</td><td>2.49</td><td>11</td><td>2</td><td>1</td><td>1.22</td><td>0</td><td>1</td><td>24</td><td>4.17</td><td>15</td><td>9</td></tr><tr><td>≥6</td><td>166</td><td>61</td><td>4.76</td><td>33</td><td>28</td><td>53</td><td>4.88</td><td>30</td><td>23</td><td>17</td><td>3.26</td><td>11</td><td>6</td><td>2</td><td>2.44</td><td>0</td><td>2</td><td>33</td><td>5.73</td><td>23</td><td>10</td></tr><tr><td colspan="2">Total</td><td>3547</td><td>1281</td><td>36.12</td><td>820</td><td>461</td><td>1086</td><td>30.62</td><td>677</td><td>409</td><td>522</td><td>14.72</td><td>330</td><td>192</td><td>82</td><td>2.31</td><td>49</td><td>33</td><td>576</td><td>16.24</td><td>348</td><td>228</td></tr><tr><td colspan="3">Ratio (M/F)</td><td colspan="4">1.78</td><td colspan="4">1.66</td><td colspan="4">1.72</td><td colspan="4">1.48</td><td colspan="4">1.53</td></tr></table> |
55b56829ff9bbf305bac187e4a3621f682f0f1afa20008438f3237458e54a5d0.png | simple | <table><tr><td>Allocation concealment methods</td><td>Number of trials (%)</td></tr><tr><td>Unclear/not reported</td><td>282 (71.76)</td></tr><tr><td>Central concealment</td><td>21 (5.34)</td></tr><tr><td>Sequentially numbered, opaque and sealed envelopes</td><td>24 (6.11)</td></tr><tr><td>Unsafe envelopes</td><td>15 (3.82)</td></tr><tr><td>Non-safe methods of allocation</td><td>51 (12.98)</td></tr><tr><td>Total</td><td>393 (100)</td></tr></table> |
2c17a935972f805fa3a4e42856dc3beda4411578a2c667dcb919552ae6dff34e.png | complex | <table><tr><td>Caffeine source</td><td colspan="3">Birth weight (Marsal)</td><td colspan="3">Birth weight (Skjaerven)</td><td colspan="3">Birth weight (Gardosi)</td></tr><tr><td></td><td>β (g)</td><td>95% CI</td><td><i>P </i>value<sup>a</sup></td><td>β (g)</td><td>95% CI</td><td><i>P </i>value<sup>a</sup></td><td>β (g)</td><td>95% CI</td><td><i>P </i>value<sup>a</sup></td></tr><tr><td colspan="10">Unadjusted:</td></tr><tr><td>Total</td><td>-28</td><td>-32 to-25</td><td><10<sup>-48</sup></td><td>-27</td><td>-31 to-23</td><td><10<sup>-44</sup></td><td>-12</td><td>-16 to-9</td><td><10<sup>-10</sup></td></tr><tr><td>Coffee, all types</td><td>-25</td><td>-29 to-21</td><td><10<sup>-30</sup></td><td>-22</td><td>-26 to-18</td><td><10<sup>-24</sup></td><td>-15</td><td>-19 to-11</td><td><10<sup>-12</sup></td></tr><tr><td>Caffeinated soft drinks<sup>b</sup></td><td>-11</td><td>-24 to 1</td><td>0.08</td><td>-19</td><td>-32 to-6</td><td>0.005</td><td>-18</td><td>-30 to-5</td><td>0.006</td></tr><tr><td>Black tea</td><td>-53</td><td>-65 to-41</td><td><10<sup>-18</sup></td><td>-53</td><td>-65 to-42</td><td><10<sup>-18</sup></td><td>-3</td><td>-15 to 8</td><td>0.5</td></tr><tr><td>Chocolate</td><td>-164</td><td>-222 to-106</td><td><10<sup>-7</sup></td><td>-196</td><td>-254 to-138</td><td><10<sup>-10</sup></td><td>159</td><td>103 to 215</td><td><10<sup>-7</sup></td></tr><tr><td colspan="10">Adjusted:</td></tr><tr><td>Total</td><td>-28</td><td>-32 to-24</td><td><10<sup>-43</sup></td><td>-25</td><td>-29 to-21</td><td><10<sup>-34</sup></td><td>-21</td><td>-24 to-17</td><td><10<sup>-25</sup></td></tr><tr><td>Coffee, all types</td><td>-24</td><td>-28 to-19</td><td><10<sup>-26</sup></td><td>-20</td><td>-24 to-15</td><td><10<sup>-18</sup></td><td>-19</td><td>-24 to-15</td><td><10<sup>-19</sup></td></tr><tr><td>Caffeinated soft drinks<sup>b</sup></td><td>-34</td><td>-47 to-22</td><td><10<sup>-7</sup></td><td>-38</td><td>-50 to-25</td><td><10<sup>-8</sup></td><td>-23</td><td>-35 to-11</td><td><3 × 10<sup>-4</sup></td></tr><tr><td>Black tea</td><td>-50</td><td>-61 to-39</td><td><10<sup>-17</sup></td><td>-48</td><td>-59 to-36</td><td><10<sup>-15</sup></td><td>-29</td><td>-40 to-18</td><td><10<sup>-6</sup></td></tr><tr><td>Chocolate</td><td>-129</td><td>-188 to-70</td><td><10<sup>-4</sup></td><td>-133</td><td>-192 to-73</td><td><10<sup>-4</sup></td><td>-4</td><td>-62 to 53</td><td>0.9</td></tr></table> |
2264ec9d658fac97bbf8e43ede8168f78a2f7e26455abb23e716f3bef1e032f6.png | simple | <table><tr><td>Group division (n)</td><td>Mean alpha angle ± SD</td></tr><tr><td>Semiprofessional group (14)</td><td>55.16 ± 6.58°</td></tr><tr><td>Amateur group (14)</td><td>51.65 ± 4.43°</td></tr><tr><td><i>P</i> value</td><td>0.11</td></tr></table> |
636cb9c86bf77ab6399f1aa6566cfe93ab8e62538b50e9da8e41d21557d65737.png | complex | <table><tr><td>Characteristics/Outcome</td><td>Group I</td><td>Group II</td><td>Group I and II</td></tr><tr><td></td><td>600/750 mg ≥30 kg</td><td>300/375 mg 15 – 30 kg</td><td>All Participants</td></tr><tr><td>Number enrolled</td><td>208</td><td>238</td><td>446</td></tr><tr><td>Number completed</td><td>203</td><td>228</td><td>431</td></tr><tr><td>Withdrawal/loss to follow up</td><td>5(2.5%)</td><td>10(4.45)</td><td>15(3.5%)</td></tr><tr><td colspan="4">Adequate Clinical and Parasitological Response (ACPR)</td></tr><tr><td> Day 28*</td><td>202(99.5%)</td><td>222(97.4%)</td><td>424(97.45%)</td></tr><tr><td>Parasite Clearance Time</td><td>40.1 hrs</td><td>42.4 hrs</td><td>41.3</td></tr></table> |
0794a94b2f1315d94689ee5cd94578e24053beee1c068c071886dc02eb9bd552.png | simple | <table><tr><td> </td><td>USDA</td><td>F009</td><td>G002</td><td>W106</td></tr><tr><td>USDA</td><td> </td><td>185</td><td>183</td><td>51</td></tr><tr><td>F009</td><td>24</td><td> </td><td>203</td><td>184</td></tr><tr><td>G002</td><td>51</td><td>45</td><td> </td><td>176</td></tr><tr><td>W106</td><td>16</td><td>28</td><td>49</td><td> </td></tr></table> |
598601c490eba7dec3b5b09fc4c1977acaf46b39a5f5c4858f56fb3b83da3f9d.png | simple | <table><tr><td>GS Method</td><td>F/B</td><td>S/F</td><td>K/F</td><td>M/F</td><td>O/P</td><td>O/DM</td><td>Mean</td></tr><tr><td>RR-BLUP</td><td>0.28</td><td>0.25</td><td>0.17</td><td>0.14</td><td>0.17</td><td>0.14</td><td>0.19</td></tr><tr><td>BA</td><td>0.29</td><td>0.24</td><td>0.19</td><td>0.15</td><td>0.17</td><td>0.17</td><td>0.20</td></tr><tr><td>BB</td><td>0.29</td><td>0.24</td><td>0.21</td><td>0.14</td><td>0.16</td><td>0.16</td><td>0.20</td></tr><tr><td>BC</td><td>0.29</td><td>0.23</td><td>0.20</td><td>0.14</td><td>0.18</td><td>0.18</td><td>0.20</td></tr><tr><td>BL</td><td>0.28</td><td>0.24</td><td>0.17</td><td>0.14</td><td>0.17</td><td>0.16</td><td>0.19</td></tr><tr><td>BRR</td><td>0.29</td><td>0.23</td><td>0.18</td><td>0.13</td><td>0.18</td><td>0.19</td><td>0.20</td></tr><tr><td>SVM</td><td>0.30</td><td>0.30</td><td>0.14</td><td>0.22</td><td>0.28</td><td>0.22</td><td>0.24</td></tr><tr><td>RF</td><td>0.19</td><td>0.25</td><td>0.24</td><td>0.34</td><td>0.14</td><td>0.28</td><td>0.24</td></tr><tr><td>Mean</td><td>0.28</td><td>0.25</td><td>0.19</td><td>0.18</td><td>0.18</td><td>0.19</td><td></td></tr></table> |
4fc689a3f5bb8e45fa6bbfce0f905b290275ecca6d85ff622d0771788ea13784.png | complex | <table><tr><td colspan="2">HAS2</td><td colspan="2">ZEISS Objective</td></tr><tr><td>Parameter</td><td>Value</td><td>Parameter</td><td>Value</td></tr><tr><td>Overall dimensions </td><td>30 mm × 30 mm </td><td>f</td><td>85 mm</td></tr><tr><td>Image sensor format</td><td>1024 × 1024 pixels</td><td>F/#</td><td>1.4</td></tr><tr><td>Pixel size </td><td>18 μm</td><td>Diameter</td><td>60.7 mm</td></tr><tr><td>ADC resolution </td><td>12 bit </td><td>Image diameter</td><td>43 mm</td></tr><tr><td>Saturation voltage output </td><td>1.49 V </td><td>FOV</td><td>12.42 deg</td></tr><tr><td>Full well capacity </td><td>10<sup>5</sup> e</td><td>Pixel scale</td><td>44.15 arcsec/pix</td></tr><tr><td>Quantum Efficiency </td><td>45% (500–650 nm) </td><td></td><td></td></tr><tr><td>Spectral response </td><td>33.3% (400–900 nm )</td><td></td><td></td></tr><tr><td>Conversion factor </td><td>14.8 μV/e</td><td></td><td></td></tr><tr><td>Dark current </td><td>12.5 e/pix/s</td><td></td><td></td></tr><tr><td>RON </td><td>2 e/pix</td><td></td><td></td></tr></table> |
f6d761b4247902d0344865d1af5c5400acab8d4f74c75246cb546d59097f7edd.png | complex | <table><tr><td>Outcome measures</td><td>Baseline (<i>n</i> = 15)</td><td>Post-trial (<i>n</i> = 15)</td><td><i>P</i> value</td></tr><tr><td colspan="4">CWIT</td></tr><tr><td> Color naming</td><td>48.35 ± 18.86</td><td>52.35 ± 22.57</td><td>0.0999</td></tr><tr><td> Word reading</td><td>34.00 ± 10.97</td><td>35.35 ± 9.77</td><td>0.3249</td></tr><tr><td> Inhibition</td><td>91.00 ± 39.25</td><td>93.57 ± 41.39</td><td>0.4525</td></tr><tr><td colspan="4">TMT</td></tr><tr><td> Visual scanning</td><td>38.76 ± 15.76</td><td>43.52 ± 15.98</td><td>0.1149</td></tr><tr><td> Number sequencing</td><td>55.73 ± 19.87</td><td>61.80 ± 23.49</td><td>0.0507</td></tr><tr><td> Letter sequencing</td><td>61.92 ± 34.05</td><td>66.21 ± 30.77</td><td>0.1262</td></tr><tr><td> Motor speed</td><td>58.75 ± 27.39</td><td>62.31 ± 25.90</td><td>0.2433</td></tr><tr><td colspan="4">HVLT-R</td></tr><tr><td> Free recall</td><td>17.66 ± 5.56</td><td>16.73 ± 6.21</td><td>0.2019</td></tr><tr><td> Delayed recall</td><td>4.92 ± 2.36</td><td>6.28 ± 3.14</td><td>0.0130*</td></tr><tr><td> Retention</td><td>76.16 ± 29.21</td><td>81.22 ± 27.32</td><td>0.1866</td></tr><tr><td> Recognition</td><td>8.06 ± 3.08</td><td>8.93 ± 2.34</td><td>0.0793</td></tr><tr><td colspan="4">SDMT</td></tr><tr><td> Correct written</td><td>27.00 ± 10.25</td><td>26.78 ± 9.96</td><td>0.4525</td></tr><tr><td> Correct oral</td><td>31.00 ± 14.17</td><td>28.46 ± 15.59</td><td>0.1374</td></tr></table> |
5a5d3edf0ca4f0a547920bf796f7223ff4742f11718b3afab050f2def63a51d2.png | complex | <table><tr><td colspan="7">ANOVA</td></tr><tr><td>Source of variation</td><td>SS</td><td>df</td><td>MS</td><td><i>F</i></td><td><i>P</i> value</td><td><i>F</i> crit </td></tr><tr><td>Effect of biofilm type*</td><td>0.7377</td><td>1</td><td>0.7377</td><td>0.1692</td><td>0.6837</td><td>4.170877</td></tr><tr><td>Effect of bracket</td><td>7.9896</td><td>2</td><td>3.9948</td><td>0.9164</td><td>0.4109</td><td>3.31583</td></tr><tr><td>Interaction</td><td>2.1777</td><td>2</td><td>1.0888</td><td>0.2498</td><td>0.7806</td><td>3.31583</td></tr><tr><td>Within</td><td>130.7769</td><td>30</td><td>4.3592</td><td></td><td></td><td></td></tr><tr><td>Total</td><td>141.6819</td><td>35</td><td></td><td></td><td></td><td></td></tr></table> |
407ba5b688bd62dd10199893ab3499232c9497220634d1464769286a21bc00d1.png | complex | <table><tr><td></td><td>Early-onset Disease (<i>n</i> = 22)</td><td>Late-onset Disease (<i>n</i> = 46)</td><td>Total<sup>a</sup>(<i>n</i> = 68)</td></tr><tr><td>Sex (female/male)</td><td>6/16</td><td>25/21</td><td>31/37</td></tr><tr><td colspan="4">Bacterial isolation site</td></tr><tr><td> Blood</td><td>20 (90.9%)</td><td>28 (60.9%)</td><td>48 (70.6%)</td></tr><tr><td> CSF<sup>b</sup></td><td>2 (9.1%)</td><td>18 (39.1%)</td><td>20 (29.4%)</td></tr><tr><td colspan="4">Serotype<sup>c</sup></td></tr><tr><td> Ia</td><td>1 (4.5%)</td><td>1 (2.2%)</td><td>2 (2.9%)</td></tr><tr><td> Ib</td><td>5 (22.7)</td><td>5 (10.9%)</td><td>10 (14.7%)</td></tr><tr><td> III</td><td>15 (68.2%)</td><td>38 (82.6%)</td><td>53 (77.9%)</td></tr><tr><td> V</td><td>1 (4.5%)</td><td>2 (4.3%)</td><td>3 (4.4%)</td></tr></table> |
cefdb1d1feef78547c912d78cbc4669a0958556873324c35c26eea09e725862f.png | complex | <table><tr><td>Session</td><td>Depression-specific topics</td><td>Diabetes-specific topics added</td></tr><tr><td>1</td><td>Psychoeducation</td><td>Connection diabetes and depression</td></tr><tr><td>2</td><td>Behavioural activation</td><td>Worrying about diabetes-related complications</td></tr><tr><td>3</td><td>Problem solving I</td><td>Diabetes and relationship/sexuality</td></tr><tr><td>4</td><td>Problem solving II</td><td>Rumination about diabetes</td></tr><tr><td>5</td><td>Behavioural activation, focus on physical activity and self-esteem</td><td>Physical activity and diabetes</td></tr><tr><td>6</td><td>Plan for the future</td><td>Conversation with a general practitioner</td></tr><tr><td colspan="3">Additional components</td></tr><tr><td>Session</td><td>Depression-specific topics</td><td>Diabetes-specific topics added</td></tr><tr><td>7</td><td>Overweight/obesity</td><td>Diabetes and nutrition</td></tr><tr><td>8</td><td>Insomnia</td><td>---</td></tr><tr><td>Session</td><td>Depression-specific topics</td><td>Diabetes-specific topics added</td></tr><tr><td>Booster</td><td>Summary: Behavioural activation; Problem solving</td><td>Choice of the known topics (1-6)</td></tr></table> |
a85fddf5f5893cf09fa1c4e9baca83c1c2aebcee2f4897c8e3c08c5b57b95f02.png | simple | <table><tr><td></td><td>Applied in specialty</td><td>Auditioned in specialty</td><td>% matched at audition (<i>n</i>)</td></tr><tr><td>Radiation oncology</td><td>5</td><td>5</td><td>80 (4)</td></tr><tr><td>PM&R</td><td>6</td><td>5</td><td>60 (3)</td></tr><tr><td>Orthopedics</td><td>33</td><td>31</td><td>58 (18)</td></tr><tr><td>Plastic surgery</td><td>7</td><td>7</td><td>57 (4)</td></tr><tr><td>Pediatrics</td><td>120</td><td>65</td><td>49 (32)</td></tr><tr><td>Psychiatry</td><td>35</td><td>16</td><td>44 (7)</td></tr><tr><td>Anesthesia</td><td>47</td><td>17</td><td>41 (7)</td></tr><tr><td>Med/peds</td><td>12</td><td>5</td><td>40 (2)</td></tr><tr><td>Internal medicine</td><td>150</td><td>69</td><td>39 (27)</td></tr><tr><td>Neurosurgery</td><td>6</td><td>6</td><td>33 (2)</td></tr><tr><td>Urology</td><td>11</td><td>11</td><td>36 (4)</td></tr><tr><td>Emergency medicine</td><td>59</td><td>56</td><td>32 (18)</td></tr><tr><td>Ophthalmology</td><td>19</td><td>17</td><td>35 (6)</td></tr><tr><td>Otolaryngology</td><td>14</td><td>12</td><td>33 (4)</td></tr><tr><td>Neurology</td><td>15</td><td>10</td><td>30 (3)</td></tr><tr><td>Family medicine</td><td>50</td><td>24</td><td>29 (7)</td></tr><tr><td>Radiology</td><td>46</td><td>28</td><td>28 (8)</td></tr><tr><td>OB/GYN</td><td>41</td><td>30</td><td>23 (7)</td></tr><tr><td>Dermatology</td><td>20</td><td>18</td><td>17 (3)</td></tr><tr><td>General surgery</td><td>44</td><td>33</td><td>3 (1)</td></tr><tr><td>Pathology</td><td>9</td><td>5</td><td>0</td></tr><tr><td>Prelim medicine only</td><td>3</td><td>0</td><td>0</td></tr></table> |
308c5c07ae734dc21a2df855aac9104b150d72bb4f620af29db693d4b91ae282.png | complex | <table><tr><td>Total CAS Score</td><td colspan="3">Rating of Intervention Effectiveness</td><td>Total No. Studies with each CAS Score</td></tr><tr><td></td><td>0</td><td>0.5</td><td>1</td><td></td></tr><tr><td>0</td><td>1</td><td>0</td><td>0</td><td>1</td></tr><tr><td>1</td><td>1</td><td>1</td><td>0</td><td>2</td></tr><tr><td>2</td><td>1</td><td>3</td><td>0</td><td>4</td></tr><tr><td>3</td><td>0</td><td>7</td><td>11</td><td>18</td></tr><tr><td>4</td><td>0</td><td>1</td><td>6</td><td>7</td></tr><tr><td>Total No. Studies at each Level of Effectiveness</td><td>3</td><td>12</td><td>17</td><td>32</td></tr></table> |
469474a708c79fb540938fe08769e47e31df9ebaaf37ad7ddd92f5bf13c8a5d3.png | simple | <table><tr><td><i>Characteristics</i></td><td><i>Number of patients</i></td><td><i>%</i></td></tr><tr><td>Total analyzed</td><td>149</td><td></td></tr><tr><td>Sex</td><td></td><td></td></tr><tr><td> Males</td><td>59</td><td><i>40</i></td></tr><tr><td> Females</td><td>90</td><td><i>60</i></td></tr><tr><td>Median Age (years)</td><td>48</td><td></td></tr><tr><td> Range</td><td>16–85</td><td></td></tr><tr><td>AJCC stage</td><td></td><td></td></tr><tr><td> IA</td><td>50</td><td><i>33</i></td></tr><tr><td> IB</td><td>22</td><td><i>15</i></td></tr><tr><td> IIA</td><td>36</td><td><i>24</i></td></tr><tr><td> IIB</td><td>12</td><td><i>8</i></td></tr><tr><td> IIC</td><td>1</td><td><i>1</i></td></tr><tr><td> III</td><td>28</td><td><i>19</i></td></tr><tr><td>Primary site</td><td></td><td></td></tr><tr><td> Head and Neck</td><td>13</td><td><i>9</i></td></tr><tr><td> Superior limbs</td><td>23</td><td><i>15</i></td></tr><tr><td> Inferior limbs</td><td>47</td><td><i>32</i></td></tr><tr><td> Trunk</td><td>63</td><td><i>42</i></td></tr><tr><td> Unknown</td><td>3</td><td><i>2</i></td></tr></table> |
63ed70baae849ef97d76f97f6de759699d988e6f5f225423f76624b7b7b42dc9.png | simple | <table><tr><td>Laboratory tests</td><td>result</td><td>Normal range</td></tr><tr><td>K</td><td>5.2</td><td>3.4–5.3 mmol /L</td></tr><tr><td>Na</td><td>137</td><td>137–147 mmol /L</td></tr><tr><td>Cl</td><td>102</td><td>99–108 mmol /L</td></tr><tr><td>Ca</td><td>9.5</td><td>8.7–10.7 mg /dL</td></tr><tr><td>Lactate</td><td>4</td><td>0.9–1.8 mmol /L</td></tr><tr><td>Ammonia</td><td>150</td><td>25-80 mmol /L</td></tr><tr><td>FBS</td><td>85</td><td>60–99 mg /dL</td></tr><tr><td>BUN</td><td>7</td><td>5–18 mg /dL</td></tr><tr><td>Cr</td><td>0.7</td><td>0.75–1.20 mg /dL</td></tr></table> |
75a13a7ca7cf4a9ce8ef43dbad9fccd993d848ecc23a37808461f7e1b3ccbb09.png | complex | <table><tr><td rowspan="2">Characteristics</td><td rowspan="2">Females (number)</td><td rowspan="2">Age (years)</td><td rowspan="2">Duration of symptoms (months)</td><td rowspan="2">Symptoms preceeding malignancy (number)</td><td colspan="2">Malignancy</td></tr><tr><td>All tumors (number)</td><td>Lung cancer (number)</td></tr><tr><td>All patients</td><td>11/18</td><td>61 (48–76)</td><td>4 (1–36)</td><td>15/18</td><td>16/18</td><td>14/18</td></tr><tr><td>Peripheral neuropathy</td><td>5/8</td><td>59 (54–76)</td><td>3 (1–36)</td><td>7/8</td><td>7/8</td><td>5/8</td></tr><tr><td>Encephalitis</td><td>6/10</td><td>61 (48–74)</td><td>4 (1–15)</td><td>8/10</td><td>9/10</td><td>9/10</td></tr><tr><td>Rhombencephalitis</td><td>3/7</td><td>61 (48–73)</td><td>13 (3–15)</td><td>6/7</td><td>6/7</td><td>6/7</td></tr><tr><td>Limbic encephalitis</td><td>3/3</td><td>55, 61, 74</td><td>1, 3, 4</td><td>2/3</td><td>3/3</td><td>3/3</td></tr><tr><td><i>p value</i></td><td>1.0</td><td>0.6</td><td>0.5</td><td>1.0</td><td>1.0</td><td>0.3</td></tr></table> |
b90beb76bed1b796a9adc8e5c01d75822163e0e0cef26ae2be9601ea62afb303.png | simple | <table><tr><td>Attribute</td><td>Value</td><td>% of Total</td></tr><tr><td>Genome size (bp)</td><td>3,086,721</td><td>100.00</td></tr><tr><td>DNA coding (bp)</td><td>2,284,152</td><td>74.00</td></tr><tr><td>DNA G+C (bp)</td><td>2,147,191</td><td>69.56</td></tr><tr><td>DNA scaffolds</td><td>109</td><td></td></tr><tr><td>Total genes</td><td>2,422</td><td>100.00</td></tr><tr><td>Protein coding genes</td><td>2,363</td><td>97.56</td></tr><tr><td>RNA genes</td><td>50</td><td>2.06</td></tr><tr><td>Pseudo genes</td><td>9</td><td>0.37</td></tr><tr><td>Genes in internal clusters</td><td>811</td><td>34.32</td></tr><tr><td>Genes with function prediction</td><td>1633</td><td>67.42</td></tr><tr><td>Genes assigned to COGs</td><td>1858</td><td>76.71</td></tr><tr><td>Genes with Pfam domains</td><td>2038</td><td>84.14</td></tr><tr><td>Genes with signal peptides</td><td>539</td><td>22.81</td></tr><tr><td>Genes with transmembrane helices</td><td>527</td><td>22.25</td></tr><tr><td>CRISPR repeats</td><td>1</td><td>0.41</td></tr></table> |
2098576e6c9cd080e0ed42420e36f2dda5a995350f4ff2157b4ac04cc51774bf.png | simple | <table><tr><td>Dependent variable in all regressions: IHD mortality</td><td>Adjusting for Beef Consumption</td><td>Adjusting for Coconut Oil Consumption</td><td>Adjusting for Milk Consumption</td><td>Adjusting for Butter Consumption</td><td>Adjusting for Cheese Consumption</td><td>Adjusting for Pork Consumption</td><td>Adjusting for Chicken Consumption</td></tr><tr><td>Palm oil consumption (kg per-capita)</td><td>18.9</td><td>3.3</td><td>-3.4</td><td>-1.2</td><td>1.7</td><td>19</td><td>19</td></tr><tr><td></td><td>[7.7 - 30]</td><td>[-1.4 - 7.9]</td><td>[-39 - 32]</td><td>[-43 - 41]</td><td>[-40 - 43]</td><td>[8.0 - 30]</td><td>[8.4 - 30]</td></tr><tr><td>Additional effect of palm oil in developing countries (kg per-capita)</td><td>52</td><td>149</td><td>70</td><td>59</td><td>65</td><td>41</td><td>72</td></tr><tr><td></td><td>[26 - 78]</td><td>[93 - 205]</td><td>[19 - 120]</td><td>[-58 - 175]</td><td>[-58 - 188]</td><td>[10 - 72]</td><td>[18 - 126]</td></tr><tr><td>Cigarette consumption (pieces per-capita)</td><td>-0.00</td><td>0.26</td><td>0.01</td><td>0.05</td><td>0.07</td><td>-0.03</td><td>0.11</td></tr><tr><td></td><td>[-0.29 - 0.29]</td><td>[0.15 - 0.37]</td><td>[-0.18 - 0.21]</td><td>[-0.20 - 0.29]</td><td>[-0.15 - 0.28]</td><td>[-0.23 - 0.18]</td><td>[-0.26 - 0.48]</td></tr><tr><td>Log per-capita GDP (%)</td><td>-2,259</td><td>-728</td><td>-2,262</td><td>-2,116</td><td>-2,469</td><td>-2,370</td><td>-2,191</td></tr><tr><td></td><td>[-3,201 - -1,317]</td><td>[-1,061 - -395]</td><td>[-2,830 - -1,695]</td><td>[-2,851 - -1,381]</td><td>[-3,160 - -1,779]</td><td>[-3,271 - -1,469]</td><td>[-3,002 - -1,381]</td></tr><tr><td>1980s (compared to 1990s)</td><td>-176</td><td>6.7</td><td>-171</td><td>-133</td><td>-152</td><td>-162</td><td>-154</td></tr><tr><td></td><td>[-348 - -4.7]</td><td>[-68 - 82]</td><td>[-341 - -1.2]</td><td>[-304 - 38]</td><td>[-328 - 23]</td><td>[-353 - 28]</td><td>[-425 - 118]</td></tr><tr><td>Beef consumption (kg per-capita)</td><td>6.6</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td>[-17 - 30]</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Coconut oil consumption (kg per-capita)</td><td></td><td>21</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td>[-35 - 77]</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Milk consumption (kg per-capita)</td><td></td><td></td><td>4.8</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>[-0.7 - 10]</td><td></td><td></td><td></td><td></td></tr><tr><td>Butter consumption (kg per-capita)</td><td></td><td></td><td></td><td>-50</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>[-119 - 19]</td><td></td><td></td><td></td></tr><tr><td>Cheese consumption (kg per-capita)</td><td></td><td></td><td></td><td></td><td>32</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td>[-15 - 79]</td><td></td><td></td></tr><tr><td>Pork consumption (kg per-capita)</td><td></td><td></td><td></td><td></td><td></td><td>9.6</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td>[-10 - 29]</td><td></td></tr><tr><td>Chicken consumption (kg per-capita)</td><td></td><td></td><td></td><td></td><td></td><td></td><td>6.3</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>[-30 - 43]</td></tr><tr><td>Constant</td><td>23,221</td><td>7,942</td><td>23,066</td><td>22,180</td><td>25,213</td><td>24,411</td><td>22,299</td></tr><tr><td></td><td>[13,631 - 32,811]</td><td>[4,505 - 11,379]</td><td>[17,424 - 28,708]</td><td>[14,900 - 29,460]</td><td>[18,243 - 32,183]</td><td>[15,454 - 33,368]</td><td>[13,483 - 31,115]</td></tr><tr><td>Observations</td><td>217</td><td>153</td><td>181</td><td>177</td><td>177</td><td>209</td><td>202</td></tr><tr><td>R-squared</td><td>0.60</td><td>0.89</td><td>0.70</td><td>0.64</td><td>0.64</td><td>0.61</td><td>0.59</td></tr><tr><td>Number of countries</td><td>22</td><td>13</td><td>20</td><td>19</td><td>19</td><td>21</td><td>20</td></tr></table> |
041f8d1a3b62f50bcc31c1c07cdff9a5cf0ecca3cbdbb62fb8a4a197da3d297b.png | simple | <table><tr><td> </td><td>PE patients</td><td>DVT patients</td></tr><tr><td> </td><td>(n=305)</td><td>(n=138)</td></tr><tr><td>Fatal pulmonary embolism</td><td>76 (24.9%)</td><td>6 (4.3%)</td></tr><tr><td>Respiratory insufficiency</td><td>55 (18.0%)</td><td>22 (15.9%)</td></tr><tr><td>Neoplasia</td><td>44 (14.4%)</td><td>37 (26.8%)</td></tr><tr><td>Infection</td><td>32 (10.5%)</td><td>14 (10.1%)</td></tr><tr><td>Fatal bleeding</td><td>17 (5.6%)</td><td>8 (5.8%)</td></tr><tr><td>Heart failure</td><td>10 (3.3%)</td><td>6 (4.4%)</td></tr><tr><td>Sudden death</td><td>6 (2.0%)</td><td>6 (4.4%)</td></tr><tr><td>Multi-organ failure</td><td>6 (2.0%)</td><td>5 (3.6%)</td></tr><tr><td>Myocardial infarction</td><td>5 (1.6%)</td><td>2 (1.5%)</td></tr><tr><td>Bowel occlusion</td><td>3 (1.0%)</td><td>1 (0.7%)</td></tr><tr><td>Liver insufficiency</td><td>2 (0.7%)</td><td>1 (0.7%)</td></tr><tr><td>Stroke</td><td>1 (0.3%)</td><td>2 (1.4%)</td></tr><tr><td>Terminal renal insufficiency</td><td>1 (0.3%)</td><td>2 (1.4%)</td></tr><tr><td>Critical limb ischemia</td><td>1 (0.3%)</td><td>0</td></tr><tr><td>Other</td><td>11 (3.6%)</td><td>2 (1.5%)0</td></tr><tr><td>Unknown</td><td>35 (11.5%)</td><td>24 (17.4%)</td></tr></table> |
a0868dc6d932efb0c7092a7e2f5f1d21d034f9e00733982f4837634f3a5cbe31.png | simple | <table><tr><td>Characteristics</td><td>n</td><td>%</td></tr><tr><td>Age (y)</td><td></td><td></td></tr><tr><td>≤35</td><td>110</td><td>10.7</td></tr><tr><td>36–50</td><td>527</td><td>51.1</td></tr><tr><td>>50</td><td>395</td><td>38.3</td></tr><tr><td>cT stage</td><td></td><td></td></tr><tr><td>T1</td><td>575</td><td>55.7</td></tr><tr><td>T2</td><td>398</td><td>38.5</td></tr><tr><td>Tx</td><td>59</td><td>5.7</td></tr><tr><td>pT stage</td><td></td><td></td></tr><tr><td>T1</td><td>658</td><td>63.8</td></tr><tr><td>T2</td><td>271</td><td>26.2</td></tr><tr><td>Tx</td><td>103</td><td>10.0</td></tr><tr><td>pN stage</td><td></td><td></td></tr><tr><td>N0</td><td>736</td><td>71.3</td></tr><tr><td>N1</td><td>209</td><td>20.3</td></tr><tr><td>N2</td><td>50</td><td>4.8</td></tr><tr><td>N3</td><td>30</td><td>3.9</td></tr><tr><td>Unknown</td><td>7</td><td>0.7</td></tr><tr><td>Grade</td><td></td><td></td></tr><tr><td>G1</td><td>83</td><td>8.1</td></tr><tr><td>G2</td><td>590</td><td>57.4</td></tr><tr><td>G3</td><td>354</td><td>34.5</td></tr><tr><td>Menopausal status</td><td></td><td></td></tr><tr><td>Pre-</td><td>652</td><td>63.2</td></tr><tr><td>Post-</td><td>379</td><td>36.8</td></tr><tr><td>Margin status</td><td></td><td></td></tr><tr><td>Negative</td><td>823</td><td>79.7</td></tr><tr><td>Carcinoma <i>in situ</i></td><td>87</td><td>8.4</td></tr><tr><td>Invasive carcinoma</td><td>122</td><td>11.8</td></tr><tr><td>Presence of LVI</td><td>114</td><td>11.9</td></tr><tr><td>Presence of EIC</td><td>102</td><td>9.9</td></tr><tr><td>ER or PR positive</td><td>826</td><td>80.0</td></tr><tr><td>HER-2 positive</td><td>216</td><td>12.0</td></tr><tr><td>Histological subtype</td><td></td><td></td></tr><tr><td>Invasive ductal carcinoma</td><td>805</td><td>78.0</td></tr><tr><td>Presence of DCIS component</td><td>83</td><td>8.0</td></tr><tr><td>Invasive lobular carcinoma</td><td>29</td><td>2.8</td></tr><tr><td>Other</td><td>115</td><td>11.2</td></tr><tr><td>Breast cancer subtype</td><td></td><td></td></tr><tr><td>Luminal A</td><td>540</td><td>52.3</td></tr><tr><td>Luminal B</td><td>154</td><td>14.9</td></tr><tr><td>Luminal-HER-2</td><td>132</td><td>12.8</td></tr><tr><td>HER-2 positive</td><td>84</td><td>8.1</td></tr><tr><td>TN</td><td>122</td><td>11.8</td></tr></table> |
66f553d8ac612c6fa4fe96ab47196c634463b431b9a19824ca4fcd1e0a4c756c.png | complex | <table><tr><td></td><td colspan="3">Perceived general health ('excellent/very good/good' = 1)</td></tr><tr><td></td><td>Model 1a</td><td>Model 1b</td><td>Model 2</td></tr><tr><td>% of green (1 km)</td><td>.010 (.003) [p = .002]</td><td>.011 (.003) [p = .005]</td><td></td></tr><tr><td>% of green (3 km)</td><td></td><td></td><td>.006 (.005) [p = .194]</td></tr><tr><td>Time spent on cycling for commuting purposes (minutes)</td><td></td><td>-.001 (.001) [p = .095]</td><td></td></tr></table> |
3c4fb765b10e353d80516ec91f8578d76eb445c4fcf5a1a3eb6b6d8831da374f.png | complex | <table><tr><td></td><td>Rice</td><td></td><td></td><td><i>Arabidopsis</i></td><td></td></tr><tr><td>Groups</td><td>Tissues</td><td>Genes</td><td>Groups</td><td>Tissues</td><td>Genes</td></tr><tr><td colspan="3"><i>Preferential expression in young vegetative tissues</i></td><td></td><td></td><td></td></tr><tr><td>IA</td><td>Youngest seedling (w/o root)</td><td><i>CESA5,6; CSLC1,7; CSLD4</i></td><td>IIIC</td><td>Youngest seedling (w/o root)</td><td><i>CESA5; CSLC4; CSLA3,7</i></td></tr><tr><td>IB</td><td>Young seedling (w/root)</td><td><i>CESA1,3,8; CSLF6,8; CSLC2; BC1L14</i></td><td>IIID</td><td>Young seedling (w/root)</td><td><i>CESA1,3,6,2; COB</i></td></tr><tr><td colspan="3"><i>Preferential expression in reproductive stages</i></td><td></td><td></td><td></td></tr><tr><td>/</td><td>/</td><td>/</td><td>IA</td><td>Seed, silique</td><td><i>CESA9,10; COBL2,6</i></td></tr><tr><td>IIA(a)</td><td>Hull</td><td><i>CSLF2, 7</i></td><td></td><td>Silique</td><td><i>CSLC5</i></td></tr><tr><td>IIA(b)</td><td>Stem, hull</td><td><i>CESA4,7,9; BC1</i></td><td>IB</td><td>Stem, silique</td><td><i>CESA4,7,8;COBL4</i></td></tr><tr><td>/</td><td>/</td><td>/</td><td>IC</td><td>Flowers(sepals)</td><td><i>CSLG2,3; CSLB2</i></td></tr><tr><td>/</td><td>/</td><td>/</td><td></td><td>Flowers(Carpels)</td><td><i>CSLG1</i></td></tr><tr><td>IIB</td><td>Flag leaf and sheath</td><td><i>CSLE1; CSLH3; CESA11</i></td><td>/</td><td>/</td><td>/</td></tr><tr><td>IIC</td><td>Flag leaf and endosperm</td><td><i>CSLA3,6,11; BC1L9</i></td><td>/</td><td>/</td><td>/</td></tr><tr><td colspan="3"><i>Preferential expression in tissues undergoing rapid extension</i></td><td></td><td></td><td></td></tr><tr><td>/</td><td>/</td><td>/</td><td>IIA</td><td>Shoot apex, Cauline leaf, Carpel</td><td><i>CSLD5; CSLC8; CSLA15; COBL1,7</i></td></tr><tr><td>/</td><td>/</td><td>/</td><td>IIB</td><td>Flowers (Carpels)</td><td><i>CSLD6; CSLA1,2,10,11</i></td></tr><tr><td>IIIB</td><td>Stamen and endosperm</td><td><i>CSLC9,CSLD3,5; CSLH2; BC1L5</i></td><td>IIC</td><td>Stamen (Pollen)</td><td><i>CSLA9; CSLC6,12; CSLD1,4; COBL10,11</i></td></tr><tr><td>IIID</td><td>Radicle and root</td><td><i>CSLD1,2; CSLC3; CSLF3; BC1L1</i></td><td>IIIA, IIIB</td><td>Roots</td><td><i>CSLD2,3; CSLA14; CSLB3,4;COBL5,8,9; CSLE1</i></td></tr><tr><td>IIIA</td><td>Callus and young panicle</td><td><i>CSLA2,4,7; CSLE2; CSLH1</i></td><td>/</td><td>/</td><td>/</td></tr><tr><td>IIIC</td><td>Young panicle</td><td><i>CESA2,9; CSLC10; BC1L2</i></td><td>/</td><td>/</td><td>/</td></tr><tr><td>IIIE</td><td>Seed imbibition</td><td><i>CESA1; CSLF9</i></td><td>-</td><td>-</td><td>-</td></tr></table> |
ecb560c6b7be212f631835ebc3c2ceaf528e9b177d582e8478ef997eb7c0d787.png | simple | <table><tr><td>Classification Algorithm</td><td>Acronym</td></tr><tr><td>Fisher Discriminant Analysis</td><td>FDA</td></tr><tr><td>Fuzzy Min-Max Neural Network</td><td>FMMNN</td></tr><tr><td>Kernel Linear Discriminant Analysis</td><td>GK-FDA</td></tr><tr><td>Kernel Support Vector Machine</td><td>GK-SVM</td></tr><tr><td>Fuzzy C-Means </td><td>FCM</td></tr></table> |
380c741aa1d16c4746f6a3a7da1fe360ed837309fe9ee7cb319fe75fc2e766f8.png | simple | <table><tr><td>Target</td><td><i>cyp19a2</i>-1</td><td><i>vasa</i>-3</td><td><i>vasa</i>-5</td><td><i>vtg1</i>-3</td></tr><tr><td>effect</td><td>-/↑ 164</td><td>↑ 61.6/-</td><td>↑ 143/-</td><td>-/↑ 74.7</td></tr></table> |
058f0df5a01c81270d2625ba5fe74e42c3f2ed95c40160f5a4a62b127482b0ed.png | complex | <table><tr><td></td><td colspan="2">PlateliaTM Dengue NS1 Ag-ELISA</td><td>Sensitivity(95% CI)</td><td><i>p</i>-value</td></tr><tr><td rowspan="2">Overall sensitivity</td><td colspan="2">Non-dissociated</td><td>47.8(39.3 – 56.4)</td><td rowspan="2"><i>p</i> < 0.001</td></tr><tr><td colspan="2">Heat dissociated</td><td>57.7(49.5 – 65.5)</td></tr><tr><td rowspan="4">Type of infection</td><td rowspan="2">Primary</td><td>Non-dissociated</td><td>80.9(58.1 – 94.6)</td><td rowspan="2"><i>p</i> < 0.001</td></tr><tr><td>Heat dissociated</td><td>84.6(65.1 – 95.6)</td></tr><tr><td rowspan="2">Secondary</td><td>Non-dissociated</td><td>42.0(33.0 – 51.4)</td><td rowspan="2"><i>p</i> < 0.001</td></tr><tr><td>Heat dissociated</td><td>52.3(43.3 – 61.1)</td></tr></table> |
3522ca8a6bf827fb7bf70e85c72001afab0df344ee4286abfdc62befd40256ac.png | complex | <table><tr><td>Assemblathon metrics</td><td>RJ</td><td>SGA</td><td>Edena</td><td>LEAP</td></tr><tr><td>Number of contigs</td><td>120712</td><td>231594</td><td>120462</td><td>113428</td></tr><tr><td>Genome size (bp)</td><td>34894545</td><td>34894545</td><td>34894545</td><td>34894545</td></tr><tr><td>Total contigs length</td><td>45667531</td><td>55880641</td><td>44737441</td><td>43099113</td></tr><tr><td>- as% of genome</td><td>130.87</td><td>160.14</td><td>128.21</td><td>123.51</td></tr><tr><td>Mean contig size</td><td>378.32</td><td>241.29</td><td>371.38</td><td>379.97</td></tr><tr><td>Median contig size</td><td>132</td><td>101</td><td>120</td><td>117</td></tr><tr><td>Longest contig</td><td>41352</td><td>41352</td><td>41352</td><td>39379</td></tr><tr><td>Shortest contig</td><td>102</td><td>100</td><td>100</td><td>101</td></tr><tr><td>Contigs > 500 bp</td><td>13467 (11.16%)</td><td>13416 (5.79%)</td><td>13439 (11.16%)</td><td>13430 (11.84%)</td></tr><tr><td>Contigs > 1 Kbp</td><td>8700 (7.21%)</td><td>8684 (3.75%)</td><td>8696 (7.22%)</td><td>8578 (7.56%)</td></tr><tr><td>Contigs > 10 Kbp</td><td>264 (0.22%)</td><td>264 (0.11%)</td><td>264 (0.22%)</td><td>228 (0.20%)</td></tr><tr><td>N50</td><td>1614</td><td>815</td><td>1699</td><td>1617</td></tr><tr><td>L50</td><td>5684</td><td>10118</td><td>5416</td><td>5488</td></tr><tr><td>NG50</td><td>2737</td><td>2739</td><td>2733</td><td>2461</td></tr><tr><td>LG50</td><td>3120</td><td>3113</td><td>3121</td><td>3429</td></tr><tr><td colspan="5"> </td></tr><tr><td>Plantagora metrics</td><td>RJ</td><td>SGA</td><td>Edena</td><td>LEAP</td></tr><tr><td>Covered Bases</td><td>34343945</td><td>34357693</td><td>34300114</td><td>12968118</td></tr><tr><td>Ambiguous Bases</td><td>159997</td><td>154584</td><td>182952</td><td>696334</td></tr><tr><td>Misassemblies</td><td>4</td><td>4</td><td>4</td><td>3693</td></tr><tr><td>Misassembled Contigs</td><td>4</td><td>4</td><td>4</td><td>2344</td></tr><tr><td>Misassembled Contig Bases</td><td>1283</td><td>417</td><td>1245</td><td>2797710</td></tr><tr><td>SNPs</td><td>104</td><td>125</td><td>120</td><td>46270</td></tr><tr><td>Insertions</td><td>5</td><td>2</td><td>1</td><td>2403</td></tr><tr><td>Deletions</td><td>43</td><td>23</td><td>28</td><td>5187</td></tr><tr><td>Positive Gaps</td><td>2679</td><td>2471</td><td>2925</td><td>26495</td></tr><tr><td>Internal Gaps</td><td>0</td><td>0</td><td>0</td><td>21</td></tr><tr><td>External Gaps</td><td>2679</td><td>2471</td><td>2925</td><td>26474</td></tr><tr><td>- total length</td><td>547408</td><td>558921</td><td>589979</td><td>19064103</td></tr><tr><td>- average length</td><td>204</td><td>226</td><td>202</td><td>720</td></tr><tr><td>Negative Gaps</td><td>110888</td><td>218908</td><td>110811</td><td>18198</td></tr><tr><td>Internal Overlaps</td><td>0</td><td>0</td><td>0</td><td>17</td></tr><tr><td>External Overlaps</td><td>110888</td><td>218908</td><td>110811</td><td>18181</td></tr><tr><td>- total length</td><td>−10247647</td><td>−20078971</td><td>−9424823</td><td>−1859835</td></tr><tr><td>- average length</td><td>−92</td><td>−92</td><td>−85</td><td>−102</td></tr><tr><td>Redundant Contigs</td><td>864</td><td>1158</td><td>607</td><td>6329</td></tr><tr><td>Unaligned Contigs</td><td>3262</td><td>4686</td><td>3221</td><td>60563</td></tr><tr><td>- partial</td><td>18</td><td>57</td><td>21</td><td>3252</td></tr><tr><td>- total length</td><td>462668</td><td>599320</td><td>447922</td><td>27666823</td></tr><tr><td>Ambiguous Contigs</td><td>2631</td><td>3876</td><td>2619</td><td>799</td></tr><tr><td>- total length</td><td>369284</td><td>483895</td><td>366418</td><td>93102</td></tr></table> |
9e643438a9598c3dc06f1c0a5e6762fc4d0fff6796e877161cb8447cc3c84520.png | simple | <table><tr><td>Groups</td><td>VT</td><td>AF</td></tr><tr><td>sham (n=5)</td><td>0</td><td>0</td></tr><tr><td>t-AUCB(5 mg/L)+ sham (n=5)</td><td>0</td><td>0</td></tr><tr><td>MI (n=10)</td><td>7(70%)<sup>*</sup></td><td>3(30%)<sup>*</sup></td></tr><tr><td>t-AUCB(0.2 mg/L) + MI (n=5)</td><td>3(60%)</td><td>1(20%)</td></tr><tr><td>t-AUCB(1 mg/L) + MI (n=5)</td><td>2(40%)<sup>#</sup></td><td>1(20%)</td></tr><tr><td>t-AUCB(5 mg/L) + MI (n=8)</td><td>3(38%)<sup>#</sup></td><td>2(25%)</td></tr></table> |
fa4ca662e0b941c8ae4fea64053c63b840502c39ab242b1cb79edd20b998a599.png | simple | <table><tr><td>Population</td><td>Sample size</td><td>Sampling location</td><td>Longitude and latitude</td></tr><tr><td></td><td>90</td><td>Minqing County, Fujian Province,</td><td>118.3, 25.6</td></tr><tr><td>Han</td><td>95</td><td>Chengdu City, Sichuan Province,</td><td>104.1, 30.6</td></tr><tr><td></td><td>30</td><td>Yining, Xinjiang Autonomous Region</td><td>80.5, 43.3</td></tr><tr><td>Oroqen</td><td>66</td><td>Arlihe, Inner Mongolia Autonomous Region</td><td>131.0, 53.5</td></tr><tr><td>Ewenk</td><td>45</td><td>Molidawa, Inner Mongolia Autonomous Region</td><td>118.6, 48.0</td></tr><tr><td>Korean</td><td>157</td><td>Yanji City, Jilin Province</td><td>121.4, 40.2</td></tr><tr><td>Daur</td><td>37</td><td>Molidawa, Inner Mongolia Autonomous Region</td><td>118.6, 40.8</td></tr><tr><td>Hezhen</td><td>95</td><td>Tongjiang, Heilongjiang Province</td><td>132.5, 46.7</td></tr><tr><td>Man</td><td>103</td><td>Xiuyan City, Liaoning Province</td><td>123.2, 40.2</td></tr><tr><td>Kyrgyz</td><td>42</td><td>Wuqia, Xinjiang Autonomous Region</td><td>73.4, 39.2</td></tr><tr><td>Uygur</td><td>57</td><td>Yining City, Xinjiang Autonomous Region</td><td>80.5, 43.3</td></tr><tr><td>Mongol</td><td>99</td><td>Hailar City, Inner Mongolia Autonomous Region</td><td>126.0, 51.0</td></tr><tr><td>Hui</td><td>118</td><td>Tongxin County, Ningxia Autonomous Region</td><td>105.9, 36.9</td></tr><tr><td>Xibo</td><td>74</td><td>Yili, Xinjiang Autonomous Region</td><td>80.5, 43.3</td></tr><tr><td>Hazakh</td><td>91</td><td>Yining City, Xinjiang Autonomous Region</td><td>80.5, 43.3</td></tr><tr><td>Bouyei</td><td>115</td><td>Guizhou City, Yunnan Province</td><td>105.7, 26.0</td></tr></table> |
204e0b617fc2b49f746fb7cd377faea18a8cc63c298aedef7aed6b88b2ccaa8a.png | complex | <table><tr><td rowspan="2">Cost</td><td rowspan="2">Parameter</td><td colspan="2">Overall cost of treatment</td><td rowspan="2">Proportion of total cost</td></tr><tr><td>Average</td><td>SD</td></tr><tr><td rowspan="6">Direct Medical</td><td>Diagnostic</td><td>37.63 (0.48)</td><td>189.71 (2.42)</td><td rowspan="6">28</td></tr><tr><td>Medicine</td><td>1064.19 (13.56)</td><td>1427.04 (18.18)</td></tr><tr><td>Consultant fee</td><td>26.37 (0.34)</td><td>121.38 (1.55)</td></tr><tr><td>Registration/admission fee</td><td>14.54 (0.19)</td><td>11.42 (0.15)</td></tr><tr><td>Medical materials (syringe/cannula etc)</td><td>27.32 (0.35)</td><td>62.43 (0.80)</td></tr><tr><td>Bed/ Cabin charge</td><td>0.28 (0.00)</td><td>7.95 (0.10)</td></tr><tr><td rowspan="7">Direct Non-Medical</td><td>Transportation cost</td><td>246.58 (3.14)</td><td>427.76 (5.45)</td><td rowspan="7">12.41</td></tr><tr><td>Food items</td><td>113.82 (1.45)</td><td>239.77 (3.05)</td></tr><tr><td>Informal payment</td><td>7.40 (0.09)</td><td>22.65 (0.29)</td></tr><tr><td>Caregiver’s payment</td><td>0.01 (0.00)</td><td>0.35 (0.00)</td></tr><tr><td>Materials (mug/glass etc.)</td><td>22.65 (0.29)</td><td>70.59 (0.90)</td></tr><tr><td>Lodging</td><td>0.00 (0.00)</td><td>0.01 (0.00)</td></tr><tr><td>Caregivers expenditure</td><td>127.87 (1.63)</td><td>456.80 (5.820</td></tr><tr><td>Total direct cost</td><td></td><td>1688.17 (21.51)</td><td>2010.95 (25.62)</td><td>40.4</td></tr><tr><td rowspan="2">In-direct cost</td><td>Patient income loss</td><td>310.51 (3.96)</td><td>1374.40 (17.51)</td><td></td></tr><tr><td>Caregiver’s income loss</td><td>2179.50 (27.76)</td><td>3445.12 (43.89)</td><td></td></tr><tr><td>Total indirect cost</td><td></td><td>2490.01 (31.72)</td><td>3881.48 (49.45)</td><td>59.6</td></tr><tr><td>Total cost</td><td></td><td>4178.68 (53.23)</td><td>5166.20 (65.81)</td><td>100</td></tr></table> |
953921be287a988f884fc0feee040f3dc73700adc002abf8a545b5802c5ee3c2.png | complex | <table><tr><td rowspan="2">Variants Coding</td><td colspan="4">Log Reduction</td></tr><tr><td><i>P. fluorescens</i></td><td><i>Y. enterocolitica</i></td><td><i>B. cereus</i></td><td><i>S. aureus</i></td></tr><tr><td>C0<i>T</i>0</td><td>2.2 ± 0.26</td><td>0.3 ± 0.13</td><td>9.2 ± 0.06</td><td>0.9 ± 0.13</td></tr><tr><td>C0.05<i>T</i>0</td><td>9.5 ± 0.05</td><td>0.3 ± 0.06</td><td>9.2 ± 0.06</td><td>2.0 ± 0.23</td></tr><tr><td>C0.1<i>T</i>0</td><td>9.5 ± 0.05</td><td>0.5 ± 0.07</td><td>9.2 ± 0.06</td><td>2.2 ± 0.06</td></tr><tr><td>C0<i>T</i>3</td><td>4.7 ± 4.12</td><td>0.3 ± 0.11</td><td>9.2 ± 0.06</td><td>0.9 ± 0.27</td></tr><tr><td>C0.05<i>T</i>3</td><td>9.5 ± 0.05</td><td>1.5 ± 0.32</td><td>9.2 ± 0.06</td><td>1.7 ± 0.48</td></tr><tr><td>C0.1<i>T</i>3</td><td>9.5 ± 0.05</td><td>9.3 ± 0.07</td><td>9.2 ± 0.06</td><td>9.2 ± 0.06</td></tr><tr><td>C0<i>T</i>20</td><td>2.3 ± 0.23</td><td>0.7 ± 0.26</td><td>9.2 ± 0.06</td><td>1.4 ± 0.10</td></tr><tr><td>C0.05<i>T</i>20</td><td>9.5 ± 0.05</td><td>9.3 ± 0.07</td><td>9.2 ± 0.06</td><td>9.2 ± 0.06</td></tr><tr><td>C0.1<i>T</i>20</td><td>9.5 ± 0.05</td><td>9.3 ± 0.07</td><td>9.2 ± 0.06</td><td>9.2 ± 0.06</td></tr></table> |
5fe4bbee04afb5ffd290bf8efacff459263bb490ff54c621e606b6282d3ae35a.png | complex | <table><tr><td rowspan="2">Author</td><td rowspan="2">N</td><td>PD-L1 (%)</td><td>Histology (%)</td><td>Stage (%)</td><td rowspan="2">Correlation withPD-L1 positive</td><td rowspan="2">Prognosis ofPD-L1 positive</td></tr><tr><td>1-49%/ >50%</td><td>ADs/Sq/others</td><td>I/II/III/IV</td></tr><tr><td>Reck M<sup>1</sup></td><td>1653</td><td>-/30.2</td><td>-</td><td>0/0/0/100</td><td>-</td><td>-</td></tr><tr><td>Herbst RS<sup>2</sup></td><td>2222</td><td>37.9/28.5</td><td>-</td><td>0/0/0/100</td><td>-</td><td>-</td></tr><tr><td>Garon EB<sup>7</sup></td><td>824</td><td>37.6/23.2</td><td>81.0<sup>*</sup>/17.2/1.8</td><td>0/0/0/100</td><td>KRAS mutation</td><td>-</td></tr><tr><td>Cooper WA<sup>12</sup></td><td>678</td><td>20.8/7.4</td><td>40.7/40.0/19.3</td><td>50/50(II+III)/0</td><td>Younger: High tumor grade</td><td>Better</td></tr><tr><td>He Y<sup>14</sup></td><td>139</td><td>-/18.0</td><td>28.8/58.3/12.9</td><td>41.7/25.2/28.1/5.0</td><td>NS</td><td>Poor</td></tr><tr><td>Sorensen SF<sup>15</sup></td><td>204</td><td>50/25</td><td>72/21.6/6.4</td><td>-/-/-/88</td><td>NS</td><td>NS</td></tr><tr><td>Rangachari D<sup>26</sup></td><td>71</td><td>28.2/29.6</td><td>100/0/0</td><td>25.4(I-III)/74.6</td><td>Smoking</td><td>-</td></tr><tr><td>Present study</td><td>170</td><td>24.7/10.6</td><td>55.3/44.7</td><td>29.4/25.3/45.3/0</td><td>Histology; TILs; tumor stage</td><td>NS</td></tr></table> |
28309125322f1493ca4c5f517b1e8b60e9ac7e71b69e94f46a43e3e7667ca4e4.png | complex | <table><tr><td></td><td>Total population (n = 257)</td><td>SR-group(n = 148)</td><td>AF-group (n = 109)</td><td><i>p</i> Value</td><td>OR (95% CI)</td></tr><tr><td colspan="6">Follow-up Minor vascular complication</td></tr><tr><td> 30 days</td><td>22.6% (58/257)</td><td>22.3% (33/148)</td><td>22.9% (25/109)</td><td>1.00</td><td>1.09 (0.61–1.96)</td></tr><tr><td> 3 months</td><td>23.0% (59/257)</td><td>22.3% (33/148)</td><td>23.9% (26/109)</td><td>0.767</td><td>1.09 (0.61–1.96)</td></tr><tr><td> 6 months</td><td>24.8% (60/241)</td><td>23.9% (33/137)</td><td>26.0% (27/104)</td><td>0.764</td><td>1.12 (0.62–2.01)</td></tr><tr><td> 12 months</td><td>27.3% (60/219)</td><td>26.4% (33/124)</td><td>28.4% (27/95)</td><td>0.762</td><td>1.11 (0.61–2.01)</td></tr><tr><td colspan="6">Follow-up Major bleeding</td></tr><tr><td> 30 days</td><td>3.5% (9/257)</td><td>4.1% (6/148)</td><td>2.8% (3/109)</td><td>0.737</td><td>0.67 (0.16–2.74)</td></tr><tr><td> 3 months</td><td>3.9% (10/257)</td><td>4.7% (7/148)</td><td>2.8% (3/109)</td><td>0.525</td><td>0.57 (0.14–2.26)</td></tr><tr><td> 6 months</td><td>4.5% (11/241)</td><td>5.8% (8/137)</td><td>2.9% (3/104)</td><td>0.360</td><td>0.48 (1.13–1.87)</td></tr><tr><td> 12 months</td><td>5.5% (12/219)</td><td>7.2% (9/124)</td><td>3.2% (3/95)</td><td>0.240</td><td>0.42 (0.11–1.60)</td></tr><tr><td colspan="6">Follow-up Minor bleeding</td></tr><tr><td> 30 days</td><td>19.8% (51/257)</td><td>21.6% (32/148)</td><td>17.4% (19/109)</td><td>1.00</td><td>1.09 (0.61–1.96)</td></tr><tr><td> 3 months</td><td>19.8% (51/257)</td><td>21.6% (32/148)</td><td>17.4% (19/109)</td><td>0.767</td><td>1.09 (0.61–1.96)</td></tr><tr><td> 6 months</td><td>21.0% (51/241)</td><td>23.0% (32/137)</td><td>18.3% (19/104)</td><td>0.764</td><td>1.12 (0.62–2.01)</td></tr><tr><td> 12 months</td><td>23.1% (51/219)</td><td>25.4% (32/124)</td><td>20.0% (19/95)</td><td>0.762</td><td>1.11 (0.61–2.01)</td></tr></table> |
2c8cd753507bb7155a98b8a0d957a57525bda82689b32c3db0f9bbf575163571.png | complex | <table><tr><td>Genotype</td><td>Actual Values</td><td>Expected Value</td><td>χ<sup>2</sup></td><td><i>p</i></td></tr><tr><td>T102C</td><td></td><td></td><td></td><td></td></tr><tr><td>TT</td><td>108</td><td>120.95</td><td rowspan="3">3.589</td><td rowspan="3">0.166</td></tr><tr><td>TC</td><td>194</td><td>169.33</td></tr><tr><td>CC</td><td>48</td><td>58.84</td></tr><tr><td>A-1438G</td><td></td><td></td><td></td><td></td></tr><tr><td>AA</td><td>73</td><td>74.61</td><td rowspan="3">0.205</td><td rowspan="3">0.902</td></tr><tr><td>AG</td><td>181</td><td>174.21</td></tr><tr><td>GG</td><td>96</td><td>99.36</td></tr></table> |
9cefbd7905ff11b3f4d7229a218847e1604a7e9f8315f6be70f5a8295fac00f9.png | complex | <table><tr><td rowspan="2">Risk factors</td><td>Univariate</td><td colspan="3">Multivariate</td></tr><tr><td>P-value</td><td>RR</td><td>95%CI</td><td>P-value</td></tr><tr><td>Age, ≤60 vs. >60 years</td><td><i>0.006*</i></td><td></td><td></td><td>0.763</td></tr><tr><td>Gender, male vs. female</td><td>0.24</td><td></td><td></td><td></td></tr><tr><td>Site, Head and neck vs. Body and tail</td><td>0.15</td><td></td><td></td><td></td></tr><tr><td>Tumor size, ≤3.5 vs. >3.5cm</td><td>0.55</td><td></td><td></td><td></td></tr><tr><td>Tumor differentiation, well/moderate vs. poor</td><td><i>0.000*</i></td><td>1.896</td><td>1.077-3.337</td><td><i>0.027*</i></td></tr><tr><td>Stage (AJCC), I-II vs. III-IV</td><td><i>0.001*</i></td><td>3.614</td><td>1.228-10.64</td><td><i>0.020*</i></td></tr><tr><td>T stage, pT1-T2 vs. pT3-T4</td><td>0.27</td><td></td><td></td><td></td></tr><tr><td>Lymph nodes, negative vs. positive</td><td><i>0.012*</i></td><td></td><td></td><td>0.26</td></tr><tr><td>Metastasis, negative vs. positive</td><td><i>0.010*</i></td><td>1.397</td><td>0.775-2.520</td><td><i>0.012*</i></td></tr><tr><td>CD133, negative vs. positive</td><td><i>0.000*</i></td><td>2.208</td><td>1.161-4.203</td><td><i>0.016*</i></td></tr><tr><td>BMI-1, negative vs. positive</td><td><i>0.000*</i></td><td>2.661</td><td>1.256-5.638</td><td><i>0.011*</i></td></tr><tr><td>Co-expression of CD133 and BMI-1, others vs. CD133+/BMI-1+</td><td><i>0.000*</i></td><td>3.523</td><td>1.365-9.089</td><td><i>0.009*</i></td></tr></table> |
80ee3b0356fdc14f5eec0dd317ab8c3dba1581077fbea9b7f0447bfafd206f72.png | simple | <table><tr><td> </td><td>AE</td><td>CE</td><td>FW</td></tr><tr><td>Total drink volume (mL)</td><td>2292.25 ± 457.99</td><td>2279.26 ± 483.63</td><td>2360.44 ± 519.75</td></tr><tr><td>Test drink volume (mL)</td><td>772.46 ± 93.17</td><td>774.73 ± 100.9</td><td>770.83 ± 96.88</td></tr><tr><td>Water drink volume (mL)</td><td>1519.79 ± 388.04</td><td>1504.52 ± 428.92</td><td>1589.62 ± 476.92</td></tr><tr><td>Total urine volume (mL)</td><td>1295.5 ± 457.56</td><td>1348.25 ± 450.94</td><td>1363.25 ± 520.44</td></tr><tr><td>Fluid retention (%)</td><td>43.5 ± 17.1</td><td>40.8 ± 18.1</td><td>42.2 ± 14.3</td></tr></table> |
5c858155c2f492c74ab68b7603fbe3e281354fbf5791743535d1fe156ad92564.png | simple | <table><tr><td>Index</td><td>Group</td><td>0-week</td><td>2-week</td><td>4-week</td><td>8-week</td><td>12-week</td></tr><tr><td>TC</td><td>NDG</td><td>1.67 ± 0.43</td><td>1.72 ± 0.45</td><td>1.72 ± 0.25</td><td>1.98 ± 0.55</td><td>2.02 ± 0.58</td></tr><tr><td></td><td>HH</td><td>1.80 ± 0.20</td><td>1.88 ± 0.22</td><td>2.59 ± 0.76*<sup>#</sup></td><td>18.57 ± 1.25**<sup>##</sup></td><td>19.08 ± 1.31**<sup>##</sup></td></tr><tr><td>TG</td><td>NDG</td><td>1.06 ± 0.31</td><td>1.09 ± 0.45</td><td>1.11 ± 0.38</td><td>1.28 ± 0.35</td><td>1.36 ± 0.55</td></tr><tr><td></td><td>HH</td><td>1.09 ± 0.15</td><td>1.12 ± 0.11</td><td>2.09 ± 0.87*<sup>#</sup></td><td>3.83 ± 1.75**<sup>##</sup></td><td>4.07 ± 1.54**<sup>##</sup></td></tr><tr><td>HDL</td><td>NDG</td><td>0.61 ± 0.20</td><td>0.69 ± 0.26</td><td>0.65 ± 0.31</td><td>0.58 ± 0.17</td><td>0.76 ± 0.27</td></tr><tr><td></td><td>HH</td><td>0.53 ± 0.07</td><td>0.55 ± 0.09</td><td>1.21 ± 0.35*<sup>#</sup></td><td>2.04 ± 1.11**<sup>##</sup></td><td>2.12 ± 1.23**<sup>##</sup></td></tr><tr><td>LDL</td><td>NDG</td><td>0.93 ± 0.21</td><td>0.95 ± 0.33</td><td>1.01 ± 0.49</td><td>0.89 ± 0.27</td><td>0.98 ± 0.25</td></tr><tr><td></td><td>HH</td><td>0.94 ± 0.26</td><td>1.06 ± 0.24</td><td>1.84 ± 0.36*<sup>#</sup></td><td>14.68 ± 1.42**<sup>##</sup></td><td>15.13 ± 1.64**<sup>##</sup></td></tr></table> |
1fc3fab7cbcd8a97d285980ef10c82a0432d32637638c7e2188bfc5dfb1fa0d5.png | complex | <table><tr><td>Subtheme</td><td>Quote</td></tr><tr><td rowspan="3">Previous experiences with teletraining</td><td>“What I actually find more useful [in Rural Grand Rounds] is quite often he gets paediatricians, emergency medicine from [bigger regional centres], from everywhere who actually do speeches and talks” [PF 4]</td></tr><tr><td>“So yeah, that lack of physical-ness about the situation means often you can get apathetic and sometimes just be a bit blasé about it all and sign on just because you have to sign on” [PF 3]</td></tr><tr><td>“Oh, I think it serves a purpose. So these people are spread off all over North Queensland and the distances that are involved are prohibitive for everyone together on a really regular basis” [PF 3]</td></tr><tr><td rowspan="2">Face to Face versus videoconference learning</td><td>“I think any access to any teaching would be appropriate and even if you do not pick up at come place like do not pick up as much from face to face teaching...Sometimes telehealth teaching can teach you maybe if you do pick up 50% of it just because it's ongoing” [PF 5]</td></tr><tr><td>“I think tele-training is the way of the future especially for people in our area that more and more of us are going out to rural sites” [RR 2]</td></tr><tr><td rowspan="2">Peer teaching</td><td>“The best benefit is you get to experience different thinking outside the box and different ways of doing things that apply to rural areas, rather than the textbook stuff that does not always apply” [PF 6]</td></tr><tr><td>“I enjoy catching up with people that are in a similar role and have a chance to debrief and have a chance to learn from each other and that is not really a lot of opportunity for that, and the peer education, just people in the same situation and learning from things they have seen and done before, that is probably the only thing I have noticed as a difference” [PF 1]</td></tr><tr><td rowspan="5">Teaching skills using videoconference</td><td>“I think though that there are certain skills that you need to do person - face-to-face and have immediate feedback on” [RG 2]</td></tr><tr><td>“Unfortunately the technology is what people take away from those learning opportunities; they do not take away the actual message of simulation” [RG 6]</td></tr><tr><td>“There is no reason why they cannot create a resus with a mannequin, put a dress on it and bring it to the ED and run their own simulation. We all have inherent skills and knowledge. Doing simple stuff, it does not need to be complex” [RG 6]</td></tr><tr><td>“The biggest issue with rural is that often you plan to do something every week ...then it just falls off the radar... I think you'd need to have a bunch of passionate people at a centralised location to really push it to happen every week” [PF 4]</td></tr><tr><td>“I do not see why you would need someone to teach a practical skill online as a teleconference when you can use YouTube, pause it and revisit all of the steps” [PF 6]</td></tr><tr><td rowspan="2">Didactic versus interactive sessions</td><td>“Interactive, I definitely prefer, but sometimes in the early years of GP training, a lot of the stuff was a bit didactic, but I did not mind that, I found it to be quiet useful” [GPRNH]</td></tr><tr><td>“There would be scope for that as long as it's not didactic lectures, as long as there can be interaction and the facilitators have a skill in that and the people who are being educated, the students, are prepared enough to interact...it would have to be an interactive thing otherwise you can get that from a YouTube, cannot you?” [RG 3]</td></tr></table> |
dc8b05760a67db0b62ac0514a1c48545968186a75d52fb62f3d7fb54ef8d3e84.png | complex | <table><tr><td></td><td colspan="6">Emotive coping</td></tr><tr><td></td><td colspan="3">Univariate</td><td colspan="3">Multivariate<sup>a</sup></td></tr><tr><td>Variables</td><td>OR</td><td>(95% CI)</td><td><i>p</i>-value</td><td>OR</td><td>(95% CI)</td><td><i>p</i>-value</td></tr><tr><td>Sex (female)</td><td>4.07</td><td>(1.12–14.79)</td><td>0.03</td><td>3.39</td><td>(1.01–11.40)</td><td>0.005</td></tr><tr><td>Age</td><td>0.94</td><td>(0.90–0.99)</td><td>0.02</td><td>0.93</td><td>(0.88–0.97)</td><td>0.004</td></tr><tr><td>Single (0–1)</td><td>1.17</td><td>(0.28–4.93)</td><td>0.83</td><td></td><td></td><td></td></tr><tr><td>University education (0–1)</td><td>0.34</td><td>(0.07–1.63)</td><td>0.17</td><td></td><td></td><td></td></tr><tr><td>Immigrants (0–1)</td><td>0.31</td><td>(0.08–1.19)</td><td>0.08</td><td></td><td></td><td></td></tr><tr><td>Physical activity (1–4)</td><td>0.08</td><td>(0.04–0.21)</td><td><0.0001</td><td>0.13</td><td>(0.06–0.32)</td><td><0.0001</td></tr><tr><td>Sleep problems (0–20)</td><td>1.35</td><td>(1.20–1.51)</td><td><0.0001</td><td>1.25</td><td>(1.11–1.42)</td><td>0.0002</td></tr><tr><td>Mental strain at work (2–10)</td><td>2.00</td><td>(1.48–2.70)</td><td><0.0001</td><td>1.44</td><td>(1.08–1.91)</td><td>0.005</td></tr><tr><td>Stress at home (0–5)</td><td>2.17</td><td>(1.43–3.29)</td><td>0.0003</td><td>1.15</td><td>(0.74–1.77)</td><td>0.89</td></tr><tr><td>Life events (0–30)</td><td>1.29</td><td>(1.12–1.49)</td><td>0.0006</td><td>1.21</td><td>(1.04–1.41)</td><td>0.01</td></tr></table> |
5bcce8edc20138dce1922ef0575e0f09debdc71e80fef5c40fadffa075af64cf.png | simple | <table><tr><td>Characteristic</td><td>N</td><td>%</td></tr><tr><td>Age (Years)</td><td> </td><td> </td></tr><tr><td> <40</td><td>39</td><td>5.6</td></tr><tr><td> 40-49</td><td>165</td><td>23.7</td></tr><tr><td> 50-59</td><td>215</td><td>30.9</td></tr><tr><td> 60-69</td><td>214</td><td>30.8</td></tr><tr><td> 70+</td><td>62</td><td>8.9</td></tr><tr><td>BMI (kg/m<sup>2</sup>)</td><td> </td><td> </td></tr><tr><td> <21</td><td>98</td><td>14.1</td></tr><tr><td> 21-24.9</td><td>228</td><td>32.8</td></tr><tr><td> 25-29.9</td><td>218</td><td>31.4</td></tr><tr><td> 30+</td><td>151</td><td>21.8</td></tr><tr><td>Biopsy technique</td><td> </td><td> </td></tr><tr><td> Stereotactic</td><td>381</td><td>54.8</td></tr><tr><td> Ultrasound-guided</td><td>194</td><td>27.9</td></tr><tr><td> MRI-guided</td><td>120</td><td>17.3</td></tr><tr><td>Referral group</td><td> </td><td> </td></tr><tr><td> Screening</td><td>83</td><td>11.9</td></tr><tr><td> History of breast cancer</td><td>90</td><td>13.0</td></tr><tr><td> Clinical symptoms</td><td>128</td><td>18.4</td></tr><tr><td> Only images</td><td>394</td><td>56.7</td></tr><tr><td>BIRADS</td><td> </td><td> </td></tr><tr><td> 2-3</td><td>75</td><td>10.8</td></tr><tr><td> 4</td><td>346</td><td>49.8</td></tr><tr><td> 5</td><td>204</td><td>29.3</td></tr><tr><td> 6</td><td>70</td><td>10.1</td></tr><tr><td>Radiological findings</td><td> </td><td> </td></tr><tr><td> Radiological focus</td><td>396</td><td>57.0</td></tr><tr><td> Microcalcification</td><td>346</td><td>49.8</td></tr><tr><td>Mammographic breast density (ACR)</td><td> </td><td> </td></tr><tr><td> almost entirely fatty</td><td>58</td><td>8.4</td></tr><tr><td> fibroglandular</td><td>282</td><td>41.0</td></tr><tr><td> heterogenous dense</td><td>283</td><td>41.1</td></tr><tr><td> extremely dense</td><td>65</td><td>9.5</td></tr><tr><td>Mammographic breast density (Computer-based assessment)</td><td> </td><td> </td></tr><tr><td> <10%</td><td>242</td><td>34.8</td></tr><tr><td> 10% to <25%</td><td>181</td><td>26.0</td></tr><tr><td> 25% to <50%</td><td>186</td><td>26.8</td></tr><tr><td> ≥50%</td><td>86</td><td>12.4</td></tr></table> |
13e6c96ed7357bd1433cb2ecb1d9d21a1805406019daa7643a8791e8f78cc4ea.png | complex | <table><tr><td rowspan="2"> </td><td colspan="2">Adult learning disability</td><td colspan="2">Head and neck cancer</td><td colspan="2">Other</td></tr><tr><td>Non aspiration pneumonia</td><td>Aspiration pneumonia</td><td>Non aspiration pneumonia</td><td>Aspiration pneumonia</td><td>Non aspiration pneumonia</td><td>Aspiration pneumonia</td></tr><tr><td>Number of subjects (M/F)</td><td>8/8</td><td>3/6</td><td>23/16</td><td>1/3</td><td>269/211</td><td>96/43</td></tr><tr><td>Age in years (mean ± sd)</td><td>52 ± 17</td><td>56 ± 11</td><td>59 ± 13</td><td>70 ± 17</td><td>73 ± 16</td><td>80 ± 13</td></tr></table> |
5445734146b66ac9e2a036dfa1e37525119547d91682724fc04d70ec9448bf2d.png | complex | <table><tr><td rowspan="2">Characteristics</td><td>PE factor</td><td>DE factor</td><td>NC factor</td><td>PS factor</td><td>NE factor</td><td>CS factor</td></tr><tr><td>Mean (SD)</td><td>Mean (SD)</td><td>Mean (SD)</td><td>Mean (SD)</td><td>Mean (SD)</td><td>Mean (SD)</td></tr><tr><td colspan="7">Residential area</td></tr><tr><td> Summer house area</td><td>0.78 (0.89)</td><td>−0.08 (1.07)</td><td>0.21 (1.01)</td><td>−0.24 (0.91)</td><td>0.26 (1.08)</td><td>−0.32 (0.99)</td></tr><tr><td> <i>Ger</i> area</td><td>−0.34 (0.93)</td><td>−0.18 (0.86)</td><td>−0.09 (1.06)</td><td>0.14 (0.99)</td><td>−0.25 (0.95)</td><td>0.18 (1.09)</td></tr><tr><td> Apartment area</td><td>−0.18 (0.91)</td><td>−0.18 (0.94)</td><td>−0.02 (0.99)</td><td>−0.05 (1.00)</td><td>0.31 (0.99)</td><td>0.12 (0.89)</td></tr><tr><td> Luxury residential area</td><td>0.30 (0.94)</td><td>0.75 (0.94)</td><td>−0.05 (0.86)</td><td>0.02 (1.04)</td><td>0.01 (0.94)</td><td>−0.29 (0.87)</td></tr><tr><td> <i>P</i> value</td><td><0.001</td><td><0.001</td><td>0.042</td><td>0.005</td><td><0.001</td><td><0.001</td></tr><tr><td colspan="7">Education</td></tr><tr><td> Basic education</td><td>−0.22 (1.14)</td><td>−0.23 (0.93)</td><td>−0.05 (1.14)</td><td>−0.16 (1.11)</td><td>0.07 (1.03)</td><td>−0.05 (1.18)</td></tr><tr><td> High school</td><td>−0.01 (0.95)</td><td>−0.20 (0.92)</td><td>0.06 (1.06)</td><td>0.00 (0.93)</td><td>0.03 (0.93)</td><td>0.04 (0.93)</td></tr><tr><td> Vocational education</td><td>−0.02 (1.03)</td><td>−0.21 (0.92)</td><td>0.04 (0.88)</td><td>−0.07 (0.94)</td><td>−0.10 (0.96)</td><td>0.04 (1.02)</td></tr><tr><td> College or university</td><td>0.09 (0.98)</td><td>0.19 (0.99)</td><td>−0.05 (1.01)</td><td>0.10 (1.02)</td><td>−0.01 (1.04)</td><td>0.08 (0.93)</td></tr><tr><td> Graduate school</td><td>0.04 (0.91)</td><td>0.46 (1.13)</td><td>−0.02 (0.79)</td><td>−0.02 (1.03)</td><td>−0.01 (1.06)</td><td>−0.35 (1.07)</td></tr><tr><td> <i>P</i> value</td><td>0.139</td><td><0.001</td><td>0.770</td><td>0.211</td><td>0.764</td><td>0.014</td></tr><tr><td colspan="7">Household income, monthly</td></tr><tr><td> <500,000 MNT (<250 USD)</td><td>−0.06 (1.13)</td><td>−0. 17 (0.97)</td><td>−0.11 (1.11)</td><td>0.03 (1.06)</td><td>−0.04 (1.11)</td><td>0.12 (1.11)</td></tr><tr><td> ≥500,000 and <800,000 MNT(≥250 and <400 USD)</td><td>−0.14 (0.93)</td><td>−0.29 (0.95)</td><td>−0.01 (1.04)</td><td>−0.14 (1.01)</td><td>−0.02 (0.90)</td><td>0.11 (1.11)</td></tr><tr><td> ≥800,000 and <1,200,000 MNT(≥400 and <600 USD)</td><td>−0.04 (0.99)</td><td>−0.03 (0.92)</td><td>0.18 (1.00)</td><td>0.05 (0.88)</td><td>−0.04 (0.95)</td><td>−0.14 (0.85)</td></tr><tr><td> ≥1,200,000 and <2,500,000 MNT(≥600 and <1240 USD)</td><td>0.07 (0.90)</td><td>0.16 (0.98)</td><td>−0.09 (0.91)</td><td>0.11 (1.06)</td><td>0.10 (1.03)</td><td>0.05 (0.89)</td></tr><tr><td> ≥2,500,000 MNT (≥1240 USD)</td><td>0.47 (1.02)</td><td>0.89 (0.89)</td><td>0.01 (0.78)</td><td>0.02 (0.98)</td><td>0.05 (1.06)</td><td>−0.33 (0.87)</td></tr><tr><td> <i>P</i> value</td><td><0.001</td><td><0.001</td><td>0.068</td><td>0.151</td><td>0.710</td><td>0.002</td></tr></table> |
d42c5cbd385ab20c8ef99f4713813a989e001ba00e8941ab90b2c7de18a13a2f.png | simple | <table><tr><td>Clinical/Laboratory/ Radiological Finding</td><td>Specification</td></tr><tr><td>Impaired consciousness or unrousable coma</td><td>Glasgow Coma Scale ≤10<sup>b</sup></td></tr><tr><td>Multiple convulsions</td><td>>2 episodes within 24 h or generalized seizures</td></tr><tr><td>Respiratory distress or acidotic breathing</td><td>Requirement of noninvasive or endotracheal mechanical ventilation<sup>b</sup> or respiratory rate of ≥40 breaths/min on room air</td></tr><tr><td>Circulatory collapse or shock</td><td>Systolic blood pressure <80 mm Hg or ≤80 mm Hg despite volume repletion</td></tr><tr><td>Acute pulmonary edema</td><td>Verified radiologically</td></tr><tr><td>Acute respiratory distress syndrome</td><td>Verified radiologically</td></tr><tr><td>Acute kidney injury/renal impairment</td><td>Serum creatinine >265 μmol/L</td></tr><tr><td>Acidosis or hyperlactatemia</td><td>pH <7.25 or plasma bicarbonate <15 mmol/L or lactate >5 mmol/L</td></tr><tr><td>Clinical jaundice plus evidence of other vital organ dysfunction</td><td>Bilirubin >50 μmol/L together with circulatory instability, respiratory distress, impaired consciousness, severe coagulopathy, or acute kidney injury</td></tr><tr><td>Severe normocytic anemia</td><td>Hemoglobin <70 g/L not related to other cause than the malaria infection</td></tr><tr><td>Abnormal bleeding</td><td>Spontaneous bleeding from gums, mouth, or gastrointestinal tract</td></tr><tr><td>Macroscopic hemoglobinuria</td><td>Unequivocally related to acute malaria and verified by urine dipstick</td></tr><tr><td>Hypoglycemia</td><td>Blood glucose <2.2 mmol/L</td></tr><tr><td>Hyperparasitemia</td><td>Parasitemia >5%</td></tr></table> |
1d3ecc78edc256c5e941cb9fb21b8c5f0b25a93c037bcbd54a74ec4d4b975b35.png | complex | <table><tr><td></td><td></td><td colspan="4"><i>T</i><sub>1</sub></td></tr><tr><td></td><td></td><td>Excellent/very good <i>N</i> (%)</td><td>Good <i>N</i> (%)</td><td>Fair/poor <i>N</i> (%)</td><td>Total<i>N</i> (%)</td></tr><tr><td rowspan="3"><i>T</i><sub>0</sub></td><td> Excellent/very good</td><td>142 (19.7)</td><td>81 (11.3)</td><td>7 (1.0)</td><td>230 (32.0)</td></tr><tr><td> Good</td><td>111 (15.4)</td><td>293 (40.8)</td><td>31 (4.3)</td><td>435 (60.5)</td></tr><tr><td> Fair/poor</td><td>6 (0.8)</td><td>29 (4.0)</td><td>19 (2.7)</td><td>54 (7.5)</td></tr><tr><td></td><td> Total</td><td>259 (35.9)</td><td>403 (56.1)</td><td>57 (8.0)</td><td>719 (100.0)</td></tr></table> |
f8cc386b3a7c2abd7f2892fba63d98433611856b045fdefb8383379bbbeec21d.png | simple | <table><tr><td></td><td>Lab studies</td><td>Outdoor studies</td></tr><tr><td>1980-1985</td><td>Collection & screening of algae</td><td>Wastewater treatment, small pond studies</td></tr><tr><td>1985-1990</td><td>Classification of algae biochemistry & physiology of lipid production</td><td>Large pond studies</td></tr><tr><td>1990-1996</td><td>Genetic engineering</td><td>Systems analysis & resource assessment</td></tr></table> |
c73cb04c0b51040c750ecd6f5c7f7ae991bfb97f322e74fbe15acef26eb5261c.png | complex | <table><tr><td>Age group (years)</td><td colspan="2">Male</td><td colspan="2">Female</td><td colspan="2">Total</td></tr><tr><td colspan="7">Levels of Systolic Blood Pressure (SBP) in different age groups (mmHg, median (Q25; Q75)</td></tr><tr><td></td><td>SBP</td><td>Q25; Q75</td><td>SBP</td><td>Q25; Q75</td><td>SBP</td><td>Q25; Q75</td></tr><tr><td>25–34</td><td>127.5</td><td>119.5; 137.5</td><td>116.0</td><td>109.0; 125.0</td><td>120.5</td><td>111.5; 130.5</td></tr><tr><td>35–44</td><td>134.3</td><td>124.3; 142.8</td><td>121.5</td><td>113.0; 132.0</td><td>126.0</td><td>116.0; 138.5</td></tr><tr><td>45–54</td><td>140.0</td><td>129.5; 148.5</td><td>130.5</td><td>118.5; 142.5</td><td>134.0</td><td>122.0; 145.0</td></tr><tr><td>55–64</td><td>144.0</td><td>135.0; 158.5</td><td>141.0</td><td>130.0; 156.5</td><td>142.5</td><td>132.5; 157.0</td></tr><tr><td colspan="7">Levels of Diastolic Blood Pressure (DBP) in different age groups (mmHg, median (Q25; Q75)</td></tr><tr><td></td><td>DBP</td><td>Q25; Q75</td><td>DBP</td><td>Q25; Q75</td><td>DBP</td><td>Q25; Q75</td></tr><tr><td>25–34</td><td>78.5</td><td>73.0; 84.5</td><td>74.5</td><td>69.0; 81.0</td><td>76.0</td><td>71.0; 82.5</td></tr><tr><td>35–44</td><td>83.5</td><td>76.3; 91.0</td><td>79.5</td><td>72.5; 88.0</td><td>82.0</td><td>74.0; 89.0</td></tr><tr><td>45–54</td><td>88.5</td><td>81.5; 93.0</td><td>82.0</td><td>72.5; 90.0</td><td>85.0</td><td>76.0; 91.5</td></tr><tr><td>55–64</td><td>88.0</td><td>80.5; 95.5</td><td>86.0</td><td>80.0; 94.0</td><td>87.0</td><td>80.0; 95.0</td></tr><tr><td colspan="7">Hypertension prevalence in different age groups (% ± 95% CI)</td></tr><tr><td></td><td>% (n)</td><td>95% CI</td><td>% (n)</td><td>95% CI</td><td>% (n)</td><td>95% CI</td></tr><tr><td>25–34</td><td>27.0 (<i>n</i> = 44)</td><td>6.86</td><td>10.8 (<i>n</i> = 25)</td><td>3.92</td><td>17.5 (<i>n</i> = 69)</td><td>3.72</td></tr><tr><td>35–44</td><td>43.3 (<i>n</i> = 52)</td><td>8.82</td><td>32.1 (<i>n</i> = 62)</td><td>6.66</td><td>36.4 (<i>n</i> = 114)</td><td>5.29</td></tr><tr><td>45–54</td><td>71.0 (<i>n</i> = 103)</td><td>7.39</td><td>53.0 (<i>n</i> = 134)</td><td>6.15</td><td>59.5 (<i>n</i> = 237)</td><td>4.90</td></tr><tr><td>55–64</td><td>79.9 (<i>n</i> = 143)</td><td>5.88</td><td>76.7 (<i>n</i> = 198)</td><td>5.15</td><td>78.0 (<i>n</i> = 341)</td><td>3.92</td></tr><tr><td colspan="7">Hypertension awareness in different age groups (% ± 95% CI)</td></tr><tr><td></td><td>% (n)</td><td>95% CI</td><td>% (n)</td><td>95% CI</td><td>% (n)</td><td>95% CI</td></tr><tr><td>25–34</td><td>70.5 (<i>n</i> = 31)</td><td>6.27</td><td>76.0 (<i>n</i> = 19)</td><td>4.51</td><td>72.5 (<i>n</i> = 50)</td><td>10.58</td></tr><tr><td>35–44</td><td>82.7 (<i>n</i> = 43)</td><td>7.25</td><td>79.0 (<i>n</i> = 49)</td><td>5.49</td><td>80.7 (<i>n</i> = 92)</td><td>7.25</td></tr><tr><td>45–54</td><td>73.8 (<i>n</i> = 76)</td><td>6.86</td><td>79.9 (<i>n</i> = 107)</td><td>4.70</td><td>77.2 (<i>n</i> = 183)</td><td>5.29</td></tr><tr><td>55–64</td><td>80.4 (<i>n</i> = 115)</td><td>5.88</td><td>77.3 (<i>n</i> = 153)</td><td>5.10</td><td>78.6 (<i>n</i> = 268)</td><td>4.31</td></tr></table> |
5412f577846f774779f8fb6500505ed702147296dbdd1de679c3cebfb96ffdbe.png | complex | <table><tr><td></td><td colspan="3">PCI</td><td colspan="3">CABG</td><td colspan="3">PCI and/or CABG</td></tr><tr><td>State</td><td>No. of Cases</td><td>Rate</td><td>Ratio to Mean (95% CI)</td><td>No. of Cases</td><td>Rate</td><td>Ratio to Mean (95% CI)</td><td>No. of Cases</td><td>Rate</td><td>Ratio to Mean (95% CI)</td></tr><tr><td>AZ</td><td>10,576</td><td>287</td><td>1.08 (1.06, 1.10)</td><td>5,131</td><td>138</td><td>0.93 (0.91, 0.96)</td><td>15.520</td><td>420</td><td>1.03 (1.01, 1.04)</td></tr><tr><td>CA</td><td>50,436</td><td>239</td><td>0.90 (0.89, 0.91)</td><td>28,537</td><td>136</td><td>0.92 (0.91, 0.93)</td><td>78,099</td><td>371</td><td>0.91 (0.90, 0.91)</td></tr><tr><td>CO</td><td>6,932</td><td>261</td><td>0.98 (0.96, 1.00)</td><td>3,035</td><td><i>118</i></td><td><i>0.80 (0.77, 0.83)</i></td><td>9,856</td><td>374</td><td>0.91 (0.90, 0.93)</td></tr><tr><td>FL</td><td>47,423</td><td><i>340</i></td><td><i>1.28 (1.27, 1.29)</i></td><td>26,023</td><td><i>182</i></td><td><i>1.23 (1.22, 1.25)</i></td><td>72,713</td><td><i>517</i></td><td><i>1.26 (1.25, 1.27)</i></td></tr><tr><td>IA</td><td>7,411</td><td>326</td><td>1.22 (1.20, 1.25)</td><td>3,440</td><td>150</td><td>1.02 (0.99, 1.05)</td><td>10,796</td><td>474</td><td>1.16 (1.14, 1.18)</td></tr><tr><td>MD</td><td>9,307</td><td>257</td><td>0.97 (0.95, 0.99)</td><td>4,620</td><td>129</td><td>0.88 (0.85, 0.90)</td><td>13,779</td><td>382</td><td>0.93 (0.92, 0.95)</td></tr><tr><td>NY</td><td>33,429</td><td>245</td><td>0.92 (0.91, 0.93)</td><td>18,182</td><td>134</td><td>0.91 (0.90, 0.92)</td><td>51,352</td><td>377</td><td>0.92 (0.91, 0.93)</td></tr><tr><td>OR</td><td>4,716</td><td><i>186</i></td><td><i>0.70 (0.68, 0.72)</i></td><td>3,812</td><td>152</td><td>1.03 (1.00, 1.06)</td><td>8,452</td><td><i>335</i></td><td><i>0.82 (0.80, 0.84)</i></td></tr><tr><td>SC</td><td>8,053</td><td>281</td><td>1.06 (1.03, 1.08)</td><td>4,859</td><td>170</td><td>1.15 (1.12, 1.18)</td><td>12,804</td><td>447</td><td>1.09 (1.07, 1.11)</td></tr><tr><td>WA</td><td>8,765</td><td>218</td><td>0.82 (0.80, 0.84)</td><td>5,475</td><td>139</td><td>0.94 (0.92, 0.97)</td><td>14,121</td><td>354</td><td>0.86 (0.85, 0.88)</td></tr><tr><td>WI</td><td>10,994</td><td>282</td><td>1.06 (1.04, 1.08)</td><td>6,704</td><td>172</td><td>1.17 (1.14, 1.20)</td><td>17,469</td><td>448</td><td>1.09 (1.08, 1.11)</td></tr><tr><td>Total</td><td>198,042</td><td>266</td><td></td><td>109,818</td><td>147</td><td></td><td>304,961</td><td>409</td><td></td></tr><tr><td>Ratio of Highest/Lowest Rates</td><td></td><td>1.83</td><td></td><td></td><td>1.54</td><td></td><td></td><td>1.54</td><td></td></tr></table> |
269a358a1e6931b12a5aba40ae57f05556aad6e948260d577fe6b7a875e4151d.png | simple | <table><tr><td>Number</td><td>Vitamin E succinate (%)</td><td>Vitamin E acetate (%)</td><td>Gamma- tocopheryl succinate(%)</td></tr><tr><td>1</td><td>112.5 ± 8.4</td><td> 0</td><td>0.38</td></tr><tr><td>2</td><td>116.9 ± 8.3</td><td> 0</td><td>0.46</td></tr><tr><td>3</td><td>104.2 ± 9.7</td><td> 0</td><td>0.71</td></tr><tr><td>4</td><td>103.9 ± 3.3</td><td> 0</td><td>0.47</td></tr><tr><td>5</td><td>99.5 ± 7.1</td><td> 0</td><td>0.37</td></tr><tr><td>6</td><td>106.1 ± 2.8</td><td> 0</td><td>0.29</td></tr><tr><td>7</td><td>110.5 ± 5.9</td><td> 0</td><td>0.74</td></tr><tr><td>8</td><td>106.4 ± 5.5</td><td> 0</td><td>0.41</td></tr><tr><td>9</td><td>116.8 ± 4.2</td><td> 0</td><td>0.94</td></tr><tr><td>10</td><td>110.0 ± 5.1</td><td> 0</td><td>0.55</td></tr><tr><td>11</td><td>103.7 ± 2.9</td><td> 0</td><td>0.81</td></tr><tr><td>12</td><td>119.3 ± 4.3</td><td> 0</td><td>0.57</td></tr><tr><td>13</td><td> 0</td><td>9.3</td><td> 0</td></tr><tr><td>14</td><td> 0</td><td>84.7</td><td> 0</td></tr></table> |
649f4cce1b3b969f5a3ca8706415fb523644e095caa029a648fd483726338a1e.png | complex | <table><tr><td></td><td colspan="3">Trimmed population</td><td colspan="3">Stratified-matched population</td></tr><tr><td></td><td>Rituximab (<i>n</i> = 265)</td><td>Anti-TNF (<i>n</i> = 737)</td><td>Standardized difference</td><td>Rituximab(<i>n</i> = 205)</td><td>Anti-TNF(<i>n</i> = 205)</td><td>Standardized difference</td></tr><tr><td colspan="7">Demographics</td></tr><tr><td> White, %</td><td>87.6</td><td>83.5</td><td>0.114</td><td>84.4</td><td>87.3</td><td>0.084</td></tr><tr><td> Female, %</td><td>81.1</td><td>79.2</td><td>0.049</td><td>82.9</td><td>81.0</td><td>0.051</td></tr><tr><td> Age, mean (SD), years</td><td>57.8 (11.7)</td><td>56.1 (12.4)</td><td>0.139</td><td>57.6 (11.7)</td><td>58.0 (11.5)</td><td>0.037</td></tr><tr><td colspan="7">Insurance</td></tr><tr><td> Medicare, %</td><td>37.7</td><td>29.4</td><td>0.176</td><td>33.7</td><td>39.0</td><td>0.111</td></tr><tr><td> Medicaid, %</td><td>7.2</td><td>6.4</td><td>0.032</td><td>7.3</td><td>6.3</td><td>0.039</td></tr><tr><td> Private insurance, %</td><td>76.6</td><td>78.7</td><td>0.050</td><td>76.1</td><td>74.6</td><td>0.034</td></tr><tr><td> No insurance, %</td><td>1.1</td><td>2.3</td><td>0.090</td><td>1.5</td><td>1.5</td><td>0.000</td></tr><tr><td colspan="7">History of comorbidities</td></tr><tr><td> Cardiovascular disease, %</td><td>11.3</td><td>7.3</td><td>0.137</td><td>9.8</td><td>11.7</td><td>0.063</td></tr><tr><td> Cancer, %</td><td>9.4</td><td>7.7</td><td>0.061</td><td>10.2</td><td>8.8</td><td>0.050</td></tr><tr><td> Diabetes, %</td><td>9.8</td><td>10.7</td><td>0.030</td><td>10.2</td><td>10.7</td><td>0.016</td></tr><tr><td colspan="7">Clinical characteristics</td></tr><tr><td> Disease duration, mean (SD), years</td><td>15.4 (10.2)</td><td>11.4 (9.4)</td><td>0.408</td><td>14.6 (10.3)</td><td>15.1 (10.5)</td><td>0.047</td></tr><tr><td> Tender joint count, mean (SD)</td><td>9.6 (7.3)</td><td>8.7 (7.3)</td><td>0.117</td><td>9.5 (7.2)</td><td>9.1 (7.8)</td><td>0.058</td></tr><tr><td> Swollen joint count, mean (SD)</td><td>8.0 (5.6)</td><td>7.5 (5.7)</td><td>0.097</td><td>7.9 (5.5)</td><td>7.4 (5.8)</td><td>0.086</td></tr><tr><td> Patient global assessment, mean (SD)</td><td>54.3 (23.6)</td><td>50.6 (25.0)</td><td>0.154</td><td>53.2 (23.4)</td><td>52.7 (25.5)</td><td>0.023</td></tr><tr><td> Physician global assessment, mean (SD)</td><td>42.7 (20.2)</td><td>39.3 (20.1)</td><td>0.169</td><td>42.3 (19.7)</td><td>39.8 (19.1)</td><td>0.130</td></tr><tr><td> Patient pain, mean (SD)</td><td>56.5 (24.5)</td><td>53.2 (25.5)</td><td>0.132</td><td>55.3 (24.8)</td><td>53.0 (26.2)</td><td>0.093</td></tr><tr><td> Disability index (mHAQ), mean (SD)</td><td>0.78 (0.5)</td><td>0.64 (0.5)</td><td>0.270</td><td>0.74 (0.5)</td><td>0.72 (0.5)</td><td>0.040</td></tr><tr><td> Clinical Disease Activity Index, mean (SD)</td><td>27.3 (12.5)</td><td>25.2 (11.9)</td><td>0.172</td><td>27.0 (12.0)</td><td>25.7 (12.3)</td><td>0.100</td></tr><tr><td colspan="7">Prior medication use</td></tr><tr><td> Prior nbDMARDs, n, mean</td><td>1.6</td><td>1.1</td><td>0.396</td><td>1.4</td><td>1.4</td><td>0.031</td></tr><tr><td> Prior use of ≥2 anti-TNF agents, %</td><td>63.0</td><td>26.6</td><td>0.786</td><td>54.6</td><td>54.6</td><td>0.000</td></tr><tr><td> Prior use of non–anti-TNF biologic agents, %</td><td>40.8</td><td>13.0</td><td>0.657</td><td>31.7</td><td>33.2</td><td>0.031</td></tr><tr><td colspan="7">Concomitant medications</td></tr><tr><td> Prednisone, %</td><td>43.8</td><td>29.3</td><td>0.303</td><td>39.0</td><td>38.5</td><td>0.010</td></tr><tr><td> Methotrexate, %</td><td>57.7</td><td>55.9</td><td>0.037</td><td>57.1</td><td>51.7</td><td>0.108</td></tr><tr><td> Non-methotrexate nbDMARD, %</td><td>29.1</td><td>24.8</td><td>0.095</td><td>29.8</td><td>30.2</td><td>0.011</td></tr></table> |
9284a9c190b12c11842ebc465c6a2c42bed826b91a02f11c7364cc5f676374c6.png | complex | <table><tr><td>Gene Family Member</td><td colspan="2">Enriched Genes</td><td colspan="2">Cases</td><td colspan="2">Controls</td><td colspan="3">Gene Network Association</td></tr><tr><td> </td><td>No.</td><td>Frequency</td><td>No.</td><td>Frequency</td><td>#</td><td>Frequency</td><td><i>P</i><sub>fisher</sub></td><td>Enrichment</td><td><i>P</i><sub>perm</sub></td></tr><tr><td>AKAP13</td><td>7/7</td><td>1.00</td><td>16</td><td>0.0035</td><td>1</td><td>0.0002</td><td>1.14E−04</td><td>16.43</td><td>0.012</td></tr><tr><td>BAG1</td><td>7/7</td><td>1.00</td><td>15</td><td>0.0032</td><td>1</td><td>0.0002</td><td>2.18E−04</td><td>15.40</td><td>0.014</td></tr><tr><td>CALM1</td><td>9/10</td><td>0.90</td><td>14</td><td>0.0030</td><td>1</td><td>0.0002</td><td>4.16E−04</td><td>14.37</td><td>0.002</td></tr><tr><td>CASP6</td><td>16/17</td><td>0.94</td><td>46</td><td>0.0100</td><td>6</td><td>0.0013</td><td>2.96E−09</td><td>7.91</td><td>0.012</td></tr><tr><td>GTF2H3</td><td>23/26</td><td>0.88</td><td>42</td><td>0.0091</td><td>8</td><td>0.0017</td><td>3.66E−07</td><td>5.41</td><td>0.009</td></tr><tr><td>MAP3K5</td><td>11/12</td><td>0.92</td><td>34</td><td>0.0074</td><td>4</td><td>0.0008</td><td>2.02E−07</td><td>8.76</td><td>0.012</td></tr><tr><td>NCOR1</td><td>9/10</td><td>0.90</td><td>26</td><td>0.0056</td><td>2</td><td>0.0004</td><td>1.11E−06</td><td>13.37</td><td>0.004</td></tr><tr><td>PARP1</td><td>5/5</td><td>1.00</td><td>5</td><td>0.0011</td><td>0</td><td>0.0000</td><td>2.95E−02</td><td>inf</td><td>0.012</td></tr><tr><td>PTPN13</td><td>6/6</td><td>1.00</td><td>9</td><td>0.0019</td><td>0</td><td>0.0000</td><td>1.75E−03</td><td>inf</td><td>0.007</td></tr><tr><td>TCEA1</td><td>22/26</td><td>0.85</td><td>39</td><td>0.0084</td><td>7</td><td>0.0015</td><td>5.94E−07</td><td>5.74</td><td>0.009</td></tr></table> |
5421d082d4d893502ce17cb4ed2e2044a8ab3d1827b16875fb84f61d5a10d4ad.png | complex | <table><tr><td rowspan="2">LA responses (mmol.L<sup>−1</sup>)</td><td>Pre-RF</td><td>Beg-RF</td><td>End-RF</td><td>After-RF</td><td>F</td><td>p</td></tr><tr><td>Resting LA</td><td>1.27±0.33</td><td>1.11±0.28</td><td>1.18±0.30</td><td>1.12±0.37</td><td>1.45</td><td>0.240</td></tr><tr><td>LA at 8 km.h<sup>−1</sup></td><td>1.91±0.50</td><td>1.85±0.40</td><td>1.79±0.38</td><td>1.66±0.45</td><td>2.15</td><td>0.107</td></tr><tr><td>LA at 10 km.h<sup>−1</sup></td><td>2.68±0.81</td><td>2.73±0.55 *</td><td>2.54±0.57</td><td>2.38±0.58</td><td>3.24</td><td>0.031</td></tr><tr><td>LA at 11 km.h<sup>−1</sup></td><td>3.82±0.99 *</td><td>3.93±0.71 #</td><td>3.58±0.73</td><td>3.37±0.85</td><td>7.67</td><td>0.000</td></tr><tr><td>LA at 12 km.h<sup>−1</sup></td><td>5.80±1.44 *</td><td>6.15±1.34 #</td><td>5.48±1.20</td><td>5.14±1.35</td><td>12.24</td><td>0.000</td></tr></table> |
cd68cab4819dbe3fc5083f56ffa05f2a77efa57711f2bd7c8da58ce91644792d.png | simple | <table><tr><td>Primer name</td><td>Direction</td><td>Nucleotide sequence (5' to 3')</td></tr><tr><td>KSC138-9</td><td>Forward</td><td>GCACAATAAATTGGGCCTGA</td></tr><tr><td></td><td>Reverse</td><td>GCGAGTGTTGGGCTAAGTCT</td></tr><tr><td>KSC138-10</td><td>Forward</td><td>CACGAATGTGAATTTGATCG</td></tr><tr><td></td><td>Reverse</td><td>CGACCAAGGAGATAAAAACAGA</td></tr><tr><td>KSC138-17</td><td>Forward</td><td>TGGAAATTCTGTGCACTTGGTG</td></tr><tr><td></td><td>Reverse</td><td>TAAAGCCGCCTAGCCGATTG</td></tr><tr><td>KSC138-22</td><td>Forward</td><td>TGCAGCAATAATCAATCAAATAGAA</td></tr><tr><td></td><td>Reverse</td><td>TTCAATCAAATTTAGCACGTGTATT</td></tr><tr><td>KSC138-23</td><td>Forward</td><td>CGGTCCAGATTTAATTCTTTCACTC</td></tr><tr><td></td><td>Reverse</td><td>TTTCCGTTTTGTCACCCTGCT</td></tr><tr><td>BARCSOYSSR_09_1388</td><td>Forward</td><td>TTGCACTCTCCAAACCAAGA</td></tr><tr><td></td><td>Reverse</td><td>ATGCACTCTGCTCGACACAT</td></tr><tr><td>BARCSOYSSR_09_1415</td><td>Forward</td><td>CACCATCCACTCCAGTTCCT</td></tr><tr><td></td><td>Reverse</td><td>CTCCACGTGTTAGACGGGTT</td></tr></table> |
a6ddd4234d88598c775f3aa8adea5a6be14ec6450b1b351e4f4b2edefef9f91b.png | complex | <table><tr><td>Decoy</td><td>RNA</td><td>Length</td><td>Method</td><td colspan="4">Enrichment score (RMSD)</td><td colspan="4">Enrichment score (DI)</td></tr><tr><td></td><td></td><td></td><td></td><td>3dRNAscore</td><td>KB</td><td>RASP</td><td>Rosetta</td><td>3dRNAscore</td><td>KB</td><td>RASP</td><td>Rosetta</td></tr><tr><td>Position restrained dynamics and REMD (A)</td><td>1duq</td><td>26</td><td>X-ray</td><td>8.5</td><td>7.6</td><td>7.6</td><td>7.1</td><td>8.3</td><td>7.5</td><td>7.6</td><td>7.0</td></tr><tr><td></td><td>1f27</td><td>30</td><td>X-ray</td><td>8.3</td><td>7.9</td><td>6.6</td><td>6.2</td><td>8.1</td><td>7.8</td><td>6.6</td><td>6.2</td></tr><tr><td></td><td>1msy</td><td>27</td><td>X-ray</td><td>7.5</td><td>5.7</td><td>5.7</td><td>3.6</td><td>7.6</td><td>6.0</td><td>5.6</td><td>3.5</td></tr><tr><td></td><td>1nuj</td><td>24</td><td>X-ray</td><td>7.7</td><td>7.3</td><td>5.2</td><td>6.9</td><td>7.4</td><td>7.2</td><td>5.2</td><td>6.7</td></tr><tr><td></td><td>434d</td><td>14</td><td>X-ray</td><td>8.0</td><td>7.7</td><td>7.0</td><td>6.8</td><td>7.6</td><td>7.7</td><td>6.9</td><td>6.8</td></tr><tr><td>Normal modes (B)</td><td>1duq</td><td>26</td><td>X-ray</td><td>7.5</td><td>7.0</td><td>5.7</td><td>3.8</td><td>6.9</td><td>7.0</td><td>5.7</td><td>3.5</td></tr><tr><td></td><td>1esy</td><td>19</td><td>NMR</td><td>4.9</td><td>5.4</td><td>4.5</td><td>5.6</td><td>6.5</td><td>5.5</td><td>4.7</td><td>5.7</td></tr><tr><td></td><td>1f27</td><td>30</td><td>X-ray</td><td>5.9</td><td>5.8</td><td>3.7</td><td>2.6</td><td>6.7</td><td>5.8</td><td>3.7</td><td>2.5</td></tr><tr><td></td><td>1i9v</td><td>76</td><td>X-ray</td><td>6.1</td><td>2.6</td><td>5.3</td><td>3.0</td><td>5.5</td><td>2.7</td><td>5.1</td><td>3.0</td></tr><tr><td></td><td>1kka</td><td>17</td><td>NMR</td><td>5.7</td><td>4.6</td><td>4.1</td><td>4.6</td><td>6.9</td><td>4.3</td><td>4.1</td><td>4.8</td></tr><tr><td></td><td>1msy</td><td>27</td><td>X-ray</td><td>5.9</td><td>5.6</td><td>2.2</td><td>4.6</td><td>6.7</td><td>5.4</td><td>2.7</td><td>4.5</td></tr><tr><td></td><td>1nuj</td><td>24</td><td>X-ray</td><td>7.1</td><td>7.4</td><td>5.9</td><td>2.4</td><td>4.5</td><td>7.0</td><td>5.9</td><td>2.2</td></tr><tr><td></td><td>1qwa</td><td>21</td><td>NMR</td><td>3.5</td><td>3.2</td><td>2.0</td><td>3.8</td><td>3.7</td><td>3.3</td><td>2.2</td><td>3.9</td></tr><tr><td></td><td>1×9k</td><td>62</td><td>X-ray</td><td>6.7</td><td>1.6</td><td>5.2</td><td>3.0</td><td>3.1</td><td>1.9</td><td>5.2</td><td>2.8</td></tr><tr><td></td><td>1xjr</td><td>46</td><td>X-ray</td><td>7.7</td><td>5.4</td><td>7.9</td><td>2.2</td><td>6.2</td><td>5.0</td><td>7.9</td><td>2.5</td></tr><tr><td></td><td>1ykq</td><td>19</td><td>X-ray</td><td>4.6</td><td>3.4</td><td>3.5</td><td>2.8</td><td>5.0</td><td>3.3</td><td>3.8</td><td>2.5</td></tr><tr><td></td><td>1zih</td><td>12</td><td>NMR</td><td>7.7</td><td>5.4</td><td>5.7</td><td>6.6</td><td>6.9</td><td>5.3</td><td>5.7</td><td>6.5</td></tr><tr><td></td><td>28sp</td><td>28</td><td>NMR</td><td>5.7</td><td>4.0</td><td>6.5</td><td>1.8</td><td>5.7</td><td>4.5</td><td>6.7</td><td>2.9</td></tr><tr><td></td><td>2f88</td><td>34</td><td>NMR</td><td>6.8</td><td>5.4</td><td>4.9</td><td>4.4</td><td>4.1</td><td>5.4</td><td>4.7</td><td>4.2</td></tr><tr><td></td><td>434d</td><td>14</td><td>X-ray</td><td>7.7</td><td>7.4</td><td>7.4</td><td>5.2</td><td>6.9</td><td>7.4</td><td>7.6</td><td>5.2</td></tr><tr><td>FARNA (C)</td><td>1a4d</td><td>41</td><td>NMR</td><td>2.4</td><td>3.8</td><td>2.0</td><td>0.8</td><td>2.1</td><td>4.0</td><td>2.0</td><td>0.7</td></tr><tr><td></td><td>1csl</td><td>28</td><td>X-ray</td><td>2.0</td><td>1.5</td><td>1.6</td><td>1.3</td><td>2.4</td><td>1.4</td><td>1.6</td><td>1.4</td></tr><tr><td></td><td>1dqf</td><td>19</td><td>X-ray</td><td>4.2</td><td>1.8</td><td>2.8</td><td>1.0</td><td>3.6</td><td>2.0</td><td>3.2</td><td>1.0</td></tr><tr><td></td><td>1esy</td><td>19</td><td>NMR</td><td>3.2</td><td>3.7</td><td>4.8</td><td>1.2</td><td>3.8</td><td>3.5</td><td>4.2</td><td>1.1</td></tr><tr><td></td><td>1i9x</td><td>26</td><td>X-ray</td><td>3.4</td><td>1.3</td><td>2.2</td><td>1.5</td><td>4.0</td><td>1.5</td><td>3.6</td><td>1.6</td></tr><tr><td></td><td>1j6s</td><td>24</td><td>X-ray</td><td>0.2</td><td>1.4</td><td>0.2</td><td>0.6</td><td>1.6</td><td>1.7</td><td>0.8</td><td>0.5</td></tr><tr><td></td><td>1kd5</td><td>22</td><td>X-ray</td><td>3.2</td><td>0.3</td><td>0.8</td><td>0.2</td><td>2.4</td><td>0.5</td><td>1.6</td><td>0.3</td></tr><tr><td></td><td>1kka</td><td>17</td><td>NMR</td><td>1.4</td><td>1.2</td><td>0.6</td><td>0.6</td><td>2.0</td><td>0.8</td><td>0.8</td><td>0.6</td></tr><tr><td></td><td>1l2x</td><td>27</td><td>X-ray</td><td>0.6</td><td>3.2</td><td>1.0</td><td>1.8</td><td>1.5</td><td>3.2</td><td>1.2</td><td>1.8</td></tr><tr><td></td><td>1mhk</td><td>32</td><td>X-ray</td><td>1.6</td><td>1.2</td><td>1.6</td><td>1.0</td><td>1.4</td><td>1.2</td><td>1.4</td><td>1.2</td></tr><tr><td></td><td>1q9a</td><td>27</td><td>X-ray</td><td>2.6</td><td>0.5</td><td>0.8</td><td>0.8</td><td>3.2</td><td>0.5</td><td>1.2</td><td>0.8</td></tr><tr><td></td><td>1qwa</td><td>21</td><td>NMR</td><td>2.2</td><td>1.2</td><td>0.4</td><td>1.0</td><td>1.4</td><td>1.3</td><td>0.6</td><td>1.0</td></tr><tr><td></td><td>1xjr</td><td>46</td><td>X-ray</td><td>2.4</td><td>2.0</td><td>2.4</td><td>1.2</td><td>3.2</td><td>1.9</td><td>3.4</td><td>1.0</td></tr><tr><td></td><td>1zih</td><td>12</td><td>NMR</td><td>4.8</td><td>5.0</td><td>4.8</td><td>2</td><td>6.8</td><td>5.5</td><td>7.2</td><td>1.9</td></tr><tr><td></td><td>255d</td><td>24</td><td>X-ray</td><td>2.4</td><td>0.7</td><td>0.6</td><td>1.3</td><td>2.0</td><td>0.7</td><td>0.6</td><td>1.1</td></tr><tr><td></td><td>283d</td><td>24</td><td>X-ray</td><td>1.4</td><td>0.8</td><td>0.8</td><td>0.7</td><td>1.8</td><td>0.8</td><td>1.0</td><td>0.7</td></tr><tr><td></td><td>28sp</td><td>28</td><td>NMR</td><td>2.8</td><td>1.5</td><td>3.0</td><td>1.7</td><td>3.8</td><td>1.2</td><td>4.2</td><td>1.8</td></tr><tr><td></td><td>2a43</td><td>26</td><td>X-ray</td><td>2.2</td><td>2.0</td><td>1.4</td><td>0.6</td><td>3.2</td><td>1.8</td><td>2.0</td><td>0.6</td></tr><tr><td></td><td>2f88</td><td>34</td><td>NMR</td><td>3.2</td><td>1.3</td><td>2.2</td><td>1.3</td><td>3.6</td><td>1.3</td><td>1.6</td><td>1.2</td></tr><tr><td>Average values</td><td></td><td>(A)</td><td></td><td>8.0</td><td>7.2</td><td>6.4</td><td>6.1</td><td>7.8</td><td>7.2</td><td>6.4</td><td>6.0</td></tr><tr><td></td><td></td><td>(B)</td><td></td><td>6.2</td><td>4.9</td><td>5.0</td><td>3.8</td><td>5.7</td><td>4.9</td><td>5.0</td><td>3.8</td></tr><tr><td></td><td></td><td>(C)</td><td></td><td>2.3</td><td>1.8</td><td>1.8</td><td>1.1</td><td>2.8</td><td>1.8</td><td>2.2</td><td>1.1</td></tr><tr><td></td><td></td><td>X-ray</td><td></td><td>4.8</td><td>3.8</td><td>3.7</td><td>2.8</td><td>4.7</td><td>3.8</td><td>3.9</td><td>2.7</td></tr><tr><td></td><td></td><td>NMR</td><td></td><td>4.2</td><td>3.5</td><td>3.5</td><td>2.7</td><td>4.4</td><td>3.5</td><td>3.7</td><td>2.8</td></tr><tr><td></td><td></td><td>All</td><td></td><td>4.5</td><td>3.7</td><td>3.6</td><td>2.7</td><td>4.6</td><td>3.7</td><td>3.8</td><td>2.7</td></tr></table> |
1d794f49459200fcd9aa0120dfef9053c8587997a3093cb9a79602ed9d6f47e4.png | complex | <table><tr><td></td><td colspan="4">Mumias (Control site)</td><td colspan="4">Butere (intervention site)</td></tr><tr><td>Health indicator</td><td>Baseline</td><td>Endline</td><td>Change</td><td><i>p</i>-value</td><td>Baseline</td><td>Endline</td><td>Change</td><td><i>p</i>-value</td></tr><tr><td>ANC</td><td>66.3</td><td>56.0</td><td>-10.3</td><td><0.0001</td><td>47.7</td><td>72.0</td><td>24.2</td><td><0.0001</td></tr><tr><td>HFD</td><td>49.5</td><td>46.3</td><td>-3.2</td><td>0.173</td><td>41.1</td><td>47.2</td><td>6.1</td><td><0.0001</td></tr><tr><td>Water</td><td>31.6</td><td>81.1</td><td>49.5</td><td><0.0001</td><td>37.1</td><td>93.2</td><td>56.0</td><td><0.0001</td></tr><tr><td>Latrine</td><td>91.1</td><td>96.0</td><td>4.9</td><td><0.0001</td><td>80.5</td><td>94.5</td><td>14.0</td><td><0.0001</td></tr><tr><td>Card</td><td>85.1</td><td>86.3</td><td>1.2</td><td>0.486</td><td>91.0</td><td>89.3</td><td>-1.7</td><td>0.025</td></tr><tr><td>ITN</td><td>58.7</td><td>94.5</td><td>35.7</td><td><0.0001</td><td>61.4</td><td>91.4</td><td>29.9</td><td><0.0001</td></tr><tr><td>Penta 1</td><td>92.0</td><td>92.1</td><td>0.1</td><td>0.95</td><td>91.4</td><td>91.7</td><td>0.3</td><td>0.732</td></tr><tr><td>Penta 3</td><td>87.5</td><td>88.6</td><td>1.1</td><td>0.46</td><td>89.5</td><td>90.1</td><td>0.7</td><td>0.417</td></tr><tr><td>Food</td><td>62.3</td><td>81.3</td><td>19.0</td><td><0.0001</td><td>36.0</td><td>56.4</td><td>20.3</td><td><0.0001</td></tr></table> |
cf1c183844920da4233612cd045fe94001a9ce1724c615eabde5f2751ec1fbd6.png | complex | <table><tr><td>Databases</td><td>PubMed</td><td>Embase</td><td>CINAHL</td></tr><tr><td>(“Saudi Arabia”[MeSH]) AND “Diabetes Mellitus, Type 2” [MeSH]</td><td>114 (76), Ex: 38 (date range)</td><td>1015 (853) Ex: 162 (DR)</td><td>20 (20) Ex: 0 (DR)</td></tr><tr><td>(“Referral and Consultation” [MeSH]) AND “Saudi Arabia” [MeSH]</td><td>77 (34) Ex: 43 (date range)</td><td>0</td><td>51 (39) Ex: 12 (DR)</td></tr><tr><td>((“Referral and Consultation” [MeSH]) AND “Saudi Arabia” [MeSH]) AND “Diabetes Mellitus, Type 2” [MeSH]</td><td>0</td><td>0</td><td>0</td></tr><tr><td>Total</td><td colspan="3">1277</td></tr></table> |
ad851522fe066085f11cb83fb4e8c2421267a9fb116c655359d9386ccb6501a0.png | simple | <table><tr><td>Exercise</td><td>Dosage</td></tr><tr><td>Abduction in sidelying</td><td>3 sets of 10 at a 10 RM resistance</td></tr><tr><td> Unilateral hip abduction performed in sidelying with the use of ankle cuff weights</td><td></td></tr><tr><td>Abduction in standing</td><td>3 sets of 10 with moderate resistance band</td></tr><tr><td> Unilateral hip abduction performed in standing with the use of resistance band</td><td></td></tr><tr><td>Standing wall isometric hip abduction</td><td>3 sets of 10 with 5 second holds</td></tr><tr><td> Performed in unipedal stance with the opposite limb in 90 degrees of hip and knee flexion. Exercises will be done for both limbs.</td><td></td></tr><tr><td>Adduction in sidelying</td><td>3 sets of 10 at a 10 RM resistance</td></tr><tr><td> Unilateral hip adduction performed in sidelying with the use of ankle cuff weights if possible</td><td></td></tr><tr><td>Abduction in standing</td><td>3 sets of 10 with moderate resistance band</td></tr><tr><td> Unilateral hip abduction performed in standing with the use of resistance band</td><td></td></tr><tr><td>Towel squeezes</td><td>3 sets of 10 with 5 second holds</td></tr><tr><td> Bilateral isometric hip adduction against a rolled-up towel in sitting</td><td></td></tr></table> |
63d7cd8f268eaa6e413e9727797fa158e93c4648e4674e8263e7337b27b1d0bd.png | complex | <table><tr><td>Study</td><td>Genotype</td><td>Sex</td><td>N</td><td>Key Experimental Outcomes</td></tr><tr><td rowspan="6">Epithelial CellProliferation</td><td rowspan="3">WT</td><td>Both</td><td>14</td><td rowspan="6">In <i>Fgf15</i><sup><i>-/-</i></sup> mice, we detected a shift of proliferating cells to upper crypt zones (<i>P</i> <0.001).</td></tr><tr><td>M</td><td>8</td></tr><tr><td>F</td><td>6</td></tr><tr><td rowspan="3"><i>Fgf15</i><sup><i>-/-</i></sup></td><td>Both</td><td>15</td></tr><tr><td>M</td><td>8</td></tr><tr><td>F</td><td>7</td></tr><tr><td rowspan="6">No Carcinogen Treatment</td><td rowspan="3">WT</td><td>Both</td><td>12</td><td rowspan="6">After >1 year surveillance without carcinogen treatment, no WT or <i>Fgf15</i><sup><i>-/-</i></sup> mouse developed colon neoplasia.</td></tr><tr><td>M</td><td>4</td></tr><tr><td>F</td><td>8</td></tr><tr><td rowspan="3"><i>Fgf15</i><sup><i>-/-</i></sup></td><td>Both</td><td>17</td></tr><tr><td>M</td><td>9</td></tr><tr><td>F</td><td>8</td></tr><tr><td rowspan="6">Colon Tumor Induction (AOM/DSS)</td><td rowspan="3">WT</td><td>Both</td><td>14</td><td rowspan="6">Colon tumors were detected in 27 of 29 mice; <i>Fgf15</i><sup><i>-/-</i></sup> mice had more colon tumors overall (<i>P</i> = 0.003), and in males (<i>P</i> = 0.03) and females (<i>P</i> < 0.05) considered separately.</td></tr><tr><td>M</td><td>6</td></tr><tr><td>F</td><td>8</td></tr><tr><td rowspan="3"><i>Fgf15</i><sup><i>-/-</i></sup></td><td>Both</td><td>15</td></tr><tr><td>M</td><td>7</td></tr><tr><td>F</td><td>8</td></tr></table> |
ef2fea18c17e56694b7adccab7328709ad849d29e1a18abdc1c71428cd69d83e.png | simple | <table><tr><td>Item</td><td>Person-time</td><td>%</td></tr><tr><td>Utilization of health services</td><td></td><td></td></tr><tr><td> Saw a doctor</td><td>118</td><td>36.4</td></tr><tr><td> Self-medication</td><td>108</td><td>33.3</td></tr><tr><td> Non use</td><td>98</td><td>30.3</td></tr><tr><td> Total</td><td>324</td><td>100.0</td></tr><tr><td>Type of selected medical institutions</td><td></td><td></td></tr><tr><td> Village health clinics or community health service stations</td><td>53</td><td>44.6</td></tr><tr><td> Township hospital</td><td>7</td><td>6.2</td></tr><tr><td> District-level hospital</td><td>20</td><td>16.9</td></tr><tr><td> City-level hospital or above</td><td>15</td><td>12.3</td></tr><tr><td> Unlicensed private clinic</td><td>24</td><td>20.0</td></tr><tr><td> Total</td><td>118</td><td>100.0</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.